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ABSTRACT
The School of Graduate Studies
The University of Alabama in Huntsville

Degree: Doctor of Philosophy

College/Program: Science/Biotechnology Science
and Engineering

Name of Candidate: David J. Ulkoski
Title: Synthesis of Amphiphilic PEGylated Poly(α-amino acid) Tercopolymers and the
Impact of Molecular Architecture on Their Use as Gene and Drug Delivery Vectors
Poly(α-amino acid)s (PAAs) are a diverse class of polymers that can be
synthesized or biologically derived. PAAs have been widely used for biomedical
applications due to their biodegradability and biocompatibility. Living polymerization
through ring opening polymerization of amino acid N-carboxyanhydrides using a
nucleophilic initiator provides the potential to manipulate polymer architecture and
physiochemical characteristics. In this study, we investigate the use of amphiphilic block
and random PAA tercopolymer constructs that contain ionic and hydrophobic
components. The amphiphilic character for each tercopolymer allows for the formation
nanoparticles that can be used in gene and drug delivery.
Each tercopolymer component provides a specific purpose that is needed to
produce biologically relevant gene and drug delivery vectors. Poly(ethylene glycol)
(PEG) is used widely as a biomaterial with the ability to lower immunogenicity. PEG has
a large excluded volume in aqueous media and repels macromolecules due to an entropic
effect which prevents nanoparticle disruption. L-lysine and L-glutamate provide ionicity
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required due electrostatically bind to DNA and provide tenability for drug encapsulation,
respectively. L-leucine was utilized to provide compaction and nanoparticle stability by
introduction of hydrophobic moieties.
PEGylated PAAs (PEG-PAAs) were successfully synthesized in the presence of
urea, yielding products with desired molecular weights and architecture. Gel permeation
chromatography (GPC) and proton nuclear magnetic resonance (1H-NMR) displayed
polydispersity indexes (PDI) between 1.1 and 1.4 and accurate chain lengths, which are
indicative of living polymerization. Higher PDIs were observed with increasing
hydrophobic character within block tercopolymers and was minimized when
hydrophobicity was spread throughout random tercopolymers.
Cationic tercopolymers were shown to bind and condense DNA into nanoparticles
less than 200 nm and increased polymer concentrations resulted in a net positive charge.
Also, DNA condensation and protection from DNAse I at 37 ℃ was dependent upon the
use of either block or random tercopolymers. Transfection and cytotoxicity in COS-1
cells was found to be dependent upon tercopolymer structure and cationic density.
Anionic tercopolymers formed drug encapsulates within both a partially soluble and a
hydrophobic drug. The size, stability, and loading efficiency of the nanoparticles altered
based upon the placement of the hydrophobic components and the loading of each
individual drug.
This study made two important contributions to the field: 1) PEG-PAA
tercopolymers are shown be tunable gene and drug delivery vectors and 2) molecular
architecture is a very important factor into the efficiency of these tercopolymers for
biomedical applications.
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CHAPTER 1

BIBLIOGRAPHIC STUDY OF POLY(AMINO ACIDS) AND POLYMER
THERAPEUTICS

1.1. Introduction
Nanomedicine is a relatively new field that has grown within the recent years in
effort to address unfulfilled therapeutic needs. Nanosystems are compounds that can be
constructed with diverse compositions and biological properties while providing
beneficial aspects in the treatment of diseases, such as cancer. Biopolymers are suitable
biomaterials that are developed from the immense assortment of building blocks that are
shown to be biocompatible and possibly biodegradable. Synthetic biopolymers are
created to allow for the modification and manipulation of specific macromolecular
characteristics for therapeutic optimization in gene delivery, drug delivery, and protein
mimicking. In the interest of scientific research, the current project will further explore
the development of therapeutics through alteration of biopolymer structural and physical
characteristics.
In order to properly illustrate the use of relevant biomaterials within this research,
several topics must be discussed. Foremost, the overall constructs of the synthetic
biopolymers used in this work must be presented. Background into their structural
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importance, along with the synthetic methods of both monomer and polymerization of
biopolymers themselves will be addressed. Secondly, the uses of polymers in biomedical
applications will be discussed, including the challenges that may dictate their efficacy
and recent polymeric therapeutic endeavors containing similar constructs.

1.2. Poly(amino acid)s
1.2.1. Background
Poly(amino acid)s (PAAs) are synthetic polymers consisting of α-amino acid
building blocks connected through amide bonds (Figure 1.1).1 Although structurally
similar to natural proteins and peptides through the use of the same monomeric units,
these biopolymers do not contain a specific amino acid sequence and biological function.
Polypeptides or proteins can be chemically manufactured through solid phase Merrifield
synthesis2,3 or native chemical ligation (NCL).4 Over the past years, the control of
polymer chain length has been a major challenge when using synthetic approaches.5
These chemical methods are limited by yields and synthetic accessibility when larger
peptides and proteins are manufactured.5,6
The majority PAAs consist as oligomeric copolymers of one or two different
amino acids that can be arranged in block or random sequences. Recently, PAAs have
gained substantial interest as biocompatible polymers due to the fact that their
degradation products lead to biocompatible L-amino acid monomers. Additionally,
linking these individual L-amino acids through peptide bonds allows for the formation of
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naturally occurring secondary structures that contribute further to the overall
biocompatibility of these biopolymers.
Synthetic PAAs have many benefits over conventional synthetic polymers due to
their ability to provide stable secondary structures in aqueous solution. Due to the
isotacticity of PAAs, the formation of these distinct secondary structures also permits
self-assembly properties that can be utilized in biomedical applications, such as drug
delivery and tissue engineering.7,8 Specifically, Deming et al. illustrated that amphiphilic
PAA copolymers containing both a charged, hydrophilic block and a hydrophobic
segment can readily undergo gelation for therapeutic applications within the central
nervous systems. The gels were used to administer drugs and/or growth factors, while
providing scaffolds to fill detects. Results showed that amphiphilic diblock copolymers
consisting of a hydrophobic L-leucine and a hydrophilic L-lysine, L-arginine, or Lglutamate segment maintained biocompatibility while not causing any adverse effect
when delivering nerve growth factors.9–11 Poly(amino acid)s can been utilized as
constructs for the investigation of a variety of biological approaches or therapeutics, such
as drug delivery12 and polymer coatings13.

Figure 1.1. General structure of poly(amino acid)s.
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A variety of amphiphilic block and random poly(amino acid) copolymers of
controlled dimensions, such as molecular weight distribution, sequence, and composition,
have been designed for therapeutic delivery. These polypeptide-based random and block
copolymers have been extensively studied, as they can self-assemble into nanometersized structures in aqueous solution and the size and morphology of these materials can
be adjusted by varying the composition of the block copolymers.

Figure 1.2. General polymer structure of random and block copolymers.

In this study, all PAA copolymers will contain a poly(ethylene glycol) (PEG)
fragment by using α-methoxy ω-amino polyethylene glycol (α-methoxy-ω-amino PEG)
(mPEG-NH2) as a macroinitiator. Poly(ethylene glycol) (PEG) is a polyether that has
many applications from industrial manufacturing to medicine. PEG is a widely used
biomedical polymer, as it is capable to induce a stealth character upon PEGylated moieties
and surfaces.14,15 PEG has shown, in combination with PAAs, to exhibit low toxicity and
high hydrophilicity16,17, which can make it acceptable for therapeutic applications, such as
drug and gene delivery.18
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Figure 1.3. General structure of Poly(ethylene glycol) and the functionalized derivative αmethoxy-ω-amino PEG (mPEG-NH2) macroinitiator.

Poly(ethylene glycol) has excellent blood compatibility and contributes a stealth
character to delivery systems due to its ability to repel proteins through high surface
mobility.19,20 In aqueous medium, PEG exhibits rapid chain motion and a large excluded
volume resulting from low interfacial free energy and loss of configurational entropy of
PEG chains in the presence of a foreign particle, respectively.21–24 Hence, PEGylated
biomaterials are biocompatible and possess increased stability in nanosystems, while
reducing thrombogenic and antigenic effects of potential pilot molecules and specific
antibodies.

1.2.2. Synthesis of α-amino acid N-carboxyanhydrides (NCAs)
1.2.2.a. Synthetic Purpose
Biologically produced polypeptides or proteins are tailored to contain a wide
range of structures that are relevant to their function within the human body. The
arrangement and specificity of their amino acid sequences can create distinct secondary
structures, for example α-helices, β-sheets, and random coils, that define the ability of
these proteins to bind and interact with certain substrates.25 Scientists are trying to
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develop structures with conformities that are as intricate as those that are naturally
produced. As discussed previously, PAAs are biomaterials that can operate as biomimics
by carefully considering the molecular length/weight, composition, and incorporation of
specific amino acids through polymerization of α-amino acid N-carboxyanhydrides
(NCAs).1 The specificity of this polymerization can help lead to a distinctive function
and purpose of the polymer being created.
NCA synthesis can be performed through two methods depending upon the nature
of the amino acid substrate. The first is the Leuchs method based on the cyclization of Nalkoxycarbonyl amino acids halides to form oxazolidine-2,5-dione.26,27 The second,
Fuchs-Farthing method, involves direct phosgenation of amino acids to synthesize a
cyclic anhydride product.

1.2.2.b. Leuchs Method of NCA Synthesis
In 1906, Herman Leuchs developed a method using N-alkoxycarbonyl amino acid
chlorides in order to perform stepwise peptide synthesis. The halogenation of the
carboxyl group allows for the formation of NCA upon heating when the acid halogenide
group attacks the carbonyl oxygen of the carbamate creating a cyclic intermediate, along
with alkyl halide byproducts (Scheme 1.1). These impurities have been shown to affect
the precipitation and crystallization of NCA in solution.28 The rate determining of this
method involves the nucleophilic attack of the free halide on the alkyl group producing
the NCA and alkyl halide byproduct. The nucleophilicity of the halide ion and
electrophilicity of the alkyl group can play an important role in the rate of the cyclization.
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For example, bromide ions increase the rate of the reaction and lower the activation
energy needed to yield desired NCA products.

Scheme 1.1. Leuchs method for NCA synthesis.

1.2.2.c. Fuchs-Farthing Method of NCA Synthesis
The Fuchs-Farthing method is an abundantly used procedure for the synthesis of
NCA compounds.29,30 As depicted in Scheme 1.2, this method involves the phosgenation
of α-N-unprotected amino acids where cyclization proceeds through an N-chloroformyl
amino acid intermediate and a further loss of a second hydrogen chloride molecule.
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Scheme 1.2. Fuchs-Farthing method using phosgene for NCA synthesis.

A number of compatible solvents have been used in NCA formation, such as
tetrahydrofuran (THF), dioxane, and ethyl acetate, due to their inert nature with
phosgene. These solvents can produce contamination of amino acid chloride
hydrochlorides which in turn can be phosgenated to α-isocyanato acid chlorides (Scheme
1.3).31–33
Traditionally, protected amino acids are reacted with excess phosgene gas.34 Excess

contamination can result from the use of phosgene gas because it cannot be precisely
controlled when being bubbled into the reaction mixture. This factor can be minimized
by employing a crystalline equivalent, bis(trichloromethyl) carbonate or triphosgene, as
phosgene precursor. The use of solid triphosgene permits stoichiometric addition and
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prevents the side reactions associated with excess phosgene.35 This component requires
heating in order to disrupt trimer formation and thus release reactive phosgene molecules.

Scheme 1.3. Contaminant production due to the presence of excess HCl and phosgene.

The production of excess HCl through use of phosgene reagents can produce
unwanted chlorinated side products and hinder the reaction.36 Reduction in purity is
particularly undesirable for later use in ring-opening polymerization. Therefore, HCl
scavengers must be employed to improve ring conversion and eliminate all side reactions.
In this project, α-pinene is used where the addition of HCl to the double bond of α-pinene
produces an unstable isomer, pinene hydrochloride. Instability of this intermediate is
caused by small-ring strain producing rapid isomerization and ring rearrangement leading
to bornyl chloride (Scheme 1.4). The use of this proton quenching compound reduces the
buildup of HCl and speeds up the NCA reaction which allows for larger scale NCA
production of a variety of amino acids.36
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Scheme 1.4. The chlorination of the α-pinene HCl scavenger.

1.2.3. Polymerization of N-carboxyanhydrides
1.2.3.a. Living Polymerization Overview
Some traditional polymerization techniques generate chain transfer during
propagation and produce products with end groups that cannot be galvanized after
termination, consequently stopping chain elongation. These factors do not allow for
control of molecular weights or architectures that may hinder biopolymers, such as
PAAs, from being used as biomimetics.37 Diminishing chain transfer and termination
during the polymerization will enable control over polymer formation. Recent
advancements in synthetic techniques have enabled the preparation of complex polymers
with controlled molecular weight (Mw) and sequence often seen with natural
polypeptides/proteins.
In 1956, Michael Swarc termed “living” polymerization where reactive polymer
end groups are used and are not manipulated during chain propagation and polymer
completion.12,38 The polymerization will ensue until all of the monomer is consumed and
the polymer chain ends will remain active or “alive” allowing for continued
polymerization upon further addition of monomer. “Living” polymerizations lead to very
narrow molecular weight distributions or polydispersity (Mw/Mn ≤ 1.2).12,39 Hence, all
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chain propagation form concurrently and grow at the same rate. If this condition does not
transpire, the earliest chains formed during initiation would become larger than those
initiated later causing the polydispersity of the polymers to widen.
Polymerization using α-amino acid N-carboxyanhydrides have been carefully
investigated over the past decades.12 Latest synthetic methods have been developed for
living polymerization of PAAs that can provide lower polydispersity through ring
opening polymerization (ROP) of NCAs for a variety of α-amino acids.26 It is worth
noting that NCA monomers have multiple reaction sites: two carbonyl carbons and
nucleophilic positions consisting of an amine and a methine. These reactive regions can
cause the formation of multiple different products and need to being taken into account
when selecting the proper initiator. As seen in Scheme 1.5, NCA-ROP consists of three
common mechanisms: amine, carbamate and activated monomer mechanism. Each
mechanism dictates a specific polymerization and depends on reaction conditions, such as
temperature, solvent, and CO2 pressure and initiator basicity.
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12
Figure 1.4. Amine-initiated mechanisms of amino acid N-carboxyanhydride ring-opening
polymerizations: amine, carbamate, and activated monomer mechanism. Figure is taken from
previously published material.159

1.2.3.a. Amine Mechanism
When primary aliphatic amines are used as initators, NCA polymerization will
likely follow the amine mechanism pathway. The nucleophilic amine will attack the
more electrophilic C(O)-2 carbonyl causing NCA ring opening and the simultaneous
release of CO2. After decarboxylation, the amine end of the polymer acts as a
nucleophilic initiator and the living polymerization is allowed to maintain the amine
mechanism until all monomer is consumed. It is important to realize that water and
alcohol can also react with NCA in a slower manner due to its decreased nucleophlicity
when compared to primary amines. The presence of such compounds will slow the
initiation step and lead to a larger polydispersity. Because of this, reactions should be
conducted under anhydrous conditions using inert solvents.12,39–41

1.2.3.b. Carbamate Mechanism
If decarboxylation is decelerated or hindered through deprotonation and
stabilization of the carbamic acid intermediate, the reaction will take on the carbamate
mechanism. The presence of carboxylate end groups eliminates the living characteristics
of the polymerization disrupting the molecular weight distribution, generating shortened
polymer chains. Theoretically, the amine mechanism can be resumed through
nucleophilic attack of the carboxylate on NCA monomer. This would create an
integration of anhydride units that will influence polymer properties. Primary amines are
weakly basic and do not, in all likelihood, deprotonate and stabilize the carbamic acid.42
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Scheme 1.5. Amine and Carbamate mechanism of NCA ROP using amino acids through use of a
primary amine.

1.2.3.c. Activated Monomer Mechanism
The use of a tertiary amines or sterically hindered bases as initiators generate an
activated monomer (AM) mechanism via deprotonation of the NH group. This activated
monomer will initiate the polymerization through subsequent attack of another activated
monomer on the carbonyl C(O)-2 carbon and ensuing decarboxylation. The NCA ring
will provide the end group for the growing chain.43,44

Scheme 1.6. Activated monomer mechanism for NCA ROP when using basic amines.
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1.3. Polymer Therapeutics
In medicine, the subject of pharmacological therapeutics is currently
experiencing a continuous shift from the use of traditional pharmaceutical
administration to the development of systems that deliver gene and drugs to specific
sites. Numerous drugs are chemically unstable and notably degraded during the course
of digestion and absorption, which in turn prevents these drugs from reaching their
intended physiological sites. Over the last several years, there has been a concentrated
effort to provide biomaterial delivery systems that allow for allocation of a drug or gene
at a specific site for extended periods, while exhibiting controlled release rates and lack
of any side effects. Until recently, delivery systems have not shown such optimal
properties and a more effective method to deliver a gene or drug is required.
The ability to design, improve, and implement many different types of
therapeutics in areas, such as cancer, inflammatory, and infectious diseases, helps aid in
the overall therapeutic options. The search for innovative modes of drug delivery and
protein mimicking will assist in disease prevention through combating illness or
determining how diseases occur. For this reason, polymer therapeutics has gained
considerable recognition within the last few years.
Biocompatible biomaterials such as synthetic polymers are the most promising in
the forefront of pharmaceutical and biopharmaceutical research because they can act as
carriers for the delivery of DNA or drug molecules and act as structural protein mimics.
Synthetic polymers have become attractive for medical applications for numerous
reasons. Most importantly, physical and chemical properties of these materials can be
altered based on the polymerization reaction, monomer units used, and the blending of
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monomer units to form copolymers consisting of diverse components at changeable
concentrations.45 Aspects of toxicity, stability, and degradation need to be considered
and must be deliberated when utilizing biomaterials as pharmacological products. In
this project, we have designed three separate PAA constructs that can be used for small
molecule drug delivery, gene delivery, and as a protein mimic.

1.3.1. Gene Delivery Systems
There are two main objectives of gene delivery. The first is to transport plasmid
DNA encoding for genes of interest into cells with the intention of studying the cellular
effects. Secondly, one needs to consider the rational of how the delivery of these genes
can be applied, i.e. the expression of a therapeutic protein being produced through the
translation of the gene itself. Consequently, many factors need to be taken into account
when dealing with both in vitro and in vivo gene expression. The application of the
Human Genome Project has given rise to new research by offering many insights into
gene sequence and function. The commercial development and expansion of DNA
related genomics research has allowed for the discovery and design of gene
therapeutics.46,47
The term “gene therapy” is described as the self production of therapeutic proteins
within an organism via delivery of a gene plasmid.48 A major tool in studying gene
therapeutics is the addition and expression of genes synthesized in bacteria‐derived
plasmids through recombinant methods. In order to deliver external genetic material to
the cells and eventually the nucleus, a vector or vehicle is necessary. The demand for
16

these vectors has created an industry that has developed a broad collection of molecules
designed to overcome the barriers associated with the cellular delivery of genetic
material.49
The efficacy of in vivo gene delivery can be affected by several factors. The
vector must condense plasmid DNA into small nanoparticles below a particular size that
protect the DNA from extracellular nucleases and rapid clearance, while also avoiding
cytotoxicity and immune response. There are two general approaches when using gene
vectors: (1) the employment of attenuated viruses (viral) and (2) the use of
macromolecules (non‐viral).
Thus far, the practice of using modified viruses as gene transfer vectors has been
demonstrated to be more efficacious than the non-viral methods in gene transduction.50,51
Nevertheless, a key drawback to viral vectors is their toxicity due to in vivo immune
response. When compared with viral systems, non-viral vectors are cost effective and
more importantly provides less stimulation of the immune system, while not experiencing
any limitations on the size of plasmid DNA being transferred.52
Recently, gene delivery through some physical methods, such small molecule and
polymer synthesis, has obtained efficient expression while also avoiding immunogenic
effects. Less toxic nonviral methods that have been established include several types of
polymers, for instance polyethyleneimine (PEI), polyesters, and polypeptides. However,
these non-viral substitutes can also be less effective in gene delivery than viruses in vivo.
Hence, an improvement in non-viral gene delivery systems is still desirable and all
barriers affecting gene delivery need to be taken into account. Next, viral and non-viral
vectors will briefly detailed.
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1.3.1.a. Viral Vectors
Viral gene delivery involves the cellular induction of a viral genome containing a
relevant gene of interest. Infection of cells can transpire by utilization of many different
modified viruses, including retroviruses, adenoviruses, herpes viruses, and human foamy
virus (HFV).53 All viral vector genomes are modified through deletion of sequences
affecting replication which makes them safer. Viral vectors are successful gene therapy
systems, but individually each virus type has its limitations. The application of viral
delivery systems can be limited by: the transgenic capacity size being transferred, toxin
production and the insertional mutagenesis of the host, and immunogenic characteristics
that may cause adverse effects through inflammatory responses or degeneration of
transducted tissue.54,55
All viral gene delivery systems have the potential for extensive toxicity in vivo.
Gene therapy by adenoviral vectors have been known to cause serious and fatal adverse
effects with one patient.56 In 1999 during a clinical safety trial, an unfavorable reaction
had occurred with a patient being injected with an adenovirus vector that had been
modified with the gene for ornithine transcarbamylase. The consequence of not fully
understanding the biological interactions of the vector with the human body led to the
patient’s death. The misfortune of that event led to efforts towards the use of less toxic
non‐viral systems for gene therapeutics. The next sections will discuss the use of non‐
viral carriers, the major barriers to effective gene delivery, along with polymeric
examples applied in the field of gene delivery.
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1.3.1.b. Non-viral Vectors
Non-viral gene delivery methods use synthetic or natural compounds to deliver
DNA/gene into a cell. Non-viral delivery systems offer certain benefits over viral
systems. They can be made by simple, large scale production and the materials used
generally induce a lower immune response than viral equivalents. These factors will
allow the potential for repeat administration to a patient.
Although viewed as less efficacious than viral methods, non‐viral carriers can be
synthesized and optimized for specific needs by manipulating their characteristics.
Recent advances show that gene delivery by some physical methods has developed
efficiency and expression that is clinically significant. The topics of synthetic organic
and polymer chemistry have manufactured many macromolecules that can be adjusted to
construct operative gene delivery vehicles. Some of the most prevalent types of synthetic
polymer used for non‐viral methods will be discussed shortly, such as polyethyleneimine
(PEI), polyesters, and polypeptides.

1.3.2. Obstacles of gene delivery
1.3.2.a. Polyplex Formation and Size
Vectors for gene delivery need to able to bind with the genetic material in order to
transport it into targeted cells. In order to accomplish this, the majority of polymeric and
macromolecular compounds have been cationic at physiological environments due to the
presence of protonable amines. DNA is inherently negatively charged as a result of the
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phosphodiester linkages within its backbone, which allows for the protonated amines to
attach to the DNA through electrostatic interactions.
The structure of gene delivery systems can be engineered to obtain different
moieties, varying cationic densities, and different cationic positioning that will alter the
characteristics of the molecules. Once bound to DNA, the cationic vector will neutralize
DNA’s negative charge and considerably reduce its size by forming condensed
polymer/DNA complexes (polyplexes). It is vital to ensure that neutralization has
transpired through the charge (N:P) ratio of the nitrogen/amine (N) from the polymer to
phosphorus (P) from the nucleic acid. Excess of cationic charge with this N:P ratio will
prevent against polyplex nanoparticle aggregation and the overall size of the complexes
lessen. The physiochemical properties of polyplexes, such as size and surface charge, are
regularly investigated due to their influence on therapeutic efficiency.
Useful reagents must deliver DNA to the interior of the cell by assembling
into complexes of adequate size and positive charge that allows for entrance into
the cell through endocytosis (<200 nm).57 Size distributions of several polyplex
constructs have been revealed to be independent upon the physical form, size, and
sequence of DNA.58–61 Conversely, the total polyplex size can depend upon the use and
characteristics of the polymer. Polyplex size distributions can vary based on several
factors, including polymer chain length, cationic amine density, aqueous solubility, and
N:P ratio or amount of polymer used within the formulation.62,63
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1.3.2.b. DNA Protection
The ability of non-viral gene vectors to protect nucleic acids from being
enzymatically cleaved through nuclease degradation is imperative. Nucleases within the
body will hydrolyze the backbone of DNA (phosphodiester bonds) between each
nucleotide, which renders a target gene useless. Macromolecular vectors of adequate size
can block this hydrolysis by sterically obstructing the enzymes and shielding the
DNA.64,65 The DNA will become electrostatically entangled with the cationic vectors
where the cleavable DNA bonds are not accessible to the active sites of the nucleases.
The duration of protection can depend on the specific vectors being used where the
strength of the vector/DNA interaction can differ.66 Polycationic polymers are examples
of the compounds used to circumvent nuclease disruption.

1.3.2.c. Polyplex Stability
Once the polyplex formation has been established, the stability of this complex
needs to be considered. Strong electrostatic interactions between the DNA and cationic
vector need to be maintained until cellular uptake has taken place. In addition,
decomplexation of the polyplex is important before the gene can be transcribed, enabling
proficient gene expression. The binding affinity of the DNA to the cationic vector
requires dissociation that is strong enough to avoid premature release before cellular
incorporation and low enough to allow for intracellular release before entering the
nuclear envelope.
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1.3.2.d. Polymer/Polyplex Toxicity
The efficacy of non-viral gene delivery systems can provide efficient gene
transfer but also exhibit problematic effects. A major concern when applying gene
vectors is the toxicity of both the vector and the polyplex that delivers the DNA to the
cell. Cationic materials not only condense and protect the genetic cargo, but also produce
cellular membrane interactions that may lead to considerable toxicity. Structural changes
in vectors, such as polymers, can affect their cytotoxicity due to either a change in
polymer length or a change in the cationic density throughout the polymer construct.67,68
Cationic polymers may cause both in vitro and in vivo toxicity. The toxic effect
of these cationic carriers is dose‐dependent, with elevated toxicity profiles being
observed at higher concentrations of vectors. In accordance with N:P charge ratio, the
amount of DNA, which is normally added at an optimal dose, is proportionate to the
amount of cationic carrier. Therefore, a balance is desired between the amount of DNA
and quantity of vector used where maximum gene delivery is achieved and the lowest
levels of toxicity are seen. Many factors can affect the balance of the
efficiency/cytotoxicity profile in polymeric gene delivery systems, for instance molecular
weight, zeta potential, particle size, ionic strength of the solution, and polymer structure,
i.e. degree of branching.69–72
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1.3.3. Examples of Polymeric Non-viral Gene Delivery Vehicles
1.3.3.a. Polyethyleneimine (PEI)
Polyethyleneimine (PEI) has been studied thoroughly for its ability to complex
and deliver DNA. PEI can be either in linear or branched conforms (Figure 1.5) and has
been widely investigated. Its aptitude for DNA binding is due to the large presence of
amines within its structure. The extensive cationic charge density is useful at higher
charge ratios where the overall positive charge encourages interactions with compounds
within the extracellular matrix, therefore enhancing induction of the polyplexes into the
cell.71,73

Figure 1.5. The structure of linear (left) and branched (right) polyethyleneimine.

The structure of PEI is an important factor in its gene transfer efficiency.
Commercially available PEI is composed of primary, secondary, and tertiary amines.
The acid dissociation constant (Ka) of each type of amine is different, meaning only a
partial proportion of the amines are protonated and electrostatically interact with nucleic
acids at physiological pH (7.4). Particularly, tertiary amines remain unprotonated at
physiological pH until they are within lysosomal partitions (pH ~ 4-5). Although still
heavily debated74, this property is believed to attribute to a “proton sponge” effect that
changes the osmolarity of acidic vesicles, resulting in endosomal swelling and rupture.
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Although the high cationic nature of PEI is the main strength, it can also lead to in
vitro and in vivo toxicity. Delivery systems with high cationic charge density like PEI
usually have exposed regions that may interact with macromolecules within the body,
causing toxicity or adverse effects due to immune response, protein agglutination, or
membrane destabilization.67,71 Additional factors affecting cytotoxicity of PEI have been
briefly mentioned in the previous section 1.3.2.d. In order to counterbalance the
undesirable effects of high charge density, PEI can be branched or grafted with
polyethylene glycol, which assist in shielding a portion of the charge without intruding on
polymer‐DNA interactions.75–77

1.3.3.b. Polyesters
Polyesters are non-ionic in character and do not allow for the condensation of
DNA. These polymers have advantages when targeting solid tissues such as tumors
where delivery of condensed DNA can be inadequate.78 Polylactic acid (PLA),
polyglycolic acid (PGA), and their copolymers poly(D,L-lactide-co-glycolide) (PLGA)
have been widely investigated for their use in the delivery of nucleic acids. Although
these polymers contain non-ionic characteristics, they can entrap DNA when complexed
with micelle inducing agents or cationic surfactants.79
Nucleic acids can also be entrapped within a dense sponge-like matrix or gel
without the help of other reagents. PEG‐PLGA‐PEG (Figure 1.6) triblock copolymers
have been produced in order to provide water solubility and maintain the advantageous
characteristics of PLGA copolymers. This hydrophilic-hydrophobic-hydrophilic
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copolymer construct formed a hydrogel in aqueous solutions and presented a matrix in
which plasmid DNA could be implanted and slowly secreted in tissue.80 Poloxamers or
pluronics are hydrophilic‐hydrophobic‐hydrophilic triblock copolymers that utilize
polypropylene glycol (PPO) instead of PLGA (Figure 1.6) and they are tunable based on
the relative ratio of PEG and PPO. Poloxamers are typically used for transfection of solid
tissues because, unlike cationic vectors, they allow for comparatively free movement of
DNA within the intersticial space. In vivo transfection of pluronics have shown moderate
success, but ether linkages are not biodegradable, which may cause tissue damage.81

Figure 1.6. Structures of PEG-PLGA-PEG (left) and PEG-PPO-PEG (right) triblock copolymers.

Due to the non-ionic character of polyesters, DNA condensation cannot occur and
the DNA susceptibility to hydrolysis may cause inefficient gene transfer. In recent years,
modifications of natural and synthetic polyesters have created cationic analogs allowing
for DNA complexation. Poly(β-hydroxyalkanoates) (PHAs) are bacterial polyesters
formed by a variety of bacterial strains. They have been synthetically customized to
create the first cationic PHA, poly(β-hydroxyoctanoate)-co-(β-hydroxy-11-(bis(2hydroxyethyl)-amino)-10-hydroxyundecanoate) (PHON) (Figure 1.7) which can be used
as a plasmid DNA delivery system. PHON was shown to electrostatically bind and
condense DNA into cationic nanoparticles, protecting the plasmid DNA from nuclease
degradation for 30 min. In vitro transfection of PHON/DNA complexes also resulted in
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gene expression of mammalian cells.82 Other such modifications have also been
designed through the grafting of amino groups on the side chains of polyesters.83,84

Figure 1.7. Structure of poly(β-hydroxyoctanoate)-co-(β-hydroxy-11-(bis(2-hydroxyethyl)amino)-10-hydroxyundecanoate) (PHON).

1.3.3.c. Polypeptides/Poly(amino acid)s
As discussed previously, PAAs and polypeptides are similar in polymer
construction but polypeptides contain sequence specificity and have biological roles.
These polymers are widely investigated for their use in the delivery of nucleic acids due
to their polyamide backbone that makes them inherently biodegradable and
biocompatible. The functionality of each amino acid side chain gives rise to various
chemical characteristics that can be utilized for biomedical applications. The most
widely used PAA in gene delivery is poly(L-Lysine) (PLL) (Figure 1.8) because its
terminal side chain contains a protonable primary amine group.
At physiological pH, PLL has a net positive charge due to the relatively high pKa
values (pKa ~9-10) of its amines.85 PLL has been examined at different molecular
weights and shown moderate transfection, due to either aggregation or toxicity.86 The
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cytotoxicity of PLL is directly correlated to the molecular weight of the polymer, where
larger blocks dramatically increase toxicity.87 To enhance in vitro and in vivo gene
transfer via increased complex stability and reduced toxicity, PLL was attached to other
macromolecules, such as PEG.88,89 Recently, PEG has been complemented with
copolypeptides in order to enhance stability biocompatibility of the micelles in in vivo
circulation systems.10,90 Similar to lysine, cationic amino acids like arginine and histidine
have also been integrated into polypeptide structures in order to bind to nucleic acids.91–94

Figure 1.8. Structure of poly(L-Lysine).

1.3.4. Drug Delivery Systems
An immense amount of clinically used drugs are small molecules (≤ 500 g/mol)
that display a short half-life in the blood stream, along with high overall clearance rates.
These low molecular weight drugs normally create a therapeutic effect through
interaction with a given receptor. They can also diffuse quickly into healthy tissues and
become distributed throughout the body. Consequently, only a small amount of the drug
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reaches the target site, lowering the therapeutic efficacy and causing side effects within
other tissues.
Furthermore, conventional administration of drugs (i.e. oral and intravenous) can
require higher drug dosing that is often attributed to the limited solubility of the certain
drugs, where in order to reach a proper therapeutic effect, large concentrations of the drug
need to be administered. In other cases, some therapeutic practices require the repeat
administration of a drug to maintain a sufficient concentration of drug in the circulatory
system to provide a therapeutic action.95 High blood concentrations of drugs can lead to
variabilities of the drug in the bloodstream, which at high enough levels can reach the
toxicological limits and generate adverse reactions.96
All of these drawbacks have lead to the development of new, more efficient
therapeutic strategies with fewer side effects. A number of macromolecular drug
delivery systems have been investigated to avoid these limitations and expand the
prospective of the individual drug. The key goals of these drug delivery applications are
to generate a sustained release of a drug, reduce the quantity of doses necessary to treat
diseases, and to optimize the targeting of tissues through the protection of the drugs from
premature inactivation. Normally when talking about polymer therapeutics, most of
these carriers can be classified as nanoparticulate drug delivery systems or as drug–
polymer conjugates. These systems will be briefly discussed within the next sections.
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1.3.4.a. Drug-polymer conjugates
The utilization of polymers in the design of therapeutics has been extensively
explored for many decades. In 1975, Helmut Ringsdorf proposed a model (Figure 1.9)
for pharmacologically active polymers, where a biocompatible polymer is used as a
backbone or scaffold to hold three vital components. The polymeric backbone is attached
to: 1) a hydrophilic solubilizer, which ensures water solubility and modified
bioavailability, 2) a drug, usually bound via a linker, and 3) a targeting moiety whose
purpose is to provide transportation to a desired physiological or biological target.97

Figure 1.9. Ringsdorf’s model for drug-polymer conjugates for drug delivery systems.

This proposed concept involving covalently bound drug-polymer conjugates is
still the basis for the research work currently being performed in this area because it
allows for precise delivery of therapeutic agents to intended sites of action, while trying
to improve efficacy and minimize toxicity. Numerous adaptations of this “magic bullet”
concept have been developed. For example in Figures 1.10 and 1.11, the progression and
development of novel synthetic polymeric carriers for clinically useful drug-polymer
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conjugates has been limited mainly to poly(N-(2-hydroxypropyl)methacrylamide)
(HPMA) and PEG.98–134

Figure 1.10. Chemical structures of PK1 (left) and PK2 (right) HPMA-derived copolymers used
as antitumor therapeutics.
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Figure 1.11. Chemical structures of PEG-Doxorubicin and PEG-camptothecin drug-polymer
conjugates linked through peptidyl linkers.

1.3.4.b. The Use of Polymer Micelles in Drug Delivery
Micelles are colloidal particles ranging from 5 to 150 nm in size of amphiphilic
molecules. At lower concentrations, these amphiphiles exist as unimers in aqueous
solutions. Conversely, as concentrations are increased, entropically driven processes
allow for the formation of aggregates which isolate hydrophobic regions from the
aqueous environment. Thus, these particles arrange into core like structures that are
encircled by a hydrophilic corona. The concentration at which the onset of aggregation
transpires is commonly known as the critical micelle concentration (CMC). Hydrophobic
drugs can be confined within the inner regions of the micelle due to associations through
hydrophobic interactions, such as Van der Waals forces. The encapsulation of the
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hydrophobic drugs will increase their solubility and lower drug clearance when compared
to the administration of the free drug itself. Nevertheless, following administration of a
given pharmaceutical formulation, dilution will occur and the micelle concentration will
drop below its CMC. At this point, the stability of the micelle will be compromised and
the drug contained within will be released.
Earlier work by Kataoka, Kabanov, and others has illustrated the prospective use
amphiphilic copolymers as drug delivery vehicles.135,136 These polymeric block
copolymer constructs are composed of a hydrophilic and hydrophobic segments that self
assemble in water. Amphiphilic copolymers tyupically consist of diblock or triblock
copolymers. The increased stability of polymeric micelles compared to low molecular
weight surfactants makes these systems more advantageous. Usually, low molecular
weight surfactants have relatively high CMCs of 10-3 to 10-4 M,137 while polymeric
micelles commonly exhibit CMCs in the range of 10-6 to 10-7 M range.138 Superlative
polymeric micelles must exhibit biocompatibility and stability, while demonstrating high
drug loading ability and controllable drug release. Polymeric micelles are largely based
on the physiochemical properties and characteristics, including the lengths of both the
hydrophilic and hydrophobic blocks.
PEG is the most frequently utilized hydrophilic polymer, due to its high hydration
characteristics and resistance to absorbance through the reticuloendothelial system (RES).
Other hydrophilic polymers have also been employed, including poly(vinyl alcohol)
(PVA),139 but PEG still remains the most viable polymer due to its widespread tolerance
within biological systems and availability through large scale production. Numerous
polymers, for example propylene oxide, caprolactone, and styrene, can be used for
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hydrophobic block segments allowing for the formation of the micelle core.140 CMC
sensitivity is shown to be dependent upon the type of hydrophobic unimer and its block
length, with lower CMC values being linked to larger hydrophobicity and hydrophobic
block lengths.81,141
The continuous expansion of polymeric micelles is very important for the growth
of polymer therapeutics. There is a progressive trend towards the development of
“smart” polymeric micelles that respond to a range of biological environments, such as
changes in pH, temperature, and ionic content within tissues and cells that can permit
chemically triggered site-specific drug release from polymeric NPs. An assortment of
hydrophobic drugs have been encapsulated within these micelles and show promising in
vitro data to establish their potential as carriers.142,143

1.4. Polypeptide-Based Therapeutics
Polypeptides or poly(amino acid)s can be applied to a number of different
relevent areas such as biomedicine and biotechnology. The development and increasing
knowledge of peptides and proteins has established a large assortment of biopolymers
whose physical, chemical, and physiological properties are led by their controlled
sequences and composition. These polymer therapeutics have helped to create
polypeptide-based constructs that are used for different applications, such as disease
treatment through gene and drug therapy.
The ability to utilize various amino acids as polymeric building blocks can help
generate homopolymers or hybrid block copolymers with diverse macromolecular
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architectures. These numerous monomeric options allow for the alteration of the final
nanovector system that can be customized for a specific therapeutic application. Specific
characteristics of polypeptides make them excellent candidates for gene and drug
delivery, such as the presence of functional side chain groups that provide hydrophilicity,
hydrophobicity, and ionic charge. For example, poly(L-glutamic acid) (PGA),144 poly(Llysine) (PLL),145,146 and poly(L-aspartate) (poly(Asp))147 have been used as gene and drug
carriers due to favorable features such as biodegradability, biocompatibility, and welldefined structures.

Polypeptides can degrade enzymatically in the presence of specific

proteases (i.e., cathepsin B) to yield small non-toxic metabolites that can be excreted
through natural mechanisms without adverse effects.
Successful peptide-based polymer therapeutics are largely represented by linear
polymers and polymeric nanoparticles or micelles. These structures are composed of
homopolymers, diblock, or triblock copolymers formed overall by particular amino acids.
As discussed beforehand, PAAs are capable of adopting stable conformations and
undergo highly organized nanoscale self-assemblies. Ordered sequences can form
secondary structures (e.g., α-helices and β-sheets) and even tertiary structures148 that can
be liable for the distinct functionality of the biopolymer material.
Polypeptides offer structural entities that provide non-viral vectors for evolving
macromolecular gene therapeutics (e.g., siRNA, oligonucleotides) while improving the
cytosolic delivery and nuclear localization essential for a certain therapeutic result.
PAAs with intrinsic ionic charges on their pendant side chains can complex to oppositely
charged molecules, such as DNA, siRNA, and small molecules, and act as carriers. Most
PAA gene delivery systems are block copolymers that form nanoparticle complexes.
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These nanoparticle structures can encapsulate the free drug or conjugate it to the polymer
backbone.
Kataoka et al. first reported the use of PEG-PLL and PEG-poly(Asp)
systems.149,150 The complexation of anionic PAAs with positively charged proteins is
also possible by taking advantage of electrostatic interactions with PEG-poly(Asp) at
physiological pH. Poly(L-lysine) has shown success in the complexation and favorable
nuclear localization of genetic material.151 Dissociation of complexes containing only
charged moieties can lead to premature release of the drug cargo. By introducing particle
stability through the use of hydrophobic PAAs, such as poly(L-phenylalanine),
copolymerization of poly((L-lysine)-co-(L-phenylalanine)) (PLL-co-PPhe) has shown
endocytic translocation and successive drug release.152
Polypeptides are also clinically investigated for use as cancer drug therapeutics.
Polyglutamate is a highly biocompatible, bifunctional class of polymers that have been
effectively used as both polymer backbones in drug-polymer conjugates and polymeric
micelles for several biomedical uses.153,154 For example, OpaxioTM, a PGA-Paclitaxel
(PTX) conjugate, was developed for the treatment of various cancers including ovarian
and prostate cancer.155 A RGD targeting moiety has also been linked a PGA-PTX
conjugate which considerably improved tumour accumulation and increased anti-tumour
effects.156,157

35

CHAPTER 2

SYNTHESIS OF γ-BENZYL-L-GLUTAMATE, N6-TRIFLUOROACETYL-LLYSINE, L-LEUCINE, N-δ-ISOPROPYL-L-GLUTAMINE, AND N-δ-TRITYL-LGLUTAMINE N-CARBOXYANHYDRIDES

2.1 Introduction
In order to synthesize PAAs, amino acids must be first transformed into activated
NCA monomers. L-amino acids with reactive side chain groups require special attention,
as some reactive groups will interfere with the nucleophilic ROP and disrupt the proper
formation of the desired NCA products. It is important that these side groups are
protected with removable protective groups that can be removed under mild conditions
without main chain cleavage.158
In this study, γ-benzyl-L-glutamate (Bnl-L-Glu), N6-trifluoroacetyl-L-lysine
(TFA-L-Lys), L-leucine (L-Leu), N-δ-isopropyl-L-glutamine (Iso-L-Gln), and N-δ-tritylL-glutamine (Trt-L-Gln) were used in the production of PAAs. A modified FuchsFarthing method of NCA synthesis was utilized for all NCA syntheses.159,160 As
previously discussed, the use of phosgene during NCA monomer synthesis produces
excess HCl which was scavenged by α-pinene. NCAs were synthesized and shown to
possess high purities with yields above ≥ 80%. The NCAs were characterized using 1H
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nuclear magnetic resonance (1H-NMR) spectroscopy and melting points. All NCA
monomers were stored under vacuum to maintain purity.

Figure 2.1. Structures of protected Bnl-L-glutamate NCA, TFA-L-lysine NCA, and Iso-Lglutamine, Trt-L-glutamine, along with L-leucine NCA used to synthesize PAA copolymers.

2.2. Experimental
2.2.1. Materials
All solvents, including ethyl acetate (EtOAc), hexanes, tetrahydrofuran (THF),
were purchased from Fisher Scientific (Waltham, MA). EtOAc and hexanes were
distilled under argon. THF was placed over molecular sieves (3Ǻ) for at least one day
before use and petroleum ether was dried over CaCl2 pellets. The triphosgene was
purchased from Tokyo Chemical Industry Co., LTD. (Tokyo, Japan) and stored in the
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refrigerator at 5°C per the manufacturer’s specifications. Potassium hydroxide (KOH)
was obtained from Fisher Scientific (Waltham, MA). (1S)-(−)-α-pinene 98%, was
purchased from Acros Organics, a part of Thermo Fischer (New Jersey, US). The γbenzyl-L-glutamate, L-leucine, and N-δ-isopropyl-L-glutamine, and N-δ-trityl-Lglutamine were purchased from Bachem (Torrence, CA) and stored at room temperature.
N-δ-trityl-L-glutamine was purchased from Bachem (Torrence, CA) and stored at -15°C.
N6-trifluoroacetyl-L-lysine was purchased from Chem-Impex International (Wood Dale,
IL) and stored in the refrigerator at 5°C. All deuterated solvents were obtained from
Cambridge Isotope Laboratories, Inc. (Tewksbury, MA, USA).

2.2.2. Methods
2.2.2.a. NCA Synthesis of Bnl-L-Glu, TFA-L-Lys, and L-Leu
A modified Fuchs-Farthing method was used for all NCA syntheses. All roundbottom flasks, Schlenk flasks, and stir bars were kept in an 80 ºC oven overnight and
cooled in a dessicator before carrying out the synthesis procedure. A saturated aqueous
solution of KOH was prepared and added to a bubbler. The bubbler was attached via
tygon hose to the top of a grease-sealed condenser to neutralize phosgene gas (Figure
2.2.). Excess phosgene gas reacted with KOH to form potassium chloride, water, and
carbon dioxide. Consumption of phosgene gas was also used as a vector to determine
reaction completion. During the reaction, phosgene gas is being created through
decomposition of triphosgene. Phosgene is bubbled through saturated KOH solution and
once exhausted, a reduction of gas pressure can be observed. Eventually, the lack of
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pressure will cause negative pressure and a rise of the bubbler solution, indicating
minimal phosgene formation and reaction completion unless more triphosgene is added.
In a round-bottom flask, the amino acid was weighed and 6.1 mole equivalents of
α-pinene was added dropwise. Triphosgene (1.5 equiv.) was then dissolved in a minimal
amount of ethyl acetate and subsequently added to the round bottom flask containing the
amino acid solution. Small amounts of ethyl acetate were used to wash the residual
triphosgene from the beaker. Approximately 40 mL of EtOAc was used per 1 gram of
amino acid. The round bottom flask was fitted with a condenser and the reaction was
refluxed at 105-110 ºC until the mixture became transparent. The reaction mixture was
stirred from 2 to 4 hours depending on the α-amino acid used (Table 2.1). The mixture
was cooled and filtered through a glass Buchner funnel that has a frit in order to remove
any unreacted amino acid. The filtrate was concentrated via rotary evaporation under
reduced pressure.
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Figure 2.2. Reaction apparatus and setup for synthesis of Bnl-L-Glu, TFA-L-Lys, and L-Leu αamino acid N-carboxyanhydrides.

Crystallization was performed on the reaction solution by adding in a small
amount (5 mL) of EtOAc. Recurrent dropwise additions of hexanes was used to achieve
the onset of crystallization which will emit cloudiness within the solution The flask was
sealed with a septum and placed in a standard freezer at -20 ºC overnight. Hexanes
additions were repeated three more times over six hours using the equivalent volumes of
hexanes necessary for the initial addition. The crystals were filtered, placed in a Schlenk
flask, and vacuum dried overnight. The dried crystals were then re-dissolved in minimal
EtOAc and a sufficient amount of hexanes was added until cloudiness persisted.
Stoichiometric amounts of solvents can vary relative to the chemical properties of the αamino acid side chains and the protective groups attached to them.
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The solution was filtered into a 250-mL Schlenk flask purged with dry argon gas
and placed into an ice bath and hexane was added until recrystallization occurred. Three
extra aliquots of hexane were used after allowing the crystals to stir in the ice bath for 10
minutes before each addition. After the last addition, the crystals were filtered using a
fritted Buchner funnel stored under vaccum overnight. Dried crystals were characterized
by 1H NMR and melting point analysis.

2.2.2.b. NCA synthesis of Iso-L-Gln and Trt-L-Gln
Trt-L-Gln and Iso-L-Gln act differently than other α-amino acids, therefore
synthesis and characterization are discussed separately. L-glutamine protected with both
a trityl and an isopropyl group were studied in an effort to address solubility challenges.
All glassware was dried and reaction apparatus was set up similarly as shown for the
other amino acids with the addition of an addition funnel (Figure 2.3.). To an oven-dried
round-bottom flask, protected glutamine amino acid (1.0 mol), α-pinene (6.1 mol), and
EtOAc (10 mL) were added and stirred vigorously under reflux for 30 min in a 110 °C oil
bath. In a separate oven-dried beaker, triphosgene (1.5 mol) was dissolved in EtOAc (5
mL). The triphosgene solution was slowly added to the glutamine mixture via an
addition funnel after 30 minutes had elapsed (one drop every five seconds).
Gas evolution was routed through the top of the reflux condenser into a KOH
bubbler. After all of the triphosgene solution was added and cloudiness subsided, the
reaction was stopped after approximately 2 hours. The reaction mixture was filtered
through glass wool into an oven-dried round bottom flask then evaporated to dryness
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using rotary evaporation. The residue was redissolved in minimal THF and the NCA was
precipitated slowly in stirred petroleum ether (90 mL, -20 °C).
The mixture was allowed to stir for 10 min in an ice bath. The supernatant was
decanted and the solid was isolated by centrifugation (2500 rpm, 1.5 min). The pellet
was resuspended in petroleum ether (90 mL, –20 °C); the mixture was allowed to stir for
10 min in an ice bath. The solid was again isolated by centrifugation (3000 rpm, 3 min)
and decantation of the supernatant. A white powder was collected and dried under
vacuum.

Figure 2.3. Reaction apparatus and setup for synthesis of Trt-L-Gln and Iso-L-Gln α-amino acid
N-carboxyanhydrides.
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2.3. Results and Discussion
Each of the α-amino acid NCA was synthesized by a modified Fuchs-Farthing
method, described above. 1H nuclear magnetic resonance (1H-NMR) analysis was used to
verify the formation of NCAs. 1H NMR spectra were acquired on a Varian Unity Inova
500 MHz instrument equipped with a 5 mm Penta (H,C,N,P,D) PFG VT probe. Each
NCA sample was dissolved at a concentration of ~5 mg/mL. Spectra were taken 25°C
with 32 scans and a 2 second relaxation delay time. NCAs need to be synthesized to
exceptional purity for later use in living ring-opening polymerization. Product yields
(Table 2.1) from the procedures discussed below were verified to be greater than 80%
with relatively short reaction times.

Table 2.1. Physical properties of α-amino acids and NCA reaction conditions and results.
Amino
Acid
(AA)

AA Mw
(g/mol)

NCA
Mw
(g/mol)

Rxn
Solvent

Rxn
Time
(hrs)

AA
Starting
Weight
(g)

Theoretical
Yield (g)

Actual
Yield
(g)

Percent
Yield

Bnl-LGlu

237.26

265.26

EtOAc

3

1.0

1.118

0.897

80.2%

TFA-LLys

242.20

270.20

EtOAc

4

1.0

1.116

0.953

85.4%

L-Leu

131.17

157.17

EtOAc

2

1.0

1.198

1.080

90.1%

Iso-LGln

188.23

216.23

EtOAc

2

0.1

0.115

0.094

81.5%

Trt-LGln

388.47

416.47

EtOAc

2

0.2

0.214

0.178

83.2%

43

The synthesis of Bnz-L-Glu, TFA-L-Lys, L-Leu, Iso-L-Gln, and Trt-L-Gln NCAs
took 2-4 hours. At these time intervals, the reactions became clear showing cyclic
formation of NCAs. The clarity of the solution at low time points revealed that the amino
acids exhibited optimal reactivity with phosgene and allowed for high yields. The N6TFA-L-Lys required a longer reaction time when compared to γ-benzyl-Lglutamate.
Nevertheless, this abnormality did not affect yield or purity shown within its 1H-NMR.

2.3.1. 1H-NMR Characterization of Bnl-L-Glu, TFA-L-Lys, and L-Leu NCAs
Spectra of Bnl-L-Glu (Figure 2.4), TFA-L-Lys (Figure 2.5), and L-Leu (Figure
2.6) NCAs were taken at 25°C with 32 scans and a 2 second relaxation delay time. BnlL-Glu was dissolved in both DMSO-d6 and deuterated chloroform (CDCl3) due to the
overlap of sample and solvent peaks. The downfield chemical shift of the proton on the
amino acid chiral carbon from ~3.0 ppm to ~4.39-4.46 ppm confirmed ring formation.
This proton shift is a result of the addition of a carbonyl electron-withdrawing group next
to the α-amine upon ring closure. The carbonyl carbon will pull electrodensity away
from the NH group within the ring, allowing for the deshielding of the chiral carbon
proton. The signals at 9.04 ppm, and 9.07 ppm, respectively, also illustrate the formation
of an amide not seen in the amino acid due to NCA ring formation.
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Figure 2.4. The 1H NMR spectrum (500 MHz) of γ-benzyl-L-Glu NCA in DMSO-d6 (top) and
CDCl3 (bottom).

Gamma-benzyl-L-glutamate NCA (Bnl-L-Glu NCA). 1H NMR (DMSO-d6, 500
MHz): δ/ppm = 2.04 and 2.05 (2H, CH-CH2-CH2), 2.62 (2H, -CO-CH2-CH2), 4.47 (1H, 45

CO-CH-NH-), 5.10 (2H, -O-CH2-C6H5), 9.04 (1H, -OC-NH-CH) and in CDCl3 (bottom),
δ/ppm = 2.14 and 2.29 (2H, CH-CH2-CH2), 2.62 (2H, -CO-CH2-CH2), 4.39 (1H, -COCH-NH-), 5.16 (2H, -O-CH2-C6H5), 6.37 (1H, -OC-NH-CH), 7.37 (2H, -O-CH2-C6H5).

Figure 2.5. The 1H NMR spectrum of TFA-L-Lys NCA in DMSO-d6.

N6-trifluoroacetyl-L-lysine NCA (TFA-L-Lys). 1H NMR (DMSO-d6, 500 MHz):
δ/ppm = 1.25-1.35 (2H, -CH2-CH2-NH), 1.50 (2H, -CH2-CH2-CH2-), 1.67−1.72 (2H, CH-CH2-CH2), 3.17 (2H, -CH2-CH2-NH-), 4.43 (1H, -CO-CH-NH-), 9.04 (1H, -CONH-CH-), 9.35 (1H, -CH2-NH-CO-).
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Figure 2.6. The 1H NMR spectrum of L-Leu NCA in DMSO-d6.

L-Leucine NCA (L-Leu NCA). 1H NMR (DMSO-d6, 500 MHz): δ/ppm = 0.870.90 (6H, (CH3)2-), 1.55-1.58 (2H, -CH2-CH-(CH3)2), 1.73-1.74 (1H, -CH-(CH3)2), 4.434.46 (1H, -CO-CH-NH-), 9.07 (1H, -CO-NH-CH-).

2.3.2. Characterization of N-δ-Isopropyl-L-Gln and N-δ-Trityl-L-Gln NCAs
The synthesis and characterization of L-glutamine NCAs and polymers seems to
be difficult based on the minimal amount of historical literary references. To further this
discussion, the synthesis and characterization N-δ-isopropyl-L-Gln and N-δ-trityl-L-Gln
NCAs were attempted.
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2.3.2.a. 1H-NMR of N-δ-Isopropyl-L-Gln NCA
Synthesis of N-δ-Isopropyl-L-Gln NCA was confirmed by first comparing the
proton chemical shifts against the α-amino acid itself, Figures 2.7 and 2.8. The change of
chemical shift of the chiral carbon from 3.57 ppm to 4.46 ppm is indicative of NCA
formation. NCA purification needs to be carefully considered due to solubility
differences of amino acids containing different protecting groups. Removal of impurities
is accomplished by multiple recrystallization steps in large volumes of petroleum ether
(~90 mL) at -20 °C. The NCA spectrum was shown to be clean and all peaks are sharp,
the integration ratios are in agreement with the correct NCA structure. The spectrum
shows a definitive production of isopropyl protected glutamine NCA with no indication
of contamination by α-pinene.

Figure 2.7. The 1H NMR spectrum of N-δ-Isopropyl-L-Gln amino acid in methanol-d4.
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N-δ-Isopropyl-L-Gln amino acid (Iso-L-Gln). 1H NMR (methanol-d4, 500 MHz):
δ/ppm = 3.94 ppm (1H, (CH3)2-CH-), 3.57 ppm (1H, -CO-CH-NH2), 2.38 ppm (2H, -COCH2-CH2), and 2.08 ppm (2H, -CH-CH2-CH2-).

Figure 2.8. The 1H NMR spectrum of N-δ-Isopropyl-L-Gln NCA in DMSO-d6.

N-δ-Isopropyl-L-Gln NCA (Iso-L-Gln NCA). 1H NMR (DMSO-d6, 500 MHz):
δ/ppm = 1.88-1.95 (2H, -CH-CH2-CH2-), 2.12 (2H, -CO-CH2-CH2), 3.79 (1H, (CH3)2CH-), 4.46 (1H, -CO-CH-NH-), 7.72 (1H, -CO-NH-CH-(CH3)2), 9.02 (1H,
-CO-NH-CH-).
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2.3.2.b. Heteronuclear Multiple Bond Correlation (HMBC) NMR of N-δ-IsopropylL-Gln NCA
Synthesis of N-δ-Isopropyl-L-Gln NCA was also investigated through
heteronuclear multiple bond correlation (HMBC). HMBC provides information on long
range correlations of carbons bonded to protons which are 2-3 bonds away. The splitting
of signals into multiples indicates that that carbon is directly coupled to that hydrogen.
The HMBC spectrum for the Iso-L-Gln NCA can be seen in Figure 2.9.
The HMBC spectrum of N-δ-Isopropyl-L-Gln (Figure 2.9) gave an absolute
indication of N-δ-Isopropyl-L-Gln NCA synthesis. Both carbonyl carbons (labeled 1 and
2) within the NCA ring showed long range correlations with the downfield shifted chiral
carbon (b; δ/ppm = 4.50) and the newly formed amide group (a; δ/ppm = 9.02). This
would not be possible if these groups were not connected between multiple bonds.
Carbonyl-carbon (2) within the NCA also showed a long range connection to the protons
in the alkyl chain (c and d), whereas carbonyl carbon (1) does not show these couplings
as the distance, i.e. number of bonds, is too large, respectively. The functionalities
display these correlations because they are within the same cyclic structure due to NCA
formation. To the best of our knowledge, this is the first known synthesis, purification,
and production of N-δ-Isopropyl-L-Gln NCA.
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Figure 2.9. The HMBC spectrum of Nδ-Isopropyl-L-Gln NCA in DMSO-d6, 500 MHz.

2.3.3.c 1H-NMR of N-δ-Trityl-L-Gln NCA
Similar to Iso-L-Gln, the synthesis of Trt-L-Gln NCA was confirmed through the
chemical shift of the chiral carbon (2) at 4.33 ppm as seen in Figures 2.10. The signals at
9.03 ppm (1) also illustrates the formation of an amide seen due to NCA formation.
Methylene protons (3 and 4) located in the side chain are also shown at 1.81-1.88 ppm
and 2.36-2.42 ppm, respectively, while the trityl hydrogens located on the protecting
group are found at 7.15-7.28 ppm.
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Figure 2.10. The 1H NMR spectrum of N-δ-Trityl-L-Gln NCA in DMSO-d6.

N-δ-Trityl-L-Gln NCA (Trt-L-Gln NCA). 1H NMR (DMSO-d6, 500 MHz): δ/ppm
= 1.81-1.88 (2H, -CH-CH2-CH2-), 2.36-2.42 (2H, -CO-CH2-CH2), 4.33 (1H, -CO-CHNH-), 7.15-7.28 (15H, -CO-NH-C-(C6H5)3), 8.66 (1H, -CO-NH-C-(C6H5)3), 9.03 (1H, CO-NH-CH-)
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CHAPTER 3

SYNTHESIS AND CHARACTERIZATION OF AMINE INITIATED
PEGYLATED BLOCK AND RANDOM POLY(AMINO ACID)S THROUGH
LIVING POLYMERIZATION

3.1. Introduction
This study focused on the synthesis of block and random PEGylated poly(amino
acid)s through living ring-opening polymerization (LROP) using N-carboxyanhydrides
(NCAs) of L-leucine, γ-benzyl-L-glutamate (Bnl-L-Glu), N6-trifluoroacetyl-L-lysine
(TFA-L-Lys), N-δ-Isopropyl-L-glutamine (Iso-L-Gln), and N-δ-Trityl-L-glutamine (TrtL-Gln). Polymers synthesized by living polymerization are classified as having a polydispersity index (PDI) close to unity (PDI = 1) and yields greater than 90%. Lower PDI
values ensure monodispersity of a polymer population.
As discussed in Chapter 1, polymerizations of PAAs via LROP follow one of
three common mechanisms: amine, carbamate, and activated monomer mechanisms. For
this project, the amine mechanism predominates due to the utilization of an aminoterminal macroinitiator α-methoxy-ω-amino PEG (mPEG-NH2) and n-hexylamine (HexNH2) (Figure 3.1). The mechanism for the syntheses of PEGylated PAA tercopolymers,
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using mPEG-NH2 as the initiator, are shown in Scheme 1.5. PEGylated poly(amino acid)
random and block tercopolymers were synthesized, at a variety of lengths and amino acid
monomer feed ratios.

Figure 3.1. Functionalized derivative α-methoxy-ω-amino PEG (mPEG-NH2) macroinitiator and
n-hexylamine (Hex-NH2).

Specific amino acids used within this project contain reactive side chains.
Protection of these amino acid side groups is required to prevent unwanted side reactions.
For these PAAs to be beneficial in chosen biological applications, deprotection of these
protected PAA side chains regenerates the ionic side groups.
PEGylated-PAA copolymers characterized using gel permeation chromatography
(GPC), infrared spectroscopy (IR), and proton nuclear magnetic resonance (1H- NMR).
GPC results indicate monodispersity based on low molecular weight distributions,
although aggregation can occur at higher levels of hydrophobicity. Proton and infrared
spectra indicate that the appropriate length and molecular weight of desired PAAs have
been achieved.
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3.2. Experimental
3.2.1. Materials
N,N-Dimethylformamide (DMF), tetrahydrofuran (THF), petroleum ether (35/60),
urea, and Drierite™ were purchased from Fisher Scientific (Waltham, MA). Dialysis
bags (Spectrum™ Labs Spectra/Por™ 6 3500 D MWCO Standard RC) were purchased
from Thermo Scientific (Waltham, MA). The DMF was distilled under argon and stored
over 3Å molecular sieves to prevent water contamination prior to use. Argon gas was
purchased from Airgas (Huntsville, AL) and passed through a desiccator trap containing
Drierite™ to remove any water vapor from the argon gas prior to entering the reaction
vessel. α-Methoxy-ω-amino PEG (mPEG-NH2 5k Da) was purchased from Laysan Bio
(Huntsville, AL), and stored at -20°C per the manufacturer’s instructions. n-Hexylamine
was purchased from Sigma-Aldrich (St. Louis , Mo) All deuterated solvents were
obtained from Cambridge Isotope Laboratories, Inc. (Tewksbury, MA, USA). Activated
NCA monomers of Bnl-L-Glu, TFA-L-Lys, L-Leu, Iso-L-Gln, and Trt-L-Gln were
synthesized immediately prior to polymer synthesis (See Section 2.2.2.a).

3.2.2. Synthetic Methods
3.2.2.a. Ring Opening Polymerization of PEGylated Block Tercopolymers
All glassware, including Schlenk flasks, were heated in an oven to 80 °C and
cooled in a dessicator before use. Urea was ground using a mortar and pestle to increase
surface area in order to facilitate drying and remove any trace moisture. The necessary
amount of urea was weighed to achieve a final concentration of 0.2 M in DMF. The urea
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was placed in a clean, dry 50- mL Schlenk flask. The mPEG-NH2 initiator was weighed
to achieve the appropriate monomer/initiator feed ratio for the desired composition and
was placed in a clean, dry 50-mL Schlenk flask. Urea and mPEG initiator were dried
under vacuum overnight using a vacuum line.
The urea was then dissolved in accurate amounts of distilled DMF to give a
concentration of NCA at 0.1 M. The urea mixture was degassed under vacuum for 5
minutes or until bubbling subsides. The flask containing mPEG-NH2 was flushed with
argon and a small aliquot (~2 mL) of urea/DMF solution was added. Minimal heat from
a heat gun was applied to completely dissolve the mPEG-NH2. The mPEG
NH2/urea/DMF mixture was degassed for an additional 5 minutes. The remainder of
urea/DMF mixture was used to dissolve the first NCA under argon.
The initiator solution was quickly injected under argon via syringe to the
dissolved NCA to initiate the reaction. The polymerization was conducted for several
days at 25 ºC, while periodically (≥ 2 times a day) monitoring CO2 production through
back pressure in a Schlenk line. After CO2 production was checked, the sample was
purged of CO2 and replaced with argon. This process was used to indirectly determine
the completion of the polymerization based on pressure as well as drive the reaction
equilibrium towards polymer production. The reaction is complete when the gas
evolution and pressure ceases.
When synthesizing the block copolymers, one must allow the PEGylated diblock
copolymer to completely polymerize prior to addition of the NCAs used to create the
third block. The second α-amino acid NCA was stored in a Schlenk flask and placed
under vacuum until needed.
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Once the first polymerization step was complete, the second NCA was added
under argon to the reaction flask containing the diblock copolymer. The flask was then
purged and replaced with argon. The second polymerization step was conducted for
several more days until the gas evolution and pressure stopped, indicating that the second
monomer was completely consumed (Scheme 3.1).
After the polymerization of the third block, the polymer reaction solution was
transferred to a round-bottom flask and the solvent was reduced and concentrated through
evaporation in vacuo. THF (~ 40-50 mL) was added to the concentrated solution and
stirred for 2 hours to recrystallize the urea. The solution was then filtered through a
medium-fritted filter in order to dispose of urea. The precipitate was dissolved in a small
amount of water to ensure only urea was obtained. The filtrate was concentrated to 2-4 mL,

placed into a dialysis bag, and suspended overnight in 4 L of deionized water using a
Spectra/Por CE membrane (MWCO: 3,500 g mol-1). The next day, water was replaced
with fresh deionized water and this process was repeated a total of 3 times. This allows for

the removal of any remaining urea, DMF, or THF.
Polymer was then rinsed from the dialysis bag into a pre-weighed beaker using
deionized water. The contents within the bag were flash frozen with liquid nitrogen and
the polymer was isolated through lyophilization. The resulting polymer product was
stored under vacuum until needed.
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Scheme 3.1. Ring opening polymerization of block PEGylated tercopolymer using Bnl-L-Glu,
TFA-L-Lys, and L-Leu NCA.

3.2.2.b. Ring Opening Polymerization of PEGylated Random Tercopolymers
The synthetic method and conditions for PEGylated random tercopolymers were
the same as described in section 3.2.2.a., except, both monomers were added
simultaneously.

Scheme 3.2. Ring opening polymerization of random PEGylated tercopolymer using Bnl-L-Glu,
TFA-L-Lys, and L-Leu NCA.

3.2.2.c. Deprotection of PEGylated Cationic Block and Random Copolymers
A stir bar and 100 mg of polymer were added to a 50-mL round bottom flask. A
9:1 methanol to water mixture (20 mL) was added to the flask and the polymer was
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allowed to stir for an hour. K2CO3 (120 mg) was placed into the flask the solution was
heated to between 60-70 ºC for a total of 3-4 hours or until clear. After completion, the
solution was directly transferred into a dialysis bag with a molecular weight cut-off of
3,500 Da. The solution was then dialyzed against 4 L deionized water overnight, water
was replaced three more times in four hour increments. The contents inside the bag was
frozen with liquid nitrogen and placed within a pre-weighed beaker and lyophilized. The
dried polymer was stored under vacuum until use.

Scheme 3.3. Deprotection of cationic PEGylated tercopolymers using TFA-L-Lys.

3.2.2.d. Deprotection of PEGylated Anionic Block and Random Copolymers
The procedure was the same as in section 3.2.2.c., with the significant difference
of the solvent composition, which here was 9:1 H2O/MeOH at 0.28 M K2CO3. The
solvent solution containing mainly water is important to prevent transesterification with
alcohol.

59

Scheme 3.4. Deprotection of anionic PEGylated tercopolymers using Bnl-L-Glu.

3.2.2.e. Ring Opening Polymerization of Hex-b-(Trt-L-Gln)x Copolymers
The polymerization of N-δ-isopropyl-L-glutamine NCA, using n-hexylamine as a
macroinitiator, was performed under the same setup as the tercopolymers discussed in
section 3.2.2.a, however a stock solution of freshly distilled n-hexylamine in DMF was
prepared before each polymerization. The stock solution was stirred moderately for 5
min. An aliquot of the stock solution was quickly added to a stirring NCA/urea/DMF
mixture to initiate polymerization as previously described in section 3.2.2.a. The amount
of urea being used was increased to obtain a concentration of approximately 0.3 M in
order to increase solubility and minimize aggregation of the polymer products. This will
ensure that monomer incorporation is maximized.

3.2.2.f. Ring Opening Polymerization of Hex-b-(Iso-L-Gln)x and PEG-b-(Iso-L-Gln)
Copolymers
As discussed in section 3.2.2.e., the same general procedure was followed for the
ring opening polymerization with n-hexylamine and mPEG-NH2 (Mw = 5,000 Da) as the
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initiators. mPEG-NH2 and n-hexylamine initators were dissolved in minimal amount (3
mL) of urea/DMF reaction solution before being quickly added to the reaction flask.

3.2.3. Characterization Methods
3.2.3.a. Nuclear Magnetic Resonance (NMR) Characterization
The samples of purified PEGylated PAA tercopolymers and amine-initiated PAA
products were dissolved in deuterated trifluoroacetic acid (TFAA-d) and dimethyl
sulfoxide (DMSO-d6), respectively, at a concentration of 5 mg/mL. Proton nuclear
magnetic resonance 1H-NMR experiments were carried out using a Varian Unity Inova
500 MHz spectrometer equipped with a 5 mm Penta (H,C,N,P,D) PFG VT 98 probe.
All experiments were performed at 25 °C at 32 scans with a 25 second relaxation delay.

3.2.3.b. Infrared (IR) Spectroscopy Characterization
PEGylated PAA tercopolymers were characterized qualititatively through IR
spectroscopy. Attenuated total reflection fourier transform infrared spectroscopy (ATRFTIR) was performed on solid PEGylated PAAs. Each ATR-FTIR experiment was
carried out using a Perkin Elmer Spectrum 2 IR Spectrometer equipped with an UATR
two attachment.
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3.2.3.c. Gel Permeation Chromatography (GPC) Characterization
The purified PEGylated PAA tercopolymers were characterized by GPC in order
to determine polydispersity. Each PEG-b-PAA1-b/co-PAA2 was dissolved in 0.1 M LiBr
in dimethylformamide by vortexing. Slight heating was used if necessary. All samples
were passed through a 0.45 μm polyvinylidene difluoride (PVDF) syringe filter before
they were put into sample vials. Each sample was injected into a Waters 1515 High
Pressure Liquid Chromatography (HPLC) system equipped with a Waters 2414
Refractive Index detector. Tosoh TSK-Gel® Alpha-M and Alpha-3000 columns were
used at a flow rate of 0.45 mL/min at 50 °C. The system was calibrated with
monodisperse polystyrene samples of various molecular weights (1,131, 3.370, 13,900,
30,200, 55,100 g·mol-1) (Showa Denko, Tokyo, Japan) preceding sample injection. The
Waters Breeze software (version 3.30) was used for data analysis.

3.2.3.d. Thermal Gravimetric Analysis (TGA)
Thermal gravimetric analysis (TGA) was performed using Q500 TGA (TA
Instruments, New Castle, DE) by placing the sample in a platinum pan and purging with
nitrogen at a rate of 30.0 mL/min. The instrument was calibrated using calcium oxalate
monohydrate standard using the procedure provided by the instrument manufacturer.
Samples were tested by taking the mass reading from the micro-balance during the
temperature ramping to 600 °C at a rate of 20 °C/min. The results were plotted and
analyzed using TA Instruments Universal Analysis 2000 package.
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3.3. Results and Discussion
In this project, the application of living ring opening polymerization using a
nucleophilic initiator has permitted successful synthesis of a variety of PEGylated and
amine initiated poly(amino acid)s that allows for control over PAA architecture. The
methods discussed previously enabled for the production of random and block
copolymers of desired molecular weight as determined by 1H NMR, containing an
acceptable number of repeat units based on the monomer to initiator feed ratio.

3.3.1. 1H-NMR Analysis of α-methoxy-ω-amino Polyethylene Glycol
The methoxy-PEG-amine (mPEG-NH2) (Mw = 5,000) was characterized in
chloroform-d (CDCl3) prior to its use as a polymerization initiator. In PEGylated PAAs,
the determined molecular weight and length of the mPEG-NH2 initiator was used as
reference standard to normalize the integrations of the poly(amino acid) polymer unit
peaks in subsequent 1H-NMR experiments. The integration was determined by
normalizing the methoxy -CH3 end group (a) of mPEG-NH2 to 3 at 3.38 ppm. End-group
analysis of the mPEG-NH2 indicated that ethylene oxide main chain yielded an
integration of approximately 518 protons at 3.64 ppm (b) (Figure 3.2). The identical
batch of initiator was used for all polymerizations, therefore the integration of the PEG
main chain was utilized to define the composition of each PEG-PAA polymer.
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Figure 3.2. 1H NMR spectrum of α-methoxy-ω-amino PEG macroinitator (Mw = 5,000 Da) used
for ROP of α-amino acid NCAs.

3.3.2. 1H-NMR and IR Analysis of Protected Cationic PEG-b-(PAA1)x-b/co-(PAA2)y
Tercopolymers
Using the procedures above (Sections 3.2.2.a. and 3.2.2.b.), protected PEGylated
cationic PAAs were synthesized. The 1H-NMR spectra shown in Figures 3.3-3.5 confirm
the synthesized PEG-b-p(TFA-L-Lys)40-b-p(L-Leu)10, PEG-b-p(L-Leu)10-b-p(TFA-LLys)40, and PEG-b-p((L-Leu)10-co-(TFA-L-Lys)40) tercopolymers. Each purified
tercopolymer was dissolved in deuterated TFAA and immediately analyzed.
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Figure 3.3. 1H NMR spectrum of PEG-b-p(TFA-L-Lys)42-b-p(L-Leu)12.

Poly(ethlyene glycol)-block-poly(N6-trifluoroacetyl-L-lysine)x-block-poly(Lleucine)y (PEG-b-p(TFA-L-Lys)x-b-p(L-Leu)y). 1H NMR (TFAA-d, 500 MHz): δ/ ppm =
1.06-1.11 (6H, (CH3)2-), 1.78 (2H, -CH2-CH-(CH3)2), 1.84-1.85 (1H, -CH-(CH3)2), 2.012.06 (2 H, -CH2-CH2-CH-), 3.61 (2H, -CH2-NH-CO-), 3.71 (3H, CH3-O-), 4.05 (4H, -OCH2-CH2-), 4.74 (1H, -CO-CH-NH-), 4.82 (1H, -CO-CH-NH-), 7.71 (1H,
-CH2-NH-CO-).
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Figure 3.4. 1H NMR spectrum of PEG-b-p(L-Leu)12-b-p(TFA-L-Lys)43.

Poly(ethlyene glycol)-block-poly(L-leucine)x-block-poly(N6-trifluoroacetyl-Llysine)y (PEG-b-p(L-Leu)x-b-p(TFA-L-Lys)y). 1H NMR (TFAA-d, 500 MHz): δ/ ppm =
1.06-1.11 (6H, (CH3)2-), 1.78 (2H, -CH2-CH-(CH3)2), 1.84-1.85 (1H, -CH-(CH3)2), 2.012.07 (2 H, -CH2-CH2-CH-), 3.62 (2H, -CH2-NH-CO-), 3.72 (3H, CH3-O-), 4.06 (4H, -OCH2-CH2-), 4.74 (1H, -CO-CH-NH-), 4.82 (1H, -CO-CH-NH-), 7.72 (1H,
-CH2-NH-CO-).
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Figure 3.5. 1H NMR spectrum of PEG-b-p((L-Leu)14-co-(TFA-L-Lys)45).

Poly(ethlyene glycol)-block-poly((L-leucine)x-copolymer-poly(N6-trifluoroacetylL-lysine)y) (PEG-b-p(L-Leu)x-co-p(TFA-L-Lys)y). 1H NMR(TFAA-d, 500 MHz): δ/ ppm
= 1.05-1.11 (6H, (CH3)2-), 1.78 (2H, -CH2-CH-(CH3)2), 1.83-1.84 (1H, -CH-(CH3)2),
2.00-2.06 (2 H, -CH2-CH2-CH-), 3.60 (2H, -CH2-NH-CO-), 3.72 (3H, CH3-O-), 4.05 (4H,
-O-CH2-CH2-), 4.75 (1H, -CO-CH-NH-), 4.84 (1H, -CO-CH-NH-), 7.72 (1H,
-CH2-NH-CO-).
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The peak at 4.05 ppm (2) corresponds to the peak for the mPEG-NH2 ethoxy
repeat unit determined from the proton spectrum of the initator in TFAA-d. This
integration was set to 518 to normalize the spectrum. Integrations of other corresponding
peaks after normalization represent the number of protons per mPEG group, consequently
giving the number of repeat units of each α-amino acid group found within the
tercopolymer. The methoxy end group of mPEG-NH2 was integrated at 3.80 ppm to
ensure that the normalized of PEG repeat units was accurate by obtaining an integration
value around 3.
The peak at 4.75 ppm represents the methine group found within the p(L-Lys)
polymer back bone. The integrations of roughly 42-43 indicates an L-Lys repeating unit
of 42-43 groups. The peak at 3.62 ppm corresponds to the methylene group next to the
amide protected L-Lys side chain group. With an integration of roughly 93-96, this
suggests 45 total repeat L-Lys units considering 2 identical protons for each ethyl group.
Due to the slight broadness of this peak, it was used to compare intergations with the
methine peaks within the same group. The L-Leu methine peak gives a signal at 4.84
ppm with an integration of 11-13. The peak corresponding to the methyl groups found on
L-Leu appears at 1.06-1.11 ppm with an integration ratio of 70-76. Considering this group
contains six protons, 12 repeat units of L-Leu was achieved.

The number of each type of repeat unit can be decided by the methine protons
from each α-amino acid backbone. The comparison of these protons with the side chain
protons of each α-amino acid group shows that the number of monomer units was
accurately determined and correctly obtained for the desired polymer constructs. With a
composition objective of 10 and 40 repeat units for L-Leu and TFA-L-Lys, respectively,
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the synthetic procedure used here led to an accurate composition based on the
monomer:initiator (M:I) feed ratio.
Infrared spectra of protected PEG-b-p(TFA-L-Lys)40-b-p(L-Leu)10, PEG-b-p(LLeu)10-b-p(TFA-L-Lys)40, and PEG-b-p((L-Leu)10-co-(TFA-L-Lys)40) tercopolymer
constructs were obtained to provide an example of qualitative characterization of the
tercopolymer components. In Figure 3.6, the peaks at 3289 cm-1, 1652 cm-1, and 1544
cm-1 represent the amide N-H stretching, C=O stretching, and amide N-H bond bending
found within the polymer backbone, respectively. Peaks at 2877 cm-1 and 1102 cm-1
occur due to the alkane C-H stretching of the side chains and C-O stretching within the
PEG segment. More importantly, the peak at 1705 cm-1 is representative of the
trifluoroacetyl protecting group located on the amino side chain of the p(TFA-L-Lys)
components.
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Figure 3.6. Infrared spectrum overlay of PEG-b-p(TFA-L-Lys)40-b-(L-Leu)10, PEG-b-p(L-Leu)10b-(TFA-L-Lys)40, and PEG-b-p((L-Leu)10-co-(TFA-L-Lys)40) tercopolymers.

All protected tercopolymers were examined as discussed above and results
displayed accurate incorporation of each desired PAA segment with suitable yields, as
seen in Table 3.1. The molecular weights and yields were calculated based upon
theoretically proposed polymer chain lengths provided prior to NMR characterization.
The PAA theoretical yields are calculated based on monomer/initiator feed ratios desired
to yield the degree of polymerization (

) quantified for each polymer sample listed in

Table 3.1. Actual molecular weights are derived from experimental 1H-NMR data. All
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other 1H-NMR for each protected cationic tercopolymers not shown are located in
Appendix A; Figures A.1-A.6.
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Table 3.1. Experimental data for polymer composition, molecular weights, and product yields for
protected cationic tercopolymers. *All samples were synthesized at room temperature and overall
polymer composition and molecular weights were calculated by 1H-NMR.

Tercopolymer

PEG/TFA-L-Lys
NCA/L-Leu NCA
feed ratio

PEG/TFA-LLys/L-Leu
ratio actual
composition

Mw (Da)
(actual)

Theoretical
Yield [g]

Actual
Yield [g]

%
Yield

PEG-b-p(TFAL-Lys)40-b-p(LLeu)10

1:40:10

1:42:12

15,800

0.4951

0.4566

92

PEG-b-p(TFAL-Lys)20-b-p(LLeu)10

1:20:10

1:22:12

11,300

0.7090

0.6354

90

PEG-b-p(TFAL-Lys)20-b-p(LLeu)20

1:20:20

1:23:23

12,800

0.8010

0.7132

88

Tercopolymer

PEG/L-Leu
NCA/TFA-L-Lys
NCA feed ratio

PEG/LLeu/TFA-LLys ratio
actual
composition

Mw (Da)
(actual)

Theoretical
Yield [g]

Actual
Yield [g]

%
Yield

PEG-b-p(LLeu)10-bp(TFA-L-Lys)40

1:10:40

1:12:43

16,000

0.5021

0.4499

90

PEG-b-p(LLeu)10-bp(TFA-LLys)20)

1:10:20

1:14:24

12,000

0.7511

0.6378

85

PEG-b-p(LLeu)20-bp(TFA-L-Lys)20

1:20:20

1:24:23

13,000

0.8081

0.7067

88

Tercopolymer

PEG/L-Leu
NCA/TFA-L-Lys
NCA feed ratio

PEG/LLeu/TFA-LLys ratio
actual
composition

Mw (Da)
(actual)

Theoretical
Yield [g]

Actual
Yield [g]

%
Yield

PEG-b-p((LLeu)10-co(TFA-L-Lys)40)

1:10:40

1:14:45

16,700

0.5233

0.4720

90

PEG-b-p((LLeu)10-co(TFA-L-Lys)20)

1:10:20

1:13:22

11,400

0.7159

0.6513

91

PEG-b-p((LLeu)20-co(TFA-L-Lys)20)

1:20:20

1:23:22

12,600

0.7869

0.7282

93
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3.3.3. 1H-NMR and IR Analysis of Deprotected Cationic PEG-b-(PAA1)x-b/co(PAA2)y) Tercopolymers
After polymer synthesis, these tercopolymers were deprotected using the
procedure described in section 3.2.2.c. in order to expose their functional side chains that
provide the ionic character needed for biological and therapeutic purposes. Side chain
derivatization utilizing amide protecting groups may require harsh conditions to enable
their removal, which can lead to degradation of the PAA backbone. However, using the
N-trifluoroacetyl (TFA) protecting group is an exception, as it can be removed by base
hydrolysis in organic solvent from primary and secondary amines within relatively short
times. This feature is very useful for deprotection of poly(L-lysine) protected with TFA.
Table 3.2 summarizes the deprotection product yields of random and block
cationic tercopolymers. Yields were calculated based upon polymer chain lengths prior
to deprotection, allowing for the estimation of product yield of each deprotected polymer
product. 1H-NMR and IR experiments were conducted to observe the removal of the
trifluoroacetyl protective groups from the PEGylated cationic poly(L-lysine) chains.
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Table 3.2. Experimental data for polymer composition, molecular weights, and product yields for
cationic tercopolymers after deprotection. *All samples were deprotected at 60-70 °C and overall
polymer composition and molecular weights were calculated by 1H-NMR.

Tercopolymer

PEG/L-Lys
NCA/L-Leu
NCA feed
ratio

PEG/L-Lys/LLeu ratio
actual
composition

Mw (Da)
(actual)

Theoretical
Yield [g]

Actual
Yield [g]

%
Yield

PEG-b-p((LLys)40-b-p(LLeu)10)

1:40:10

1:42:12

11,800

0.0784 g

0.0704 g

90

PEG-b-p((LLys)20-b-p(LLeu)10)

1:20:10

1:22:12

9,200

0.0983 g

0.0881 g

90

PEG-b-p((LLys)20-b-p(LLeu)20)

1:20:20

1:23:23

10,600

0.0835 g

0.0792 g
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Tercopolymer

PEG/L-Leu
NCA/L-Lys
NCA feed
ratio

PEG/L-Leu/LLys ratio
actual
composition

Mw (Da)
(actual)

Theoretical
Yield [g]

Actual
Yield [g]

%
Yield

PEG-b-p((LLeu)10-b-p(LLys)40)

1:10:40

1:12:43

11,900

0.0725 g

0.0704 g

97

PEG-b-p((LLeu)10-b-p(LLys)20)

1:10:20

1:14:24

9,700

0.0983 g

0.0814 g

83

PEG-b-p((LLeu)20-b-p(LLys)20)

1:20:20

1:24:23

10,700

0.0875 g

0.0816 g

93

Tercopolymer

PEG/L-Leu
NCA/L-Lys
NCA feed
ratio

PEG/L-Leu/LLys ratio
actual
composition

Mw (Da)
(actual)

PEG-b-p((LLeu)10-co-(LLys)40)

1:10:40

1:14:45

12,400

0.0788 g

0.0722 g

92

PEG-b-p((LLeu)10-co-(LLys)20)

1:10:20

1:13:22

9,300

0.0983 g

0.862 g

88

PEG-b-p((LLeu)20-co-(LLys)20)

1:20:20

1:23:22

10,400

0.0879 g

0.0799 g

91

74

Theoretical Actual
%
Yield [g]
Yield [g] Yield

Figures 3.7-3.9. depict 1H-NMR spectra of deprotected PEG-b-p(L-Lys)40-b-p(LLeu)10, PEG-b-p(L-Leu)10-b-p(L-Lys)40, and PEG-b-p((L-Leu)10-co-(L-Lys)40)
tercopolymers. When compared to Figures 3.5-3.7, the appearance of a primary amine
(peak 12) at 7.02 ppm of Figures 3.8-4.0 indicates the complete cleavage of the
trifluoroacetyl group. Furthermore, the CH2 group next to the amino group has shifted
upfield from ~3.60-3.62 to ~3.39-3.50 ppm, indicating that the hydrogen atoms are
experiencing a shielding effect due to the addition of a more electron donating group.
When the side chain is converted from an amide to an amine the nitrogen atom will have
more electron density and shifts the signal of the CH2 group it is attached to upfield. The
disappearance of each protecting group while maintaining the integration of the methine
chiral carbon hydrogens for each tercopolymer indicates the proper deprotection of each
ionic PAA segment without polymer degradation.
As seen in the 1H NMR spectra of each deprotected tercopolymer, the cleavage of
protecting groups occurs without considerably changing or cleaving amino acid repeat
units. As shown in Table 3.2., deprotection under basic conditions exhibited the lowest
average yield at 83% for all tercopolymers. Tables 3.1 and 3.2 summarize the average
yields of all synthesized polymers and average yields of polymer recovered after each
deprotection.
As a reference, a 1H-NMR proton spectrum of gamma-aminobutyric acid (Figure
3.11) was acquired and used as a comparison to ensure that the primary amine peak
designation is correct (δ = 7.4 ppm). All individual 1H-NMR spectra for each
deprotected cationic tercopolymers not shown are located in Appendix A; Figures A.7A.12.
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Figure 3.7. 1H NMR spectrum of PEG-b-p(L-Lys)42-b-p(L-Leu)12.

Poly(ethlyene glycol)-block-poly(L-lysine)x-block-poly(L-leucine)y (PEG-b-p(LLys)x-b-p(L-Leu)y). 1H NMR (TFAA-d, 500 MHz): δ/ ppm = 1.05-1.10 (6H, (CH3)2-),
1.78 (2H, -CH2-CH-(CH3)2), 1.81-1.89 (1H, -CH-(CH3)2), 2.01-2.06 (2H, -CH2-CH2-CH), 3.39 (2H, -CH2-NH2), 3.71 (3H, CH3-O-), 4.05 (4H, -O-CH2-CH2-), 4.74 (2H, -COCH-NH-), 4.82 (2H, -CO-CH-NH-), 7.02 (2H, -CH2-NH2).
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Figure 3.8. 1H NMR spectrum of PEG-b-p(L-Leu)12-b-p(L-Lys)43.

Poly(ethlyene glycol)-block-poly(L-leucine)x-block-poly(L-lysine)y (PEG-b-p(LLeu)x-b-p(L-Lys)y). 1H NMR(TFAA-d, 500 MHz): δ/ ppm = 1.14-1.20 (6H, (CH3)2-),
1.86 (2H, -CH2-CH-(CH3)2), 1.81-1.89 (1H, -CH-(CH3)2), 2.01-2.06 (2H, -CH2-CH2-CH), 3.49 (2H, -CH2-NH2), 3.80 (3H, CH3-O-), 4.15 (4H, -O-CH2-CH2-), 4.83 (2H, -COCH-NH-), 4.94 (2H, -CO-CH-NH-), 7.12 (2H, -CH2-NH2).
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Figure 3.9. 1H-NMR spectrum of PEG-b-p((L-Leu)14-co-(L-Lys)45).

Poly(ethlyene glycol)-block-poly((L-leucine)x-copolymer-(L-lysine)y) (PEG-b-p(LLeu)x-co-p(L-Lys)y)). 1H NMR (TFAA-d, 500 MHz): δ/ ppm = 1.16-1.21 (6H, (CH3)2-),
1.87 (2H, -CH2-CH-(CH3)2), 1.81-1.89 (1H, -CH-(CH3)2), 2.01-2.06 (2H, -CH2-CH2-CH), 3.50 (2H, -CH2-NH2), 3.81 (3H, CH3-O-), 4.15 (4H, -O-CH2-CH2-), 4.83 (2H, -COCH-NH-), 4.92 (2H, -CO-CH-NH-), 7.12 (2H, -CH2-NH2).
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Figure 3.10. 1H-NMR spectrum of γ-Aminobutyric acid, (TFAA-d, 500 MHz): δ/ ppm = 2.27
(2H, -CH2-CH2-CH2-), 2.82 (2H, -CH2-CH2-CO-), 3.49 (2H, -CH2-CH2-NH2), 7.06 (2H, -CH2NH2).

Infrared spectra comparison between protected PEG-b-p(TFA-L-Lys)40-b-p(LLeu)10 and deprotected PEG-b-p(L-Lys)40-b-p(L-Leu)10 was carried out to ensure removal
of the TFA protecting groups. As seen in Figure 3.11, the peaks at 1652 cm-1 and 1544
cm-1 represent the amide bonds found in the polymer backbone, whereas the peaks at
1102 cm-1 occur due to the C-O stretching within the PEG segment. The loss of the peak
at 1705 cm-1 after deprotection verifies that the trifluoroacetyl group is cleaved and the
C=O stretching vibration disappears. All copolymers show similar results and individual
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IR spectra for each protected and deprotected cationic tercopolymers are located in
Appendix A; Figures A.25-A.33.

Figure 3.11. ATR-FTIR spectrum comparison of PEG-b-p(L-Leu)x-b-p(TFA-L-Lys)y and PEG-bp(L-Leu)x-b-p(L-Lys)y.

3.3.4. 1H-NMR and IR Analysis of Protected Anionic PEG-b-(PAA1)x-b/co-(PAA2)y
Tercopolymers
As described in sections 3.2.2.a. and 3.2.2.b., protected PEGylated anionic PAAs
were synthesized similarly to the previously mentioned cationic tercopolymers. The 1HNMR spectra shown in Figures 3.12-3.14 confirm the synthesized PEG-b-p(Bnl-LGlu)40-b-p(L-Leu)10, PEG-b-p(L-Leu)10-b-p(Bnl-L-Glu)40, and PEG-b-p((L-Leu)10-co80

(Bnl-L-Glu)40) tercopolymers. Each purified tercopolymer was dissolved in deuterated
TFAA and immediately analyzed before degradation of the polymer backbone can occur.
The peak at ~4.84-5.03 ppm represents the methine group found within PAA
backbone containing both p(Bnl-L-Glu) and p(L-Leu). The integrations of each
tercopolymer is approximately 54-59, indicating that total PAA segment is comprised of
54-59 repeating PAA groups. The peak at 5.23-5.46 ppm corresponds to the methylene
group located on the benzyl ester protecting group. Integrations around 98-104 suggests
a total of 49-52 Bnl-L-Glu repeat units considering 2 identical protons for each group.
These integrations also directly correspond to the integrations (248-257) of the phenyl
group of the benzyl ester protecting group, indicating a repeat unit of 50. Due to the
broadness of this peak through suboptimal solubility, the phenyl group integration was
only used as comparsion against other more accurate intergations, such as the methine
peaks within the same group. The peak corresponding to the methyl groups found on LLeu was found at 0.94-1.30 ppm with an integration of 72-76. Considering that this group
contains six protons, leads to 12 L-Leu repeat units.

The comparsion between the methine protons of the PAA backbone and the
distinct side chain protons of each α-amino acid group demonstrates accurate
incorporation of each α-amino acid obtained for the desired polymer constructs. With a
composition objective of 10 and 40 repeat units for L-Leu and Bnl-L-Glu, respectively,
the synthetic procedure within this project exhibited an adequate composition based on
the monomer:initiator (M:I) feed ratio.
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Figure 3.12. 1H NMR spectrum of PEG-b-p(Bnl-L-Glu)52-b-p(L-Leu)12.

Poly(ethlyene glycol)-block-poly(L-glutamic acid γ-benzyl ester)x-block-poly(Lleucine)y (PEG-b-p(Bnl-L-Glu)x-b-p(L-Leu)y). 1H NMR (TFAA-d, 500 MHz): δ/ ppm =
1.25-1.30 (6H, (CH3)2-), 1.97 (2H, -CH2-CH-(CH3)2), 2.06 (1H, -CH-(CH3)2), 2.33-2.53
(2 H, -CH2-CH2-CH-), 2.81 (2H, -CH2-CH2-CO-), 3.71 (3H, CH3-O-), 4.24 (4H, -O-CH2CH2-), 5.03 (1H, -CO-CH-NH-), 5.46 (2H, -O-CH2-(C6H5)), 7.60 (5H, -O-CH2-(C6H5)).
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Figure 3.13. 1H NMR spectrum of PEG-b-p(L-Leu)12-b-p(Bnl-L-Glu)50.

Poly(ethlyene glycol)-block-poly(L-leucine)x-block-poly(L-glutamic acid γ-benzyl
ester)y (PEG-b-p(L-Leu)x-b-p(Bnl-L-Glu)y). 1H NMR (TFAA-d, 500 MHz): δ/ ppm =
0.98-1.08 (6H, (CH3)2-), 1.77 (2H, -CH2-CH-(CH3)2), 1.83 (1H, -CH-(CH3)2), 2.09-2.31
(2 H, -CH2-CH2-CH-), 2.60-2.73 (2H, -CH2-CH2-CO-), 3.68 (3H, CH3-O-), 4.01 (4H, -OCH2-CH2-), 4.81 (1H, -CO-CH-NH-), 5.19-5.33 (2H, -O-CH2-(C6H5)), 7.34-7.43 (5H, O-CH2-(C6H5)).
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Figure 3.14. 1H NMR spectrum of PEG-b-(p(L-Leu)12-co-p(Bnl-L-Glu)50).

Poly(ethlyene glycol)-block-poly((L-leucine)x-copolymer-(L-glutamic acid γbenzyl ester)y) (PEG-b-p((L-Leu)x-co-(Bnl-L-Glu)y)). 1H NMR (TFAA-d, 500 MHz): δ/
ppm = 0.94-1.11 (6H, (CH3)2-), 1.73 (2H, -CH2-CH-(CH3)2), 1.82 (1H, -CH-(CH3)2),
2.10-2.32 (2 H, -CH2-CH2-CH-), 2.61-2.73 (2H, -CH2-CH2-CO-), 3.69 (3H, CH3-O-),
4.02 (4H, -O-CH2-CH2-), 4.82 (1H, -CO-CH-NH-), 5.21-5.32 (2H, -O-CH2-(C6H5)),
7.34-7.44 (5H, -O-CH2-(C6H5)).

All protected anionic tercopolymer PAA compositions were examined and results
showed accurate incorporation of desired quantity for each PAA component, along with
proper yields, as seen in Table 3.3. The molecular weights and yields were calculated
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theoretically based upon the monomer/initiator feed ratios. Actual molecular weights for
each tercopolymer were derived from 1H-NMR data. All other 1H-NMR for each
protected anionic tercopolymers not shown are located in Appendix A; Figures A.13A.18.
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Table 3.3. Experimental data for polymer composition, molecular weights, and product yields for
protected anionic tercopolymers. *All samples were synthesized at room temperature and overall
polymer composition and molecular weights were calculated by 1H-NMR.

Tercopolymer

PEG/Bnl-L-Glu
NCA/L-Leu NCA
feed ratio

PEG/Bnl-LGlu/L-Leu ratio
actual
composition

Mw (Da)
(actual)

Theoretical
Yield [g]

Actual
Yield [g]

%
Yield

PEG-b-p(BnlL-Glu)40-bp(L-Leu)10

1:40:10

1:52:12

17,800

0.7565

0.7474

99

PEG-b-p(BnlL-Glu)20-bp(L-Leu)10

1:20:10

1:20:9

10,400

0.7048

0.6530

93

PEG-b-p(BnlL-Glu)20-bp(L-Leu)20

1:20:20

1:24:23

12,900

0.4052

0.3395
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Tercopolymer

PEG/L-Leu
NCA/Bnl-L-Glu
NCA feed ratio

PEG/LLeu/Bnl-L-Glu
ratio actual
composition

Mw (Da)
(actual)

Theoretical
Yield [g]

Actual
Yield [g]

%
Yield

PEG-b-p(LLeu)10-bp(Bnl-L-Glu)40

1:10:40

1:12:50

17,300

0.7282

0.7270

99

PEG-b-p(LLeu)10-bp(Bnl-LGlu)20)

1:10:20

1:12:22

11,200

0.7048

0.6340

90

PEG-b-p(LLeu)20-bp(Bnl-L-Glu)20

1:20:20

1:23:24

12,900

0.4052

0.3297
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Tercopolymer

PEG/L-Leu
NCA/Bnl-L-Glu
NCA feed ratio

PEG/LLeu/Bnl-L-Glu
ratio actual
composition

Mw (Da)
(actual)

Theoretical
Yield [g]

Actual
Yield [g]

%
Yield

PEG-b-p((LLeu)10-co-(
Bnl-L-Glu)40)

1:10:40

1:12:50

17,300

0.7968

0.7501

94

PEG-b-p((LLeu)10-co-(BnlL-Glu)20)

1:10:20

1:12:22

11,200

0.7048

0.6322

90

PEG-b-p((LLeu)20-co-(BnlL-Glu)20)

1:20:20

1:23:26

13,300

0.41903

0.3710
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Infrared spectra of protected PEG-b-(Bnl-L-Glu)40-b-(L-Leu)10, PEG-b-(L-Leu)10b-(Bnl-L-Glu)40, and PEG-b-((L-Leu)10-co-(Bnl-L-Glu)40) tercopolymer constructs were
obtained and exhibit distinct vibrational outputs that are indicative of desired polymer
architectures. In Figure 3.15, the peaks at 3291 cm-1, 1652 cm-1, and 1545 cm-1 represent
the amide N-H stretching, C=O stretching, and amide N-H bond bending found within
the polymer backbone, respectively. Peaks at 2874 cm-1 and 1103 cm-1 occur due to the
alkane C-H stretching of the side chains and C-O stretching within the PEG segment.
Notably, the peak at 1733 cm-1 is caused by the presence of the benzyl ester protecting
group located on the p(Bnl-L-Glu) components.
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PEG-b-p((L-Leu10)-co-(Bnl-L-Glu40))

Figure 3.15. Infrared spectrum overlay of PEG-b-p(Bnl-L-Glu)40-b-p(L-Leu)10, PEG-b-p(LLeu)10-b-p(Bnl-L-Glu)40, and PEG-b-p((L-Leu)10-co-(Bnl-L-Glu)40) tercopolymers.
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3.3.5. 1H-NMR and IR Analysis of Deprotected Anionic PEG-b-(PAA1)x-b/co(PAA2)y) Tercopolymers
After synthesizing protected PEGylated anionic PAAs, these tercopolymers were
deprotected using the procedure described in section 3.2.2.d in order to produce their
naturally occurring ionic character that is desirable for therapeutic applications. The γ
benzyl ester derivatives for Glu are cost effective to work with in larger quantities and are
readily cleavable. Hydrogenation or acid cleavage using glacial acetic acid saturated
with HBr have been previously accomplished.161 These conditions can be severe and
lead to polymer degradation. However, using the alkali solutions and mixtures such as
water and organic cosolvents, these groups can be removed by hydrolysis in a matter of
hours, producing carboxylate salt derivatives of the p(L-Glu) side chains.
Figures 3.16-3.18. depict 1H-NMR spectra for the deprotection and isolation of
PEG-b-p(L-Glu)40-b-p(L-Leu)10, PEG-b-p(L-Leu)10-b-p(L-Glu)40, and PEG-b-p((LLeu)10-co-(L-Glu)40) tercopolymers. The disappearance of benzyl (~5.23-5.46 ppm) and
phenyl hydrogens (~7.34-7.60 ppm) hydrogens shows complete cleavage and removal of
the γ benzyl protecting group without disturbing and degrading the methine chiral carbon
hydrogens for each tercopolymer backbone. All other individual 1H-NMR spectra for
each deprotected anionic tercopolymers are located in Appendix A; Figures A.19-A.24.
After deprotection, the chain length and composition of the each poly(amino acid)
varied from the target lengths by only ± 5 monomer units overall. Small differences in
mass can impact the final

of the product and these variances are most likely due to

scale inconsistencies while weighing the calculated amount of monomer and initiator
being used for each synthesis. The solubility of each tercopolymer in deuterated solvent
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can also cause inaccurate readings of amino acid incorporation. Tercopolymers
containing larger amounts of Bnl-L-Glu exhibited lengths longer than expected but once
deprotection of these polymer constructs was achieved, proper lengths were observed.
All deprotected anionic tercopolymers were examined and results present a more accurate
determination for each PAA component, caused by increased solubility for each
tercopolymer in the deuterated solvent due to the removal of the γ benzyl groups.
As seen in Table 3.4, proper percent yields and PAA incorporation are shown to
be accurate based upon the monomer/initiator feed ratios. Actual molecular weights for
each tercopolymer were derived from 1H-NMR data. All other 1H-NMR for each
deprotected anionic tercopolymers not shown are located in Appendix A; Figures A.13A.18. Any large deviation from the desired

is most likely a result of inaccurate

weight determination of the monomer or initiator prior to addition to the reaction flask.
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Figure 3.16. 1H NMR spectrum of PEG-b-p(L-Glu)40-b-p(L-Leu)12.

Poly(ethlyene glycol)-block-poly(L-glutamate)x-block-poly(L-leucine)y (PEG-bp(L-Glu)x-b-p(L-Leu)y). 1H NMR (TFAA-d, 500 MHz): δ/ ppm = 1.0-1.04 (6H, (CH3)2-),
1.70 (2H, -CH2-CH-(CH3)2), 1.80 (1H, -CH-(CH3)2), 2.24-2.39 (2 H, -CH2-CH2-CH-),
2.73 (2H, -CH2-CH2-CO-), 3.65 (3H, CH3-O-), 3.99 (4H, -O-CH2-CH2-), 4.77 (1H, -COCH-NH-), 4.91 (1H, -CO-CH-NH-).
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Figure 3.17. 1H NMR spectrum of PEG-b-p(L-Leu)12-b-p(L-Glu)44.

Poly(ethlyene glycol)-block-poly(L-leucine)x-block-poly(L-glutamate)y (PEG-bp(L-Leu)x-b-p(L-Glu)y). 1H NMR (TFAA-d, 500 MHz): δ/ ppm = 1.25-1.28 (6H, (CH3)2), 1.97 (2H, -CH2-CH-(CH3)2), 2.07 (1H, -CH-(CH3)2), 2.49-2.64 (2 H, -CH2-CH2-CH-),
3.00 (2H, -CH2-CH2-CO-), 3.90 (3H, CH3-O-), 4.25 (4H, -O-CH2-CH2-), 5.01 (1H, -COCH-NH-), 5.16 (1H, -CO-CH-NH-).
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Figure 3.18. 1H NMR spectrum of PEG-b-(p(L-Leu)13-co-p(L-Glu)40).

Poly(ethlyene glycol)-block-poly((L-leucine)x-copolymer-(L-glutamate)y) (PEG-bp((L-Leu)x-co-(L-Glu)y)). 1H NMR (TFAA-d, 500 MHz): δ/ ppm = 1.01-1.06 (6H,
(CH3)2-), 1.73 (2H, -CH2-CH-(CH3)2), 1.84 (1H, -CH-(CH3)2), 2.26-2.40 (2 H, -CH2CH2-CH-), 2.75 (2H, -CH2-CH2-CO-), 3.67 (3H, CH3-O-), 4.00 (4H, -O-CH2-CH2-), 4.78
(1H, -CO-CH-NH-), 4.93 (1H, -CO-CH-NH-).
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Table 3.4. Experimental data for polymer composition, molecular weights, and product yields
anionic tercopolymers after deprotection. *All samples were deprotected 70-80 °C for several
hours and molecular weights were calculated by 1H-NMR.

Tercopolymer

PEG/L-Glu
NCA/L-Leu NCA
feed ratio

PEG/L-Glu/LLeu ratio actual
composition

Mw (Da)
(actual)

Theoretical
Yield [g]

Actual
Yield [g]

%
Yield

PEG-b-p(LGlu)40-b-p(LLeu)10

1:40:10

1:40:12

13,100

0.1271

0.1184

93

PEG-b-p(LGlu)20-b-p(LLeu)10

1:20:10

1:19:11

9,400

0.1351

0.1141
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PEG-b-p(LGlu)20-b-p(LLeu)20

1:20:20

1:23:22

11,400

0.1093

0.0924
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Tercopolymer

PEG/L-Leu
NCA/L-Glu NCA
feed ratio

PEG/L-Leu/LGlu ratio actual
composition

Mw (Da)
(actual)

Theoretical
Yield [g]

Actual
Yield [g]

%
Yield

PEG-b-p(LLeu)10-b-p(LGlu)40

1:10:40

1:12:44

13,800

0.0848

0.0795

94

PEG-b-p(LLeu)10-b-p(LGlu)20)

1:10:20

1:13:18

9,500

0.0900

0.0800

89

PEG-b-p(LLeu)20-b-p(LGlu)20

1:20:20

1:24:20

11,100

0.0910

0.0795
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Tercopolymer

PEG/L-Leu
NCA/L-Glu NCA
feed ratio

PEG/L-Leu/LGlu ratio actual
composition

Mw (Da)
(actual)

Theoretical
Yield [g]

Actual
Yield [g]

%
Yield

PEG-b-p((LLeu)10-co-(LGlu)40)

1:10:40

1:13:40

13,200

0.1017

0.0876
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PEG-b-p((LLeu)10-co-(LGlu)20)

1:10:20

1:11:19

9,400

0.1081

0.0973

90

PEG-b-p((LLeu)20-co-(LGlu)20)

1:20:20

1:23:23

11,500

0.0910

0.0876
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Infrared spectra of both protected PEG-b-p(Bnl-L-Glu)40-b-p(L-Leu)10 and
deprotected PEG-b-p(L-Glu)40-b-p(L-Leu)10 were compared to also confirm removal of
the Bnl protecting groups. As seen in Figure 3.19, the polymer backbone amide
stretching peaks are seen at 1650 cm-1 and 1540 cm-1, while PEG can be seen at 1102 cm1

due to the C-O stretching. While all other major peaks remain, the loss of the peak at

1732-1735 cm-1 (dotted line) confirms the removal of the benzyl ester protecting group.
All copolymers show similar results and individual IR spectra for each protected and
deprotected cationic tercopolymers are located in Appendix A; Figures A.34-A.42.
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Figure 3.19. ATR-FTIR spectrum of PEG-b-p(Bnl-L-Glu)x-b-p(L-Leu)y and PEG-b-p(L-Glu)x-bp(L-Leu)y.

94

3.3.6. 1H-NMR and IR Analysis of Hex-b-(Trt-L-Gln)x
Huntington’s disease is an inherited genetic disorder in which nerve cells in the
brain are progressively degenerated, leading to a loss of function and death. The
neurodegeneration is caused by a mutation that leads to an increased number of repeating
glutamine residues within the Huntingtin protein. Interestingly, disease occurrence and
penetrance is dependent on the number of glutamine repeats; unaffected individuals have
<35 repeats while individuals who are affected have 36 or more. Understanding
poly(glutamine) will be central to better understanding Huntington’s disease; however,
there is no reported method for directly synthesizing poly(L-glutamine) at the relevant
lengths. As shown the Table 3.5., we pursue the synthesis of poly(L-glutamine) at
varying chain lengths in an effort to eventually uncover how small changes in the number
of repeats can cause drastic changes in macromolecular behavior.
The synthesis of poly(L-glutamine) begins with the ROP of a trityl protected
glutamine NCA. In a 0.3 molar solution of urea in N,N-dimethylformamide at room
temperature, ring-opening polymerization of the NCA monomer is initiated with a nhexylamine containing a 1° amine. Many monomer:initiator feed ratios were examined
to obtain polymers with desired number of repeat units, allowing for the investigation
into the efficiency of the poly(L-glutamine) synthesis using trityl protected side chains.
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Table 3.5. Degree of polymerization of poly(L-glutamine) with trityl and isopropyl side chain
protection using n-hexylamine and α-methoxy-ω-amino PEG initiators. *Determined by 1HNMR.

Protecting Group

Trityl

Isopropyl

Initiator

M:I Ratio

→

Actual
Length*

Percent
Yield

20

→

6

59

10

→

4

72

5

→

3

65

20

→

12

78

10

→

8

60

5

→

4

71

12

→

4

62

n-hexylamine

mPEG-NH2
(Mw = 5,000)
n-hexylamine

As shown in Figures 3.20.-3.22., ring opening polymerization using Trt-L-Gln
NCA produced unfavorable results. 1H-NMR confirms that polymerization produced
chain lengths that were lower than expected when compared to each corresponding
monomer:initiator feed ratio. This is possibly be due to the bulkiness of the trityl-side
group, which also produced an observed precipitation or aggregation of polymers during
the polymerization.
The degree of polymerization for Trt-L-Gln NCA may produce chain lengths that
lead to polymer aggregates, obstructing complete incorporation for all monomers and
prematurely ending chain propagation. Similarly, hindering the ring opening during
polymerization can allow NCA decomposition, reforming the L-amino acid. As
previously stated, a larger than normal concentration of urea (0.3 M) was used to
minimize aggregation, however it did not increase the degree of polymerization. Others
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have performed NCA polymerizations using Trt-L-Gln at low temperatures to produce
poly(amino acid) Similarly, polymers consisting of Trt-L-Gln did not yield proper
polymer lengths and weights.162
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Figure 3.20. 1H NMR spectrum of Hex-b-p(Trt-L-Gln)6 in TFAA-d.

n-hexylamine-block-poly(N-δ-trityl-L-glutamine)6 (Hex-b-p(Trt-L-Gln)6). 1H
NMR (TFAA-d, 500 MHz): δ/ ppm = 1.00 (3H, CH-(CH3)2), 1.30 (6H, CH3-(CH2)3-CH2), 1.65 (2H, -(CH2)3-CH2-CH2-), 2.25-2.5 (2H, -CH- CH2-CH2-CO-), 2.7 (2H, -CH2-CH2CO-NH-), 3.5 (2H, -CH2-CH2-NH-), 4.75 (1H, -CO-CH-NH-), 7.66-8.45 (15H, -C6H5).
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Figure 3.21. 1H NMR spectrum of Hex-b-p(Trt-L-Gln)4 in TFAA-d.

n-hexylamine-block-poly(N-δ-trityl-L-glutamine)4 (Hex-b-p(Trt-L-Gln)4). 1H
NMR (TFAA-d, 500 MHz): δ/ ppm = 0.94 (3H, CH-(CH3)2), 1.37 (6H, CH3-(CH2)3-CH2), 1.66 (2H, -(CH2)3-CH2-CH2-), 2.32-2.47 (2H, -CH- CH2-CH2-CO-), 2.78 (2H, -CH2CH2-CO-NH-), 3.42 (2H, -CH2-CH2-NH-), 4.81 (1H, -CO-CH-NH-), 7.75-8.45 (15H, C6H5).
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Figure 3.22. 1H NMR spectrum of Hex-b-p(Trt-L-Gln)3 in TFAA-d.

n-hexylamine-block-poly(N-δ-trityl-L-glutamine)3 (Hex-b-p(Trt-L-Gln)3). 1H
NMR (TFAA-d, 500 MHz): δ/ ppm = 1.36 (3H, CH-(CH3)2), 2.25-2.45 (2H, -CH- CH2CH2-CO-), 2.78 (2H, -CH2-CH2-CO-NH-), 3.83 (2H, -CH2-CH2-NH-), 4.82 (1H, -COCH-NH-), 7.79-8.34 (15H, -C6H5).
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3.3.7. 1H-NMR and IR Analysis of Hex-b-(Iso-L-Gln)x and PEG-b-(Iso-L-Gln)x
Copolymers
In order to minimize the steric effects of bulky side chain protections, N-δisopropyl-L-glutamine was used to synthesize desired poly(Iso-L-glutamine) lengths.
Similar to Hex-b-(Trt-L-Gln) polymerizations, a 0.3 molar solution of urea and nhexylamine was utilized upon initiation. As shown in Table 3.5., a monomer:initiator
feed ratio of 12:1 was initially used to examined the precision of monomer integration
with less bulky side groups. Figure 3.23. shows that only 5 repeat units of Iso-L-Gln
were obtained suggesting that although the degree of polymerization was increased the
ability to produce polymers with accurate repeat units was not achieved. Turbidity is also
seen during polymerization, signifying aggregation before completion of polymer chain
growth.
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Figure 3.23. 1H NMR spectrum of Hex-b-p(Iso-L-Gln)4 in DMSO-d6.

n-hexylamine-block-poly(N-δ-isopropyl-L-glutamine)4 (Hex-b-p(Iso-L-Gln)4). 1H
NMR (DMSO-d6, 500 MHz): δ/ ppm = 0.84 (3H, CH-(CH3)2), 1.01 (6H, -CH-(CH3)2),
1.75-1.88 (2H, -CH-CH2-CH2-CO-), 2.08 (2H, -CH2-CH2-CO-NH-), 3.80 (2H, -NH-CH-(CH3)2), 4.18 (1H, -CO-CH-NH-), 7.64 (1H, -CO-NH-CH-(CH3)2), 8.07 (1H, -CH-NHCO-).

In order to increase polymer solubility, α-methoxy-ω-amino PEG initiator is used
to drag the polymer back into solution and minimize aggregation during polymerization.
By using the same monomer to initiator feed ratios as Hex-b-(Trt-L-Gln)x, it was shown
that the introduction of PEG into the copolymer construct did improve the degree of
101

polymerization. By using monomer:initiator feed ratios of 5:1, 10:1, and 20:1, polymers
containing Iso-L-Gln repeat units of 5, 8, and 12 were produced (Figures 3.24.-3.26.).
Accurate chain lengths are obtained at lower feed ratios (5:1 and 10:1), but improper
monomer incorporation at M:I ratio 20:1 still occurs. Further studies into poly(Lglutamine) synthesis are necessary, including the possible conversion of L-glutamate
derivatives to L-glutamine through side chain manipulation before or after NCA synthesis
and polymerization.
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Figure 3.24. 1H NMR spectrum of PEG-b-p(Iso-L-Gln)12 in DMSO-d6.

Poly(ethlyene glycol)-block-poly(N-δ-isopropyl-L-glutamine)12 (PEG-b-p(Iso-LGln)12). 1H NMR (DMSO-d6, 500 MHz): δ/ ppm = 1.00 (3H, CH-(CH3)2), 1.73-1.88
(2H, -CH-CH2-CH2-CO-), 2.07 (2H, -CH2-CH2-CO-NH-), 3.22 (3H, CH3-O-), 3.50 (4H, O-CH2-CH2-), 3.79 (2H, -NH-CH--(CH3)2), 4.18 (1H, -CO-CH-NH-), 7.62 (1H, -CONH-CH-(CH3)2), 8.04 (1H, -CH-NH-CO-).

103

K

O

A

C

B

O
B

I

n

D

DMSO

B

NH I
H

O

K

J

G

H
N
E

F

K

n

NH2

O

E

F

J

A

H
G

Figure 3.25. 1H NMR spectrum of PEG-b-p(Iso-L-Gln)8 in DMSO-d6.

Poly(ethlyene glycol)-block-poly(N-δ-isopropyl-L-glutamine)8 (PEG-b-p(Iso-LGln)8). 1H NMR (DMSO-d6, 500 MHz): δ/ ppm = 1.00 (3H, CH-(CH3)2), 1.74-1.87 (2H,
-CH-CH2-CH2-CO-), 2.07 (2H, -CH2-CH2-CO-NH-), 3.22 (3H, CH3-O-), 3.50 (4H, -OCH2-CH2-), 3.79 (2H, -NH-CH--(CH3)2), 4.18 (1H, -CO-CH-NH-), 7.62 (1H, -CO-NHCH-(CH3)2), 8.03 (1H, -CH-NH-CO-).
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Figure 3.26. 1H NMR spectrum of PEG-b-p(Iso-L-Gln)4 in DMSO-d6.

Poly(ethlyene glycol)-block-poly(N-δ-isopropyl-L-glutamine)4 (PEG-b-p(Iso-LGln)4). 1H NMR (DMSO-d6, 500 MHz): δ/ ppm = 1.00 (3H, CH-(CH3)2), 1.73-1.86 (2H,
-CH-CH2-CH2-CO-), 2.07 (2H, -CH2-CH2-CO-NH-), 3.22 (3H, CH3-O-), 3.50 (4H, -OCH2-CH2-), 3.80 (2H, -NH-CH--(CH3)2), 4.18 (1H, -CO-CH-NH-), 7.66 (1H, -CO-NHCH-(CH3)2), 7.92-8.30 (1H, -CH-NH-CO-).
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3.3.8. GPC Characterization of Protected Cationic and Anionic PEG-b-(PAA1)xb/co-(PAA2)y Tercopolymers
Gel permeation chromatography (GPC) of the protected cationic and anionic
PEG-PAAs were performed at 5 mg/mL. The GPC data were analyzed for polydispersity
only as this method is not suitable for precise molecular weight determinations of
amphiphilic poly(amino acid) block and random copolymers. Polydispersity index (PDI)
data (Tables 3.6. and 3.7.) were determined from the Mw/Mn ratio obtained using the
Waters GPC instrument.
The PDIs for the PEGylated poly(amino acid)s do not display significant
differences with regard to the type of ionic amino acid content. As seen in Figures 3.27.
and 3.28., elution time was observed depending on the length of each polymer; shorter
elution times were observed for larger triblock copolymers. This trend is not dependent
upon whether p(TFA-L-Lys) or p(Bnl-L-Glu) is being used. It must be noted that
deprotected tercopolymers were not analyzed since deprotection does not change
polydispersity.
All ABC block and random tercopolymers exhibited PDI values between 1.11 and
1.46. The distinct impact of the molecular architecture can be seen on the
chromatograms, where ABC triblock copolymers with larger p(L-Leu) units show
discrete bimodal distributions. The amplification of hydrophobicity produces secondary
structures and aggregation within solvents producing broader peaks and and a multimodal
distribution. This bimodal aggregation is caused by the hydrophobic interactions (Van
der Waals forces) between the p(L-Leu) blocks and is enhanced when the p(L-Leu) block
length is increased to 20 repeat units (Appendix B; Figures B.16 and B.17).
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Tercopolymers with longer p(TFA-L-Lys) and p(Bnl-L-Glu) segments show monomodal
distributions. All random tercopolymer distributions display monomodal characteristics
(Appendix B; Figures B.12, B.15, and B.18). No aggregation is observed when the
hydrophobicity of the copolymers is spread throughout, not allowing for p(L-Leu) to
phase separate.
It should be noted that the protected PEGylated PAAs are not water soluble due to
the hydrophobicity of the protective groups. Thus, DMF organic mobile phase was
necessary and 0.1 M LiBr was added to reduce the polymer-solvent interaction causing
aggregation and giving an apparent bimodal distribution. This concentration is
considered relatively high and was not increased to ensure longevity of the
chromatography columns being utilized. Despite the solublility issues, most of the PDIs
for the block and random tercopolymers were ≤ 1.2, which would indicate a living
polymerization environment.
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Figure 3.27. GPC comparison of PEG-b-p((L-Leu))14-co-(TFA-L-Lys)45), PEG-b-((L-Leu))13-co(TFA-L-Lys)22), and PEG-b((L-Leu))23-co-(TFA-L-Lys)22) tercopolymers.
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Figure 3.28. GPC comparison of PEG-b-p((L-Leu))12-co-(Bnl-L-Glu)50), PEG-b-((L-Leu))12-co(Bnl-L-Glu)22), and PEG-b((L-Leu))23-co-(Bnl-L-Glu)26) tercopolymers.
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Figures 3.29 and 3.30 demonstrates that although PEG-PAAs of different block
and random copolymer constructs were synthesized, polymers of similar molecular
weights display very similar elution times. This is indicative that proper molecular
weight values are being proficiently created on a consistent basis despite being either a
block or random tercopolymer construct and whether p(TFA-L-Lys) or p(Bnl-L-Glu) is
be used.
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Figure 3.29. GPC chromatogram of PEG-b-p(TFA-L-Lys)42-b-(L-Leu)12 (solid red line), PEG-bp(L-Leu)12-b-(TFA-L-Lys)43 (dotted black line), and PEG-b-p((L-Leu)14-co-(TFA-L-Lys)45)
(dashed blue line) tercopolymers.
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Figure 3.30. GPC chromatogram of PEG-b-p(Bnl-L-Glu)52-b-(L-Leu)12 (solid red line), PEG-bp(L-Leu)12-b-(Bnl-L-Glu)50 (dotted black line), and PEG-b-p((L-Leu)12-co-(Bnl-L-Glu)50) (dashed
blue line) tercopolymers.
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Table 3.6. Polydispersityof the PEGylated cationic block and random copolymers derived from
GPC data. *Extensive GPC chromatogram data are located in Appendix B.

Polymer (actual composition)

DPn
(NMR)
Lys/Leu

Elution
Time
(min.)

Mw
(GPC)

Mn
(GPC)

PDI

PEG-b-p(TFA-L-Lys)42-bp(L-Leu)12

42/12

31.759

27,200

22,700

1.20

PEG-b-p(L-Leu)12-b-p(TFAL-Lys)43

43/12

31.663

28,500

24,400

1.17

PEG-b-p((L-Leu)14-co-(TFAL-Lys)45)

45/14

31.631

28,700

23,900

1.20

PEG-b-p(TFA-L-Lys)22-bp(L-Leu)12

22/12

32.333

20,700

17,000

1.21

PEG-b-p(L-Leu)14-b-p(TFAL-Lys)24

24/14

32.133

21,800

18,500

1.18

PEG-b-p((L-Leu)13-co-(TFAL-Lys)22)

22/13

32.323

20,500

17,700

1.16

PEG-b-p(TFA-L-Lys)23-bp(L-Leu)23

23/23

33.058

25,000

18,200

1.38

PEG-b-p(L-Leu)24-b-p(TFAL-Lys)23

23/24

32.137

22,600

19,000

1.19

PEG-b-p((L-Leu)23-co-(TFAL-Lys)22)

22/23

32.029

24,000

20,900

1.15
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Table 3.7. Polydispersityof the PEGylated anionic block and random copolymers derived from
GPC data. *Extensive GPC chromatogram data are located in Appendix B.

Polymer (actual composition)

DPn
(NMR)
Lys/Leu

Elution
Time
(min.)

Mw
(GPC)

Mn
(GPC)

PDI

PEG-b-p(Bnl-L-Glu)52-b-p(LLeu)12

52/12

32.210

23,400

20,400

1.14

PEG-b-p(L-Leu)12-b-p(Bnl-LGlu)50

50/12

32.266

21,700

19,300

1.12

PEG-b-p((L-Leu)12-co-(BnlL-Glu)50)

50/12

32.267

22,600

20,300

1.11

PEG-b-p(Bnl-L-Glu)20-b-p(LLeu)9

20/9

32.887

17,300

14,200

1.21

PEG-b-p(L-Leu)12-b-p(Bnl-LGlu)22

22/12

32.887

16,000

13,900

1.15

PEG-b-p((L-Leu)12-co-(BnlL-Glu)22)

22/12

32.763

16,900

14,400

1.18

PEG-b-p(Bnl-L-Glu)24-b-p(LLeu)23

24/23

32.817

19,300

15,900

1.21

PEG-b-p(L-Leu)23-b-p(Bnl-LGlu)24

23/24

32.873

14,200

9,700

1.46

PEG-b-p((L-Leu)23-co-(BnlL-Glu)26)

23/26

32.609

17,000

12,800

1.33

112

3.3.9. TGA Analysis of Deprotected Cationic and Anionic PEG-b-(PAA1)x-b/co(PAA2)y Tercopolymers
Thermal stability was examined for both cationic and anionic tercopolymers by
heating the samples from 0 to 550 °C. In Table 3.7., the TGA data are presented for
selected cationic and anionic tercopolymers. Initial weight loss of 10% for each
tercopolymer occurred around 100 ℃ through the loss of absorbed water due to
hydroscopic nature of the tercopolymers. The thermal degradation of cationic
tercopolymers transpires at a higher temperature range than anionic tercopolymers (Table
3.8.).
As shown in Figures 3.31. and 3.32., cationic tercopolymers have a main
degradation step between 310-340 °C, while anionic tercopolymers have an initial
degradation step between 265-27 5°C and an extra degradation step between 360-375 °C.
The degradation of peptides proceeds through the cyclic peptide formation, more
specifically the formation of diketopiperazines.163 The formation of these structures is
accompanied by the loss of water, in the TGA diagrams this first step was visible as a
small decrease of ~2-3 wt% right before the start of the main or initial degradation step
for each tercopolymer. Tercopolymers containing (L-Glu) as the ionic PAA component
may have developed a two step degradation profile due to its ability multiple different
cyclic products upon heating, causing an intermediate step before total polymer
degradation.164
All the oligomers left 14-45% char behind after heating to 550 °C. Although its
temperature values should still be accurate, PEG-b-p((L-Leu)23-co-(L-Lys)22) gave a
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residual weight much higher than other tercopolymers due to a taring issue that caused it
to start below 100% weight.

Table 3.8. TGA analysis and degradation temperatures of cationic and anionic PEGylated PAA
tercopolymers.
Tercopolymer

T1 (℃)

T2 (℃)

wt% char

PEG-b-p(L-Lys)22-b-p(L-Leu)12

310

-

22

PEG-b-p(L-Leu)14-b-p(L-Lys)24

317

-

24

PEG-b-p((L-Leu)13-co-(L-Lys)22)

321

-

14

PEG-b-p(L-Lys)23-b-p(L-Leu)23

337

-

19

PEG-b-p((L-Leu)23-co-(L-Lys)22)

329

-

45

PEG-b-p(L-Glu)40-b-p(L-Leu)12

272

368

24

PEG-b-p(L-Leu)12-b-p(L-Glu)44

271

365

25

PEG-b-p(L-Glu)19-b-p(L-Leu)11

265

373

17

PEG-b-p((L-Leu)11-co-(L-Glu)19)

268

373

19

PEG-b-p((L-Leu)23-co-(L-Glu)23)

272

363

16
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Figure 3.31. TGA curves of PEGylated cationic PAA tercopolymers.

100

Weight (%)

80

60
PEG-b-p(L-Glu)40-b-p(L-Leu)12

40

PEG-b-p(L-Leu)12-b-p(L-Glu)44
PEG-b-p(L-Glu)19-b-(L-Lys)11

20

PEG-b-p((L-Leu)11-co-p(L-Glu)19)
PEG-b-p((L-Leu)23-co-(L-Glu)23)

0
30

130

230

330

430

530

Temperature (℃)
Figure 3.32. TGA curves of PEGylated anionic PAA tercopolymers.
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CHAPTER 4

PEGYLATED CATIONIC POLY(AMINO ACID) TERCOPOLYMERS AS
TUNABLE GENE DELIVERY VECTORS

4.1. Introduction
Considerable advancements have been achieved in the biomedical field through
the development of natural and synthetic biomaterials. The primary objective for the
majority of these biomaterials is their ability to mimic naturally occurring substances
while performing therapeutic functions. Poly(amino acid)s (PAA)s possess several
properties such as biodegradability and biocompatibility, while providing polymers
consisting of L-amino acid units found in naturally occurring proteins. Particular
monomers can provide a variety of physical characteristics (i.e. ionic charge and
hydrophobicity) that can be combined to allow for a tunable optimization of PAAs for
different therapeutic purposes.
The microstructure of these polymers can be varied by using two or three
different amino acids that are linked in block or random copolymer sequences. In
Chapter 3, the synthesis and characterization of amphiphilic PEGylated PAA
tercopolymers containing poly(ethylene glycol) (PEG), poly(L-lysine) (p(L-Lys)), and
poly (L-leucine) (p(L-Leu)) was described in order to design polymeric gene vectors.
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These non-viral vectors contain the appropriate characteristics found to produce
nanoparticle self assemblies, consisting of polycationic side chains that bind
electrostatically to nucleic acid phosphate groups.165–167 The properties of these
tercopolymers were assessed through a series of biological experiments used to
characterize these constructs for gene delivery, including particle size, charge potential,
complexation and condensation of plasmid DNA, protection against nuclease
degradation, colloidal stability in serum, acute toxicity, and gene transfection of
mammalian cells in vitro. It is projected that by changing tercopolymer cationic density
and position, by modifying the length and placement of p(L-Lys) and p(L-Leu) segments,
the transfection efficiency and biocompatibility can be altered or improved.

4.2. Experimental
4.2.1. Materials
Vybrant® MTT cell proliferation assay kit, Promega™ Luciferase Assay System,
10x glycerol loading dye, and ethidium bromide were purchased Fisher Scientific (Fair
Lawn, NJ). Fetal Bovine Serum (FBS), Dulbecco's Modified Eagle Medium (DMEM)
with and without phenol red, Pierce™ BCA Protein assay kit, and DNase I (RNase free)
was purchased from Thermoscientific (Waltham, MA). CMV-luciferase plasmid DNA
(CMV-luc-pDNA) and mammalian primate COS-1 cells were provided by CelsionEGEN (Huntsville, AL). Agarose gel, Quant-iT™ RiboGreen® Assay Kit, and Arrest-In
was purchased from Thermo Scientific (Huntsville, AL). Dimethyl sulfoxide (DMSO),
sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium
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dihydrogen phosphate, and heparin sodium salt were purchased from Sigma Aldrich (St.
Louis, MO). Water was deionized through a Millipore Milli-Q using a UV Gradient A10
Ultrapure Water System.

4.2.2. Methods
4.2.2.a. Cationic Nanoparticle Formation and Critical Micelle Concentration
Nanoparticles of protected and deprotected cationic PEG-PAA tercopolymers
were investigated and prepared in three different ways.
Nanoprecipitation Method: 3 mg of a protected cationic PEG-PAA triblock
copolymer was dissolved in 1 mL of THF and vortexed for 5 sec. The THF solution was
then added dropwise into 3 mL of deionized water while stirring. The mixture was
allowed to evaporate overnight at 50°C in order to remove THF. The remaining aqueous
solution was brought back up to a total volume of 3 mL to achieve a total polymer
concentration of 1 mg/mL. The solutions were sonicated for 5 minutes and filtered
through a 0.22 μm PVDF syringe filter directly into polystyrene cuvettes.
Direct Solvation/Sonication Method: 3 mg of a deprotected cationic PEG-PAA
triblock was dissolved in 3 mL of deionized water. The solutions were vortexed for 10
seconds and sonicated for 5 minutes. Vortexing and sonication were repeated twice. The
solution was filtered through a 0.22 μm PVDF syringe filter directly into individual
polystyrene cuvettes.
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THF Evaporation Method: 3 mg of a deprotected cationic PEG-PAA triblock
copolymers was dissolved in 3 mL of deionized water. The solution was vortexed for 10
sec and sonicated for 5 minutes. Vortexing and sonication were repeated twice. 1 mL of
THF was added dropwise to the aqueous solution and the mixtures were vortexed for 5
seconds and sonicated for 2 min. Solutions were allowed to evaporate overnight and
water was added to achieve a total volume of 3 mL and a polymer concentration of 1
mg/mL. The solution was filtered through a 0.22 μm PVDF syringe filter directly into a
sample cuvette.
Particle sizes of PEGylated cationic PAAs were measured by DLS using a
Brookhaven Instruments 90 Plus Particle Size Analyzer at λ = 532 nm. All
measurements were analyzed by BIC software (Brookhaven Instruments) and diameter
results are obtained from the mean radius of lognormal size distribution. Particle size
was measured in triplicate at a single angle approach of 90° and at 25 °C.
The critical micelle concentrations for all deprotected copolymers was determined
using pyrene as a hydrophobic fluorescent probe. Steady-state fluorescence spectra were
recorded on a FluoroMax-3 spectrometer (Horiba, JobinYvon) equipped with a
GRAMS/32 data analysis system. Temperature control of the samples was achieved
using a water-jacketed cell holder connected to a Cary circulating water bath. The
temperature of the sample fluid was measured with a thermocouple immersed in a waterfilled cell placed in one of the four cell holders in the sample compartment. All
measurements were carried out at 25 °C. Slit widths were set at 2 nm and 1.5 nm for the
excitation and emission monochromators, respectively. Pyrene fluorescence was
recorded from 360 to 500 nm using an excitation wavelength of 334 nm. To determine
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the onset of association (cass), polymer concentrations ranged from 3.0 mg/mL to 6.0 ×
10−6 mg/mL (prepared by dilution of a polymer stock solution (3.0 mg/mL) in water
containing pyrene (Py ~ 10−6 M)). The aqueous pyrene solution was prepared by adding
a solution of pyrene in ethanol (10 μL, 6.5 × 10−3 M) to an empty flask. The ethanol was
evaporated at 70 °C for 10 min to form a thin film on the bottom of the flask. Water was
added and solutions were stirred at room temperature for 48 h prior to measurement. The
emission intensities measured at the first (373 nm (I1)) and third (383 nm (I3)) vibronic
peaks in the fluorescence emission spectrum of pyrene were utilized to calculate the ratio
I1/I3. Ratios of the emission intensities (I1/I3) were then plotted against polymer
concentrations to determine CMC values for the PEGylated PAA triblock copolymer.

4.2.2.b. DNA complexation and Polyplex Formation
All PEGylated deprotected cationic polymer/DNA complexes were tested for
DNA complexation using lucerirase DNA plasmid (pCMV-luc-pDNA) (7,040 bp). Each
polymer was dissolved in deionized water before complexation through vortexing and
sonication. Each polyplex solution was incubated at room temperature for 20 minutes to
allow for complexation. The amount of polymer and DNA used for polyplex formation
is dependent upon the quantity of cationic charge for each tercopolymer.
Polyplexes were prepared at N/P ratios ranging rom 0.5 to 40 (containing 0.25 µg
DNA per lane) and mixed with 1 µl of 10x glycerol loading buffer solution (60%
Glycerol, 0.25% Xylene cyanol, and 0.25% Bromophenol blue). The polyplexes were
loaded into a 1% (w/v) agarose gel containing 0.5 µg mL -1 ethidium bromide with Tris-
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acetate-EDTA (TAE, pH 8.5) running buffer at 100 V for 120 min. Aliquots of
complexes at 10:1, 20:1, and 40:1 N:P ratios were mixed with 10 µl of heparin (8
mg/mL) to provide DNA release from the complexes. After decomplexation, these
solutions were added to a 96-well plate and measured against the same polyplex samples
without heparin addition. DNA location and mobility was then visualized using a Bio
Rad Gel DocTM EZ Imager (Bio Rad, Hercules, California).

Table 4.1. Polymer‐DNA binding as measured in an agarose gel mobility shift assay. The
solutions containing increasing amounts of polymer and fixed amounts of plasmid DNA were
loaded into an agarose gel in the listed lanes.
Lane

ng plasmid

μg cationic
polymer

N:P

1

250

-

-

2

250

0.11-0.18

0.5

3

250

0.21-0.36

1

4

250

1.04-1.80

5

5

250

2.08-3.60

10

6

250

4.16-7.20

20

7

250

8.32-14.40

40

8

250

6.25 (AI)

20

4.2.2.c. Ethidium bromide exclusion assay
The ability of PEG-b-p(L-Lys)x-b-p(L-Leu)y, PEG-b-p(L-Leu)x-b-p(L-Lys)y, and
PEG-b-p((L-Leu)x-co-(L-Lys)y) to form complexes with pDNA was determined by
measuring the change in ethidium bromide-DNA fluorescence. A PBS solution of CMV-
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luc-pDNA solutions (40 µg/mL) and ethidium bromide (800 ng/mL) were mixed within
96 well plates and shaken for 10 minutes to form stable complexes. Various amounts of
cationic tercopolymers were added to achieve N:P ratios seen for complexation within gel
retardation studies. Fluorescence intensity changes were measured on SpectraMax M2
multi-detection reader (Molecular Devices Corporation, Sunnyvale, California) at room
temperature (25 ± 2℃). The excitation and emission wavelengths were 510 and 590 nm,
respectively. The fluorescence intensity of uncondensed plasmid DNA solution with
EtBr was set at 100%, after correction using EtBr without plasmid DNA as the
background.

4.2.2.d. DNA condensation
Fluorescent RiboGreen (Quant-iT, Invitrogen) (100 µl) was added to each
polyplex solution on the 96-well plate and the signal was measured using a plate reader
(BMG Labtech GmbH, Germany). Concentrations were determined by using a standard
curve of luc pDNA from a range of 0-2000 ng/mL prepared by serial dilution. Aliquots
(100 µL) of each polyplex solution was taken, mixed with 4 µl of heparin sulfate (1.7
mg/mL) and incubated at room temperautre for 2 hr. Each solution containing heparin
was measured in duplicate to ensure that readings were accurate. A control solution
containing only free polymer PEG-b-((Lys20-b-Leu10)) (10 ug) in 1x TE buffer (600 µL
total volume) was analyzed and showed negligible fluorescence emitted by the polymer
itself.
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4.2.2.e. Polyplex Particle Size and Zeta Potential
Particle size measurements of all polyplexes were measured at different N:P ratios
using 50 µg of lucerirase DNA plasmid (luc-pDNA) (7,040 bp). Each polyplex was
prepared through the method previously described above. Solutions were prepared in
deionized water with a total volume of 3 mL and filtered through a 0.22 μm PVDF
syringe filter directly into individual polystyrene cuvettes. Particle size was determined
by DLS. Particle size was measured in a series of four runs at an angle of 90° and at
25°C for each solution. All measurements were analyzed by BIC software (Brookhaven
Instruments) and diameter results are determined from the mean radius of lognormal size
distribution.
Due to concentration dependence of the instrument, zeta potential measurements
were performed on the solutions without filtration. Zeta potential analysis was achieved
during one cycle of 10 individual measurements at 25 °C for each solution. Both particle
size and zeta potential experiments were performed under default instrument settings
recommended by the manufacturer. Polymer and DNA amounts for each tercopolymer
grouping at different N:P ratios are described in Table 4.2.
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Table 4.2. Contents of polyplex solutions for particle size and zeta potential measurements. Total
volume for each measurement was 3.0 mL.

Tercopolymer

L-Lys
units

L-Leu
units

PEG-b-p((L-Lys)40-b-p(L-Leu)10),
PEG-b-p((L-Leu)10-b-p(L-Lys)40), and

40

10

PEG-b-p((L-Leu)10-co-(L-Lys)40)

Tercopolymer

L-Lys
units

L-Leu
units

PEG-b-p((L-Lys)20-b-p(L-Leu)10),
PEG-b-p((L-Leu)10-b-p(L-Lys)20), and

20

10

PEG-b-p((L-Leu)10-co-(L-Lys)20)

Tercopolymer

L-Lys
units

L-Leu
units

PEG-b-p((L-Lys)20-b-p(L-Leu)20),
PEG-b-p((L-Leu)20-b-p(L-Lys)20), and

20

20

PEG-b-p((L-Leu)20-co-(L-Lys)20)
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N:P

μg pDNA

μg PEG-bp((paa)x-b/cop(paa)y)

1

50

42

5

50

210

10

50

420

20

50

840

40

50

1680

N:P

μg pDNA

μg PEG-bp((paa)x-b/cop(paa)y)

1

50

63

5

50

315

10

50

630

20

50

1260

40

50

2520

N:P

μg pDNA

μg PEG-bp((paa)x-b/cop(paa)y)

1

50

70

5

50

350

10

50

700

20

50

1400

40

50

2800

4.2.2.f. DNase Protection
The capability of PEGylated tercopolymers to condense plasmid DNA and protect
it from DNase I degradation was examined using DNase protection assays. To assess
their resistance to nuclease digestion, polyplex solutions (N/P 20:1) consisting of 0.20 μg
plasmid DNA were combined in sterilized PBS buffer (pH 7.4). One unit DNase (1
U/μL) and 1 μL of 10× DNase I reaction buffer was added to each solution and incubated
for 1 to 60 minutes at 37 °C. After incubation at specific time intervals, each sample was
treated with 5 μL of 100 mM EDTA and samples were heated to 65⁰C for 10 min to
inactivate DNase I. Once inactivated, 10 μL of a 4 mg/mL heparin sulfate solution was
added to each tube and allowed to incubate at room temperature for 4 hr for complete
dissociation of DNA from the cationic polymers. 2 μL of 10x glycerol loading buffer
was added to each solution containing a total of 30 μL and each solution was added to
single lanes of a 1% (w/v) agarose gel containing 0.5 µg/mL ethidium bromide. The
experiment was run in 1X TAE buffer at 100 V and 160 mA for 90 min. Visualization
and image capture was accomplished using a Bio RadGel DocTM EZ Imager (Bio Rad,
Hercules, CA). Both treated ((+) DNase I) and untreated ((-) DNase I) experiments were
carried out alongside each other for comparison. Arrest-In (PEI) was included as a
positive control for evaluation against a known commercial transfection reagent.
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Table 4.3. DNAse I protection assay lane assignments in agarose gel after heparin separation of
PEG-b-p((paa)x-b/co-p(paa)y) from DNA. Time indicates polyplex incubation time (N:P 20:1) in
the absence and presence of DNAse I prior to separation. *T=treated, U=untreated.

ng
plasmid

μg PEG-bp((paa)xb/cop(paa)y)

N:P

Units
DNAse

Lane

*T/U

time
(min)

1

U

1

200

-

20

-

2

U

1

200

3.33-5.74

20

-

3

U

15

200

3.33-5.74

20

-

4

U

30

200

3.33-5.74

20

-

5

U

45

200

3.33-5.74

20

-

6

U

60

200

3.33-5.74

20

-

7

U

60

200

5.0 (AI)

20

-

8

T

1

200

-

20

1

9

T

1

200

3.33-5.74

20

1

10

T

15

200

3.33-5.74

20

1

11

T

30

200

3.33-5.74

20

1

12

T

45

200

3.33-5.74

20

1

13

T

60

200

3.33-5.74

20

1

14

T

60

200

5.0 (AI)

20

1

126

4.2.2.g. Polyplex Serum Stability
Nuclease degradation in 50% FBS at 37 °C was examined over 24 hours in order
to determine polyplex protection of CMV-luc-pDNA in biological media. Polyplexes
containing each unique polymer were complexed with pDNA (0.5 µg) in 100 µL of PBS
buffer (pH = 7.4) at N/P 20:1. 100 µL of FBS was added to each polyplex sample and
allowed to incubate over at specific time intervals (4 hr, 12 hr, 16 hr, 20 hr, and 24 hr).
The polyplexes were observed through gel electrophoresis and after each dedicated time
point, each mixture was halved and added to either 10 µL of heparin sulfate (8 mg/mL) or
10 µL of PBS buffer. This was done to show pDNA complexation and dissociation from
the polymers in serum. The samples were then mixed with 1 µL of 10x glycerol loading
buffer and loaded into a 1% (w/v) agarose gel containing 0.5 µg/mL ethidium bromide
with Tris-acetate-EDTA (TAE, pH 8.5) running buffer at 100 V for 120 min.
Visualization was done using a Bio Rad Gel DocTM EZ Imager (Bio Rad, Hercules,
California).
Turbidity analysis was completed on each polyplex containing 0.5 µg of CMVluc-pDNA in 50% FBS using Ultraviolet–visible spectroscopy. Each polyplex sample
was dissolved in 100 µL of PBS buffer and put into quartz cuvette. 100 µL of FBS was
added directly to the cuvette holding the polyplex sample. Immediately after serum
addition, spectroscopic readings were taken at a wavelength of 600 nm over 1 hr. UVVis spectroscopic analysis was done using an Aglient Cary 8454 UV-Vis
Spectrophotometer and UV-Vis ChemStation software.
The change in size distribution of polyplexes containing 0.5 µg of CMV-lucpDNA within serum was investigated. As described previously, polyplexes were
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incubated within 50% FBS at 37 °C over 24 hours. At dedicated time intervals, the
mixtures were analyzed through DLS to determine if there are differences in particle size
or increased aggregation over time. DLS was conducted using 90Plus particle size
analyzer (Brookhaven Instruments) at λ = 532 nm and a scattering angle of 90º. All
measurements were analyzed by BIC software (Brookhaven Instruments) and diameter
results are obtained from the mean radius of lognormal size distribution.

4.2.2.h. COS-1 Transfection
Tercopolymers were examined for potential transfection ability with COS‐1 cells
(African green monkey kidney cells, ATCC CRL‐1650). Polyplexes were formed at
various N/P ratios (10:1, 20:1, and 40:1), containing 0.5 µg of CMV-luc-pDNA (7,040
bps) in 1x PBS buffer (pH = 7.4). Each solution (30 µL total volumes) was vortexed for
5 seconds and incubated at room temperature to permit for complete complexation.
Polyplexes were added directly to COS-1 cells on a 24 well plate holding 220 µL serumfree Dulbecco's Modified Eagle's Medium (DMEM). Cells had been plated 24 hr earlier
at a density of 75,000 cells per well and grown to ~80% confluency. Serum‐free medium
was used to avoid aggregation of polyplexes with serum proteins. The cells were
incubated in the presence of polyplexes for 5-6 hrs and the medium was replaced with
500 μL DMEM medium containing 10% FBS. The cells were grown for 48 hrs, at which
time cells were measured for luciferase and total protein content.
After removing the medium, cell lysates were prepared by adding 100 μL lysis
buffer to each well. Luciferase activity was analyzed using the Promega luciferase assay
128

system with a microplate luminometer (Orion Microplate Luminometer). Total protein
concentrations in the cell lysates were determined using a bicinchoninic acid (BCA)
assay. Each standard or unknown sample replicate into a microplate well and measured
at 562 nm using a BioTek EL808 absorbance plate reader and UV-Vis ChemStation
software.

4.2.2.i. Cytotoxicity of PEG-b-p((L-Lys)x-b/co-(L-Leu)y) Copolymers and Polyplexes
The cytotoxicity of both tercopolymers and polyplexes at N:P ratios 5:1, 10:1, and
20:1 was examined using a MTT cell proliferation study. As mentioned above,
polyplexes were formed through the dissolution of polymer and the subsequent addition
of CMV-luc-pDNA in sterile PBS buffer at room temperature for 20 minutes.
Tercopolymers were tested at the same weights in the absence of plasmid DNA.
Polyplexes or tercopolymers were added directly to COS-1 cells on a 96 well
plate holding 100 µL serum-free DMEM. Cells had been plated 24 hr earlier at a density
of 15,000 cells per well and grown to ~80% confluency. The amount of tercopolymer
and pDNA added was exactly one-fourth that used for in vitro transfections. The cells
were incubated in the presence of polyplexes for 5-6 hrs and the medium was replaced
with 100 μL phenol red free DMEM medium containing 10% FBS. The cells were
grown for 48 hrs, at which time cells were measured for cell viability. After 48 hours,
medium was removed and 100 µL of fresh phenol red free DMEM medium containing
10% FBS was added. 10 µL of 12 mM MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) was added to each well and incubated at 37ᵒC for 4 hours.
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Once media was aspirated, 50 µL of DMSO was added to each well to dissolve insoluble
formazan. Each sample was mixed and read at 540 nm.

4.3. Results
4.3.1. Aggregation and Particle Formation Behavior of Polymer Self Assemblies
The way in which polymer nanoparticles are formed can affect the size of their
corresponding complexes. It has been shown that different methods of nanoparticle
formation can produce different or conflicting outcomes, where the size of self-assembled
nanoparticles of amphiphilic block copolymers is greatly reliant on the method used to
initiate particle formation.168 Various methods of particle formation were executed to
determine distinct differences between both protected and deprotected PEGylated
copolymers with cationic charges. The size of the self-assembled copolymer
nanostructures was analyzed by DLS. The aggregation behavior of copolymers was
found to be dependent on (i) the physiochemical properties of p(L-Lys) blocks,
specifically the protection and deprotection of polymer side chains, and (ii) the cationic
density throughout the entire polymer construct.
One method (nanoprecipitation method) was used to self-assemble protected
copolymers through evaporation of a THF/copolymer solution in deionized water. Two
different methods (direct solvation and evaporation methods) were used to initiate selfassembly of deprotected amphiphilic copolymers: (i) copolymer dissolved directly in
water and (ii) addition and evaporation of THF in water containing dissolved copolymer.
Tables 4.4 and 4.5 summarize the DLS results for the various protected and deprotected
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copolymers. As typically shown for DLS analyses, effective diameter or hydrodynamic
diameter measurements provide a theoretical value for the mean nanoparticle size
through determination of the hydrodynamic radius. If the colloidal system is
monodispersed, there should be only a single population, while polydispersed systems
would exhibit multiple particle populations. In this study, the tercopolymers showed a
bimodal distribution with two different particle populations.

Table 4.4. Light scattering data for solutions of PEGylated protected tercopolymers in dilute
aqueous solutions (polymer concentration: 1.0 g L−1) at 24°C via nanoprecipitation method.
Nanoprecipitation Method
Polymer

Micelle
Group (nm)

Aggregate
Group
(nm)

Effective
Diameter
(nm)

PEG-b-p((TFA-L-Lys)42-b-p(L-Leu)12)

58.8
31.7
25.6

195
121.4
115.7

132.3
92.5
97.5

66
74.8
24.5 (min.)

172.6
203.4
141.1

103.4
120.3
127.5

33.8
42.8
53.4

140.4
144
145.4

84.4
94
102.1

PEG-b-p((L-Leu)12-b-p(TFA-L-Lys)43)
PEG-b-p((L-Leu)14-co-(TFA-L-Lys)45)
PEG-b-p((TFA-L-Lys)22-b-p(L-Leu)12)
PEG-b-p((L-Leu)14-b-p(TFA-L-Lys)24)
PEG-b-p((L-Leu)13-co-(TFA-L-Lys)22)
PEG-b-p((TFA-L-Lys)23-b-p(L-Leu)23)
PEG-b-p((L-Leu)24-b-p(TFA-L-Lys)23)
PEG-b-p((L-Leu)23-co-(TFA-L-Lys)22)
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Table 4.5. Light scattering data for solutions of PEGylated deprotected tercopolymers in dilute
aqueous solutions (polymer concentration: 1.0 g L−1) at 24°C via direct solvation and evaporation
methods.
Polymer
PEG-b-p((L-Lys)42-b-p(L-Leu)12)
PEG-b-p((L-Leu)12-b-p(L-Lys)43)
PEG-b-p((L-Leu)14-co-(L-Lys)45)
PEG-b-p((L-Lys)22-b-p(L-Leu)12)
PEG-b-p((L-Leu)14-b-p(L-Lys)24)
PEG-b-p((L-Leu)13-co-(L-Lys)22)
PEG-b-p((L-Lys)23-b-p(L-Leu)23)
PEG-b-p((L-Leu)24-b-p(L-Lys)23)
PEG-b-p((L-Leu)23-co-(L-Lys)22)

Direct Solvation Method
Effective Diameter (nm)
104.5
172.9
160.9

Evaporation Method
Effective Diameter (nm)
187.5
177
211.1

51.1
52.4
88.4

157.7
151.1
158.5

53.4
73.4
64.5

141.3
157.6
192.2

Dissolving protected PAA tercopolymers directly in deionized water led mostly to
precipitation and large polymer aggregates. Nanoprecipitation was employed for
protected copolymers based on a previous method developments on polymer aggregation
of poly(amino acids).169 Effective diameters of all protected tercopolymers using
nanoprecipitation were between 84.4 and 132.3 nm. Each tercopolymer grouping did not
exhibit any substantial differences that were dependent upon the placement or
combination of each amino acid. Polymer constructs of protected copolymers did not
show any significant size trends. After syringe filtration, all protected copolymers
formed bimodal distributions with overall effective diameters of about 100 nm which is
considered a acceptable particle size for avoiding uptake and clearance by the
reticuloendothelial system(Table 4.4).170 The particle sizes of these tercopolymers are
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larger than desired because of an increase in aggregation when p(L-Lys) amino acids are
protected with trifluoroacetyl groups leading to higher hydrophobicity.
There are distinct variances when comparing protected and deprotected
copolymers using the nanoprecipitation (Table 4.4) and THF evaporation (Table 4.5)
methods where the copolymers are placed within the same environment (25% v/v %
THF). Deprotection of all copolymers led to swelling of nanoparticles attributable to the
solubility of the cationic lysine that causes increased interactions with water. Similarly, a
swelling trend where particle size is more than doubled from ~50-80 nm to ~100-170 nm
can also be seen by increasing the cationic character for all deprotected copolymers (i.e.
40 L-Lys units) within the direct solvation method (Table 4.5). This tendency cannot be
observed for the particles of protected copolymers probably due to enhanced hydrophobic
interactions due to the lack of cationic charges.
Most of unprotected copolymers developed lower particle sizes (51-88 nm) when
solvated in water (Table 4.5). Increasing the cationic character of the deprotected
tercopolymers from 20 to 40 L-Lys units led to a swelling trend that allows water
molecules to become bound by dipole interactions within the nanoparticle, causing larger
nanoparticles (104-173 nm). If the p(L-Lys) block length is kept at 22 to 23 repeat units
and the length of the p(L-Leu) block is doubled to 23 to 24 repeat units, no significant
change is observed for the block and random tercopolymers where 53, 73, and 64 nm
aggregates are formed, respectively. Although no substantial change could be seen, if the
relatively long hydrophobic p(L-Leu) block forms the B- or middle block, an small
increase in particle size from 52 to 73 nm was observed. This can be attributed to a
hindered aggregation where the hydrophilic A- and C- blocks oppose self-assembly, and
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the hydrophobic middle block cannot produce a tightly packed aggregate as hydrophobic
intermolecular interactions are sterically hindered.
The addition of THF to these dissolved copolymers leads to an increase in
diameters even though THF had been evaporated prior to DLS measurements (THF
evaporation method). THF seems to act as a nonsolvent that disrupts and eliminates most
of the micellar structures for all unprotected copolymers which leads to larger
nanoparticle structures (Table 4.5). Results show that deprotected copolymers studied
here should only be directly solvated in water in order to achieve lower-sized
nanoparticles, if micelle structures are desired.
The CMC of all deprotected tercopolymer micelles was examined using a pyrene
probe (10-6 M) in fluorescence microscopy. Pyrene is poorly soluble in aqueous media
and can be solubilized within hydrophobic domains. The ratio intensity of pyrene’s first
and third vibronic band emissions (I1/I3) in aqueous solution is ~1.7-1.8 and will decrease
when pyrene is solubilized within hydrophobic nanoparticles.171 Therefore, the polymer
concentration that associates with the decrease in the I1/I3 band ratio gives a quantitative
estimate of the CMC.
In Figure 4.1, CMC plots are shown as changes in the I1/I3 ratio as a function of
copolymer concentrations in deionized water. CMC results for all copolymers range
from 8-130 µg/mL (Table 4.6), which is typical for PEG–polyester or PEG–poly(L-amino
acid) micelles at room temperature.172,173 If p(L-Leu) forms the C- or outer block, and the
p(L-Lys) is comparatively long, 40 repeat units, compared to the 10 L-Leu repeat units,
the CMC is high (100 µg/mL), as the nanoparticles are not held strongly by hydrophobic
interaction and the unperturbed and swelling p(L-Lys) corona drives disassembly.
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Decreasing the number of L-Lys repeat units to 20 and maintaining 10 L-Leu repeat units
lowers the CMC to 80 µg/mL as the hydrophilic force that favors disassembly is reduced.
When the L-Leu content is however increased to 20 repeat units, while maintaining 20 LLys repeat units, the hydrophobic interaction between L-Leu segments overrides the
hydrophilicly driven disassembly, and the CMC decreases to 8 µg/mL.

Figure 4.1. CMC analysis of PEG-b-p((L-Lys)x-b-p(L-Leu)y), PEG-b-p((L-Leu)x-b-p(L-Lys)y),
and PEG-b-p((L-Leu)x-co-(L-Lys)y) copolymers.
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A somewhat different situation is presented when the hydrophobic p(L-Leu) block
forms the B- or middle block. Even with a large p(L-Lys) segment of 40 repeat units, a
CMC of only 50 µg/mL is observed. The p(L-Lys)’s hydrophilic interaction with the
surrounding water is obviously curtailed as the p(L-Leu) block now forms the central
block and p(L-Lys) cannot extend away from the hydrophobic core as freely as before.
The p(L-Lys) has now to bend around the hydrophobic p(L-Leu) domain, which leads to
a smaller CMC (50 µg/mL). As observed before decreasing the length of the p(L-Lys)
block, while maintaining the p(L-Leu) block length and increasing the p(L-Leu) block
length lead to further reductions in the CMC to 20 and 8 µg/mL, respectively.
CMC values were dependent upon the degree and distribution of hydrophobicity
within each copolymer (Table 4.6). When the hydrophobicity is spread throughout
random copolymers, the stabilization effect of p(L-Leu) on micelle structures is
minimized, leading to higher CMC values (100-130 µg/mL). In summary and similar to
previously published research,174 PEG-b-p(L-Lys)-b-p(L-Leu) and PEG-b-p(L-Leu)-bp(L-Lys) block copolymers comprised of larger hydrophobic p(L-Leu) segments show
higher micelle stability and lower CMC values.141,175 By adjusting the amphiphilic
balance of tercopolymers, it is possible to target desired CMC values.
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Table 4.6. Final composition of deprotected PEGylated cationic PAA tercopolymers in addition
to their CMC values.

Tercopolymer

PEG/L-Lys/L-Leu
ratio actual
composition

Mw (Da)

CMC
(µg/mL)

PEG-b-p((L-Lys)40b-p(L-Leu)10)

1:42:12

11,800

100

PEG-b-p((L-Lys)20b-p(L-Leu)10)

1:22:12

9,200

80

PEG-b-p((L-Lys)20b-p(L-Leu)20)

1:23:23

10,600

8

Tercopolymer

PEG/L-Leu/L-Lys
ratio actual
composition

Mw (Da)

CMC
(µg/mL)

PEG-b-p((L-Leu)10b-p(L-Lys)40)

1:12:43

11,900

50

PEG-b-p((L-Leu)10b-p(L-Lys)20)

1:14:24

9,700

20

PEG-b-p((L-Leu)20b-p(L-Lys)20)

1:24:23

10,700

8

Tercopolymer

PEG/L-Leu/L-Lys
ratio actual
composition

Mw (Da)

CMC
(µg/mL)

PEG-b-p((L-Leu)10co-(L-Lys)40)

1:14:45

12,400

100

PEG-b-p((L-Leu)10co-(L-Lys)20)

1:13:22

9,300

130

PEG-b-p((L-Leu)20co-(L-Lys)20)

1:23:22

10,400

110
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4.3.2. DNA Complexation and Polyplex Characterization
The majority of non-viral gene delivery agents are cationic at physiological pH
(7.4) as a result of protonable amines.176 In order to provide proficient transfection, DNA
must be compacted into a stable particle to shield nucleic acids from degradation and
allow for efficient uptake into the cell’s nucleus. PEG-b-p(L-Lys)x-b-p(L-Leu)y, PEG-bp(L-Leu)x-b-p(L-Lys)y, and PEG-b-p((L-Leu)x-co-( L-Lys)y) amphiphilic copolymers
were designed to form nanoparticles that can bind to DNA. Electrostatic interactions
form between the amino group side chains of the copolymers and the DNA phosphate
backbone.
To evaluate the DNA binding ability of PEG-b-p(L-Lys)x-b-p(L-Leu)y, PEG-bp(L-Leu)x-b-p(L-Lys)y, and PEG-b-p((L-Leu)x-co-(L-Lys)y) copolymers, the binding
interactions between the tercopolymers and pCMV-luc-pDNA was investigated through
agarose gel motility shift assays at different N/P ratios ranging from 0.5:1 to 40:1. As
depicted in Figure 4.2, retardation of DNA migration begins at N:P ratio of 1:1. Full
retardation and complete DNA charge neutralization is achieved at 5:1 for all copolymers
as no plasmid DNA bands travel through the agarose gel. While small amounts of
plasmid DNA can be seen in the wells, N:P ratios above 5:1 demonstrated DNA binding
and complexation showing that DNA mobility was completely suppressed.
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Figure 4.2. Gel Mobility Shift Assay of PEG-b-p((L-Lys)x-b-p(L-Leu)y), PEG-b-p((L-Leu)x-bp(L-Lys)y), and PEG-b-p((L-Leu)x-co-(L-Lys)y) copolymers at different N:P ratios in PBS (pH =
7.4) buffer.

The binding between polycationic polymers and DNA is not the only
essential characteristic for an effective transfection reagent. The physiochemical
properties of polyplexes, such as size and surface charge, are regularly investigated due
to their influence on therapeutic efficiency. Useful reagents must deliver DNA to the
interior of the cell by assembling into complexes of adequate size that allows for
entrance into the cell through endocytosis. 57 Nanoparticles with particle sizes below
100 nm can exhibit better cellular endocytosis than nanoparticles above 200 nm177 and
can subsequently be more effective in gene transfection.178
The potential for DNA complexation via cationic PEG-b-PAA1-b/co-PAA2
copolymers was examined by measuring the size of the copolymer/DNA complexes
using DLS. Additionally, the net surface charge of the resulting nanoparticle complexes
was determined through investigation of the zeta potential. As shown in Figure 4.3,
polymer/DNA complexes exhibit lower effective diameters ranging from 75 to 165 nm at
N:P ratios above 5:1. Particle sizes at or below an N:P ratio of 5:1 are shown to range
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from 156-224 nm, suggesting that the DNA may not be fully condensed as a result of
inadequate concentrations of PEG-b-PAA1-b/co-PAA2 copolymers. Minimizing particle
size is essential because it can directly influence the efficiency of endocytosis and
cellular incorporation of a gene vector, thus affecting the overall gene transfection.177,178
Particle size and zeta results can be found in Appendix C; Figures C.1 and C.2.
A large surface charge transition was also detected between nanoparticles at N/P
ratios of 1:1 and 5:1. This large spike in net surface charge indicates an evident change
in DNA complexation where free plasmid DNA is no longer observed. Zeta potential
measurements demonstrate that DNA charge neutralization occurs above an N:P ratio of
1:1, and nanoparticles were found to have similar net positive charges (10 to 20 mV) and
smaller effective diameters at higher N:P ratios. Plasmid DNA is therefore packaged into
positively charged nanoparticles with a positive net surface charge that levels after
attaining a maximum value at 5:1 N/P ratio. Results indicate that all cationic PEG-bPAA1-b/co-PAA2 copolymers with varying cationic positions and charge densities can
successfully bind and condense DNA successfully at or above 5:1 N:P ratios.
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Figure 4.3. Particle size (bars) and zeta potential (dotted lines) of PEG-b-p(L-Lys)40-b-p(LLeu)10, PEG-b-p(L-Leu)10-b-p(L-Lys)40, and PEG-b-p((L-Leu)10-co-(L-Lys)40) polyplexes at
different N:P ratios.

DLS results are similar to the DNA mobility data obtained from the agarose gel
electrophoresis experiments shown previously where complexation can only be seen at or
above 5:1 N:P ratios. Nanoparticle size will continue to decrease for block tercopolymers
at larger N:P ratios (i.e. 20:1 and 40:1), indicating higher plasmid DNA condensation. In
contrast, random tercopolymers show minimal differences in particle size above 5:1 N:P
ratio, signifying a difference DNA condensation and polyplex formation for these
tercopolymer constructs. Random copolymers also display lower net charges at all N:P
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ratios. As seen with polyplex size and charge, these random tercopolymers compact
plasmid DNA differently and not as fully as block copolymers. Figure 4.4 shows the
charge decrease of the random copolymers at 20:1 N:P ratio. This trend can be seen for
all N:P ratios.

Figure 4.4: Zeta Potential comparison of PEG-b-p(L-Lys)x-b-p(L-Leu)y, PEG-b-p(L-Leu)x-b-p(LLys)y, and PEG-b-p((L-Leu)x-co-(L-Lys)y) copolymers at 20:1 N:P ratios.

4.3.3. Ribogreen Analysis of Polyplexes
The onset and extent of DNA complexation and condensation was further
investigated through a RiboGreen Quant-iT assay that provides a quantitative measure of
free plasmid DNA concentrations through fluorescence microscopy. The Ribogreen
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assay is a method that complements the DNA motility and particle size analyses. Once
bound to and intercalated with DNA, RiboGreen dye expresses a fluorescent signal that is
much stronger than that of the dye itself. This amplification of the signal can only occur
if free plasmid DNA is present and not associated with polyplex nanoparticles. In order
to perform decomplexation, heparin sodium salt, an anionic polysaccharide, was added to
each polyplex sample and for all N:P ratios.
The fluorescence signal is shown to be negligible at N:P ratios ≥ 5:1 due to
complete complexation and condensation of pDNA for tercopolymer containing cationic
charge provided by p(L-Lys) units, see Figure 4.5. As shown in Appendix C (Figures C.3
and C.4), this trend can be seen for all other copolymers not shown. Fluorescence is
retained in the presence of heparin sodium salt which operates as a competitive binder
with the copolymers in the polyplexes and thus releases plasmid DNA.
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Figure 4.5. RiboGreen analysis of PEG-b-p(L-Lys)40-b-p(L-Leu)10, PEG-b-p(L-Leu)10-b-p(LLys)40, and PEG-b-p((L-Leu)10-co-(L-Lys)40) polyplexes at different N:P ratios. Release was
performed via heparin sodium salt addition to aliquots of each polyplex at different N:P ratios.

Nucleic acid release at high N:P ratios (i.e. 40:1) differed depending on the
overall composition and cationic density of each copolymer. Copolymers with a stronger
hydrophobic character, obtained by increasing the p(L-Leu) component to 20 repeat units,
displays better DNA release at N:P 40:1, indicating that there is a stronger hydrophobic
interaction between L-Leu segments than polymer-DNA interaction. The opposite can be
seen when increasing the cationic character of the copolymers. At N:P 40:1, block and
random copolymers containing 40 L-Lys repeat units bind more strongly to DNA than
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tercopolymers containing 20 L-Lys units and increasingly preventing its release from the
corresponding polyplexes (Figure 4.6). This can be seen by the increase in fluorescence
signal from ~3.5-15.4 to 28.9-58.9 ng/mL pDNA concentrations for tercopolymer
containing 20 and 40 L-Lys units, respectively.
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Figure 4.6. Plasmid DNA (lucDNA, 7040 bps) release at 40:1 N:P ratios for all copolymers.
Release obtained by adding 4 µl of heparin sulfate (1.7 mg/mL) and incubated at room temp for 2
hr.

Although the cationic and hydrophobic composition of the copolymers did not
show discernable differences, the orientation of copolymer components were found to
affect the compacting and condensation of plasmid DNA. As shown in Figure 4.7,
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random copolymer of all compositions exhibited higher fluorescence (red dot lines) than
their corresponding block copolymer constructs at 20:1 N:P ratios. Similar to zeta
potential results, elevated fluorescence indicates that DNA is not fully compacted within
random copolymer polyplexes.
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Figure 4.7. Plasmid DNA (pCMV-luc-DNA, 7040 bps) complexation and condensation
comparison at 20:1 N:P ratios for all copolymers.

4.3.4. Ethidium Bromide Exclusion of Tercopolymers
To further study the condensation of DNA, an ethidium bromide (EtBr) exclusion
assay was performed. EtBr produces strong fluorescence when intercalated with DNA,
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however it produces a very weak fluorescence when it is free in solution. The polymerDNA condensation can be characterized through the quenching of the fluorescence of
EtBr due to the formation of polyplexes, where charge neutralization and subsequent
condensation of DNA inhibits EtBr intercalation.
As shown in Figure 4.8., the fluorescence intensity of EtBr decreased with an
increase in the N:P ratio for all cationic tercopolymers. The decrease in EtBr intensity
displayed minimal change at about N:P of 2:1, which was consistent with the gel
retardation results. This indicates that the progressive complexation of copolymer with
plasmid DNA is most complete at N:P ratio of 2:1, inhibiting the intercalation of EtBr
into plasmid DNA. Although different tercopolymer constructs were measured,
surprisingly no distinguishable differences were observed in DNA condensation for
tercopolymer constructs containing the same p(L-Lys) and p(L-Leu) content. Only a very
weak advantage of the block tercopolymers over the random tercopolymer was measured.
Block tercopolymers exhibit EtBr fluorescence intensities of 21-34%, while random
tercopolymer show EtBr fluorescence intensities of 25-38% at 5:1 N:P ratio.
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Figure 4.8. Estimation of plasmid DNA condensation for A) PEG-b-p(L-Lys)x-b-p(L-Leu)y, B)
PEG-b-p(L-Leu)x-b-p(L-Lys)y, and C) PEG-b-p((L-Leu)x-co-(L-Lys)y) tercopolymers with similar
physiochemical characteristics as determined by EtBr exclusion assay.
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Figure 4.9: Estimation of plasmid DNA condensation for A) PEG-b-p(L-Lys)x-b-p(L-Leu)y, B)
PEG-b-p(L-Leu)x-b-p(L-Lys)y, and C) PEG-b-p((L-Leu)x-co-(L-Lys)y) tercopolymers with
varying cationic and hydrophobic characteristics as determined by EtBr exclusion assay.

By altering the hydrophobic and cationic content of each distinct tercopolymer
construct, it was found that DNA condensation is more sufficient in the case of the
tercopolymers with larger cationic density (Figure 4.9.). When the (L-Leu) content is
decreased by half from 20 to 10 units the intercalation of EtBr is lowered by only 1-8%,
however doubling the cationic (L-Lys) units from 20 to 40 suppressed EtBr fluorescence
intensity by 11-13%. Similar to Ribogreen analysis of condensed polyplexes at 20:1 N:P
ratio (Figure 4.7.), EtBr exclusion results indicate that DNA shielding can be more
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significantly impacted by improving the cationic density of the tercopolymers through
alteration the p(L-Lys) lengths. Differences in EtBr fluorescence can also indicate that
the binding between pDNA and tercopolymers is modified by altering the cationic
densities of the tercopolymers. In order to determine any modification in binding
capacity, the binding kinetics of polyplex formation for all tercopolymers needs to be
further explored, i.e. isothermal titration calorimetry.

4.3.5. Nuclease Protection of Plasmid DNA
A gene delivery vector must effectively condense DNA and provide protection
from nuclease degradation. DNase I is an effective plasmid DNA nuclease that readily
cleaves unprotected DNA. DNase I protection assays can be readily used to show
polyplex formation and stability between polymer and DNA. The ability of PEG-b-p(LLys)x-b-p(L-Leu)y, PEG-b-p(L-Leu)x-b-p(L-Lys)y, and PEG-b-p((L-Leu)x-co-(L-Lys)y)
tercopolymers to inhibit nuclease degradation of complexed pDNA was investigated at an
N:P ratio of 20:1 to ensure full pDNA complexation and polyplex formation. The
polymer/DNA complexes were incubated at 37 °C in the presence of one unit of DNase I
at 37 °C, which will completely degrade 1 µg of plasmid DNA in 10 minutes at 37°C.
The extent of pDNA protection was observed over a time range of 1-60 minutes. After
each time point, heparin sulfate was used as a competitive polyanion to displace pDNA
from the cationic polymer and the remaining unharmed DNA will move through the gel.
DNase I untreated experiments were performed as a comparison to ensure proper
complexation throughout the appointed time intervals.
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PEG-b-p(L-Lys)x-b-p(L-Leu)y and PEG-b-p(L-Leu)x-b-p(L-Lys)y block
tercopolymers were able to protect the plasmid from degradation for up to 60 min at 37
ᵒC and pH 7.4 based on appearance of open circular or supercoiled DNA intact plasmid
DNA (Figure 4.10 A and B; lanes 9-13; red box). Plasmid DNA without complexation is
entirely degraded after only 1 min (Figure 4.10; lane 1). A polyethyleneimine (PEI)
based system gene vector, Arrest-In, protected plasmid DNA for up to 60 min and was
used as a positive control. The favorable comparison between commercially available
gene delivery systems and the PEGylated cationic PAA block tercopolymers ensures that
these copolymers can adequately protect DNA from nuclease degradation.
Alternatively, random copolymers do not adequately protect the pDNA even at
relatively small time intervals (i.e. 1 minute) (Figures 4.10 C; lane 9-13; blue box). Like
naked plasmid DNA, the degradation of the polynucleotide strand exhibits large,
indistinct nucleotide quantities of lower molecular weights, suggesting that the random
copolymer polyplexes formed through electrostatic interactions but do not completely
condense and shield the DNA from macromolecules such as nucleases. This pattern is
seen of all tercopolymers compositions and nuclease studies for the other tercopolymer
not shown can be found in Appendix C; Figure C.5 and C.6.
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Figure 4.10. DNAse protections assays carried out on three tercopolymer constructs at N:P ratio
20:1: A) PEG-b-p(L-Lys)40-b-p(L-Leu)10, B) PEG-b-p(L-Leu)10-b-p(L-Lys)40, and C) PEG-b-p((LLeu)10-co-p(L-Lys)40.

Weak intensities of the intact DNA bands in the treated lanes (lanes 2-6) could be
due to two factors: the partial degradation of the pDNA by the nuclease and binding of
DNA with the cationic tercopolymer. Large fractions of DNA remains insides the wells
indicating that the cationic tercopolymers bind considerably to plasmid DNA and
dissociation using a heparin competitor, after several hours, is challenging. Although the
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degradation process is uncertain, the moderate degradation of the exposed plasmid DNA
to nuclease does not occur due to the degradation of the tercopolymers themselves.
DNAse free samples incubated for up to 60 min (Figure 4.10; lanes 2-7) do not exhibited
a major increase in naked DNA at shorter time intervals, as shown by little variation in
DNA band intensities. Unlike random tercopolymers, all these factors suggest that the
block tercopolymers can protect plasmid DNA from nuclease degradation over extended
periods of time through polyplex particle formation.

4.3.6. Polyplex Colloidal Serum Stability
Although many cationic polymeric polyplexes can work well in vitro in reduced
serum conditions, they can suffer from serious drawbacks through non-specific
interactions with cellular blood components (erythrocytes) and plasma proteins in vivo
due to their excess positive surface charge.179 In a biological system, this leads to
aggregation and accumulation in the “first pass organs” such the liver and spleen and
eventual clearance by the reticuloendothelial system (RES), restricting their therapeutic
capabilities.180,181 Due to this fact, stability of these polyplexes determine their
transfection efficiency. Here, we employ covalently linking polycations to a non-ionic
water soluble polymer, PEG to improve the stability and efficacy of the cationic
polyplexes.
The size distribution of polyplexes at N:P ratio 20:1 was measured by DLS in the
presence of 50% FBS serum at 37 ℃. All samples were investigated in four hour
increments over 24 hours to confirm dispersion stability over time. For most of the
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samples, intensities peaked at multiple different particle sizes, shown as multimodal
distribution of particle diameter in Figure 4.11. A-C. Small peaks observed at ∼5 nm and
∼18-34 nm represent serum particles and a combination of serum proteins and small
polyplexes, respectively. A third peak (113-249 nm) indicates the presence of large
aggregates. The size of these larger aggregates was dependent upon the amount of
hydrophobic L-Leu units in each polymer constructs where PEG-b-p(L-Lys)20-b-p(LLeu)20, PEG-b-p(L-Leu)20-b-p(L-Lys)20, and PEG-b-p((L-Leu)20-co-p(L-Lys)20)
tercopolymers showed larger aggregate sizes. The effect of aggregration cannot be seen
over 24 hours where particle sizes of each time interval do not show a distinguishable
size increase in the multimodal distributions for each polyplex. DLS data are similar for
the tercopolymers are shown in Appendix C; Figures C.8 and C.9.
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Figure 4.11. Serum stability analysis through DLS (A-C), serum nuclease protection (D), and
turbidity testing (E) of PEG-b-p(L-Lys)40-b-p(L-Leu)10, PEG-b-p(L-Leu)10-b-p(L-Lys)40, and
PEG-b-p((L-Leu)10-co-p(L-Lys)40).

Gel electrophoresis was performed to confirm complexes remained intact in the
presence of serum proteins and that nuclease degradation was not observed (Figure 4.11
D). All complexes released intact plasmid DNA in the presence of heparin sulfate
sodium salt up to 24 hours, indicating the stability of the polyplexes and protection of the
DNA cargo. Plasmid DNA itself was degraded after 4 hours while in the presence of
50% FBS (Appendix C; Figure C.7). Although results are similar to the DNAse
protection assays, all tercopolymers including random copolymers showed intact DNA
after 24 hours. Lack of complete DNA degradation is due the low DNAse concentrations
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in each serum sample. Gel electrphroresis data for other tercopolymers are located in
Appendix C; Figures C.8 and C.9.
Instantaneous or short term aggregation when polyplexes are first added to serum
can disrupt transfection efficiency before in vitro incubation with mammalian cells.
Turbidity was used to detect aggregates or particles and the increase in turbidity is due to
the increased average particle size when aggregation occurs in the fluid phase. The
turbidity index of each sample will be reflected by the reduction of the incident beam
intensity and this reduction is represented by absorbance value changes measured using a
UV-Vis spectrometer. As seen in Figure 4.11 E, particles formed with PEG-b-p(LLys)40-b-p(L-Leu)10, PEG-b-p(L-Leu)10-b-p(L-Lys)40, and PEG-b-p((L-Leu)10-co-p(LLys)40) shows no significant increase in turbidity over 60 minutes while in serum
containing media.
As shown in Table 4.7, when hydrophobic character within the polymer
constructs is increased by either decreasing p(L-Lys) and increasing p(L-Leu)
concentrations, the turbidity was shown to increase within the first 60 minutes. At t=0,
turbidity was normalized to 0 and changes in absorbance at λ=600 nm were reported.
Tercopolymers with the largest cationic density exhibited small incidence of aggregation
(ΔAbs = -4.90 x 10-2 to 1.27 x 10-2). The change in absorbance for PEG-b-p((L-Leu)10co-p(L-Lys)40) showed a decrease in aggregation (-4.90 x 10-2) that may be due to
dissipation of larger polyplexes over time. The presence of larger hydrophobicity within
the polymer/pDNA complexes results in higher aggregation from absorbance 4.54 x 10-2
to 6.78 x 10-2 in the presence of serum. Increased aggregation may effect the transfection
efficiency at higher N:P ratios each these tercopolymers.
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Table 4.7. Turbidity of polyplexes (polymer + pDNA) in serum determined by the change in
absorbance (λ = 600 nm) over 60 minutes.
Compound

ΔABS (λ = 600 nm) over 60
minutes

PEG-b-p(L-Lys)40-b-p(L-Leu)10

3.88 x 10-3

PEG-b-p(L-Leu)10-b-p(L-Lys)40

1.27 x 10-2

PEG-b-p((L-Leu)10-co-p(L-Lys)40)

-4.90 x 10-2

PEG-b-p(L-Lys)20-b-p(L-Leu)10

4.54 x 10-2

PEG-b-p(L-Leu)10-b-p(L-Lys)20

5.72 x 10-2

PEG-b-p((L-Leu)10-co-p(L-Lys)20)

5.62 x 10-2

PEG-b-p(L-Lys)20-b-p(L-Leu)20

5.95 x 10-2

PEG-b-p(L-Leu)20-b-p(L-Lys)20

6.78 x 10-2

PEG-b-p((L-Leu)20-co-p(L-Lys)20)

6.23 x 10-2

4.3.7. Cytotoxicity of Cationic Tercopolymers and Polyplexes in Mammalian Cells
Although cationic nanoparticles have been effective in the delivery of genetic
materials to cells, the toxicity is still an obstacle and has raised several safety concerns.
Highly positive surface charge of cationic nanoparticles causes electrostatic interactions
with the negatively charged cell membrane and triggers membrane disruption and
damage. It has been previously shown that both, the efficacy and toxicity of cationic
polymers, are correlated with their molecular weight as well as structure.69,87 Therefore,
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efficacy and adverse reactions related to cationic polymeric gene vectors seem to be
associated, where either a high transfection efficacy can produce an advanced toxicity.
Here, cytotoxicity was counteracted through PEGylation, manipulation of charge
density, and positioning of the poly(amino acid) blocks in order to change or lower the
non-specific electrostatic polyplex interactions with cell membranes. Charge densities
and positionings of cationic blocks of PEG-b-p(L-Lys)x-b-p(L-Leu)y, PEG-b-p(L-Leu)x-bp(L-Lys)y, and PEG-b-p((L-Leu)x-co-(L-Lys)y) tercopolymers were assessed through
acute toxicity experiments in a COS-1 cell line (15,000 cells per well) using MTT assays.
It is hypothesized that by changing the cationic density and position, biocompatibility can
be altered or improved.
Due to lower cell line concentrations in each well, tercopolymers concentrations
were chosen based on one fourth the amount of DNA used in vitro transfections at 10:1,
20:1, and 40:1 N:P ratios. As shown in Figure 4.12., increased concentrations of
tercopolymers exhibited higher toxicity for each tercopolymer construct and the amount
of toxicity varied based upon the number cationic units. For example, when the
concentration of p(L-Lys) is 40 units, the cytotoxicity of tercopolymer was dramatically
enhanced. This is consistent with prior reports that the size of p(L-Lys) in block
copolymers can directly impact their cytotoxicity.87
Tercopolymers containing the largest cationic density (Figure 4.12 A) produced
~34-44% and ~61-66% of cell death at 40 and 80 µg/mL respectively, while lower
concentrations yield 9-18% of cell death. By decreasing the cationic densities by half
from 40 to 20 L-Lys units, cell viability was improved by 25% for both block copolymer
constructs at 80 µg/mL (Figure 4.12 B). This cannot be seen in random tercopolymers
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suggesting that toxicity of these constructs may be dependent upon nanoparticle structure
and not cationic density.
Random tercopolymers were also shown to be more toxic, where larger reductions
in cell viability (50% decrease) are observed when increasing their concentrations from
20 to 80 µg/mL or 30 to 120 µg/mL (Figure 4.12 A and B). This suggests that random
tercopolymer constructs are more toxic against COS-1 mammalian cells when compared
to block conformations to show a 30% decrease in cell viability. This toxicity is lowered
by 10-20% by increasing hydrophobic p(L-Leu) concentration within these random
tercopolymers, whereas block structures show minimal effect (Figure 4.12 C).
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Figure 4.12. Cell viability of COS-1 cells incubated for 48 h with nanoparticles containing only
PEG-b-p(L-Lys)x-b-p(L-Leu)y, PEG-b-p(L-Leu)x-b-p(L-Lys)y, and PEG-b-p((L-Leu)x-co-(LLys)y) tercopolymers at various concentrations. Data are shown as mean ± SE (n= 3-6).

First, it was observed that the toxicity increases for all polyplexes when the N:P
ratios are increased from 10:1 to 40:1. The increase in toxicity was more pronounced in
PEG-b-p((L-Leu)10-co-(L-Lys)40), Figure 4.13 A. Reducing the p(L-Lys) block length
from 40 to 20 repeat units resulted in an overall boost in cell viability, Figure 4.13 B and
C. Eventhough the overall cell viability is higher for random copolymer with only 20 LLys repeat units, the inpact of the N:P ratio on cell viability is pronounced with higher
N:P ratio generating more toxicity. Thus, the alteration of cationic p(L-Lys) and
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hydrophobic p(L-Leu) concentrations within each tercopolymer construct can change or
improve the biocompatibility. The ability to manipulate PAAs and generate desirable
effects, such as lower cytotoxicity, is imperative to creating gene delivery vectors with
improved efficacy.
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Figure 4.13. Cell viability of COS-1 cells incubated for 48 h with polyplexes at various
tercopolymer and pDNA concentrations. Data are shown as mean ± SE (n= 3-6).
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4.3.8. COS-1 In vitro Gene Transfection
PEG-b-p(L-Lys)x-b-p(L-Leu)y, PEG-b-p(L-Leu)x-b-p(L-Lys)y, and PEG-b-p((LLeu)x-co-(L-Lys)y) polyplexes were also tested for their ability to transfect mammalian
cells in vitro. Transfections were performed with tercopolymers formulated with a large
pCMV plasmid (7,040 bps) encoding firefly luciferase. Polyplex formulations containing
these plasmids were added to African green monkey kidney cells (COS-1) in DMEM
culture medium supplemented with 10% FBS for 48 h and gene transfection efficiency
was examined through lucerirase protein expression as a function of N:P ratio.
Transfection can be seen for all tercopolymers at 10:1, 20:1, and 40:1 N:P ratios
when compared to naked plasmid (Figures 4.14-4.16). The transfection efficiency varied
upon the polymer structure where PEG-b-p(L-Lys)x-b-p(L-Leu)y tercopolymers displayed
a higher maximum transfection of ~2.3 x 107 RLU/mg protein (Figures 4.14-4.16 A),
while all other tercopolymers exhibit maximum transfection of ~1.5 x 107 RLU/mg
protein. As discussed for the serum stability studies (section 4.3.6.), longer hydrophobic
L-Leu segments lead to greater aggregation of the polyplexes in serum. Block
tercopolymers containing 20 L-Leu units exhibited a lower transfection efficiency at
higher N:P ratios, while maintaining total protein levels (Figure 4.16 A and B). On the
other hand, random tercopolymers showed little change in transfection efficiency at
higher N:P ratios due to improved solubility (Figure 4.16 C). PEG-b-p(L-Lys)40-b-p(LLeu)10 shows a different trend compared to all other tercopolymers, where better
transfection efficiency occurs at increasing N:P ratios (Figure 4.14 A). The reasoning for
this result is inconclusive and needs to be further evaluated.
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Similar to MTT assays, cytotoxicity was directly correlated to the increase in
polymer concentration (N:P ratio) for each tercopolymer within the polyplexes containing
higher cationic density (Figures 4.14-4.15). When compared to 10:1, the level of total
protein decreased by 9-17% at 20:1 for block tercopolymers within these groupings. At
N:P 40:1, total protein decreases even further by 24-47%. Random tercopolymers exhibit
a more dramatic toxic profile with total protein reductions of 53-56% at 20:1 and 67-83%
at 40:1 (Figures 4.14-4.15 C). The way in which random tercopolymers form polyplexes
differently than block tercopolymers clearly affects their interactions with cell
membranes, causing toxicity and cell death. By increasing hydrophobic p(L-Leu)
concentration, cytotoxicity is reduced for both block and random tercopolymers,
producing negligible toxicity and a total protein reduction of 32% at N:P of 40:1
respectively (Figure 4.16). In contrast, wells comprised of N:P 10:1 complexes displayed
minimal toxicity and an adequate level of gene expression. Therefore, it is anticipated
that the ideal balance between toxicity and transfection is between the N:P ratios of 10:1
and 20:1 for all tercopolymer polyplexes.
High charge density is obviously toxic to cells by intrusively distrupting
metabolism at the cell surface. Likewise, the introduction of foreign material into cells,
such as nanoparticles in transfection, can be naturally correlated to specified level of
toxicity by itself. While various commercial transfection reagents display low levels of
toxicity, efficient delivery systems are designed to transport genetic plasmid into the cells
by disrupting membranes, specifically the lysosomal membrane via the “proton sponge”
effect. This behavior may result in certain level of outer cell membrane destabilization,
which is observed in toxicity.
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Figure 4.14. Transfection efficiency and total protein concentration of A) PEG-b-p(L-Lys)40-bp(L-Leu)10, B) PEG-b-p(L-Leu)10-b-p(L-Lys)40, and C) PEG-b-p((L-Leu)10-co-(L-Lys)40)
polyplexes in COS-1 cells at 10:1, 20:1, and 40:1 N:P ratios. Bars shown as mean ± SE (n =3-4).
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Figure 4.15. Transfection efficiency and total protein concentration of A) PEG-b-p(L-Lys)20-bp(L-Leu)10, B) PEG-b-p(L-Leu)10-b-p(L-Lys)20, and C) PEG-b-p((L-Leu)10-co-(L-Lys)20)
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Figure 4.16. Transfection efficiency and total protein concentration of A) PEG-b-p(L-Lys)20-bp(L-Leu)20, B) PEG-b-p(L-Leu)20-b-p(L-Lys)20, and C) PEG-b-p((L-Leu)20-co-(L-Lys)20)
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At N:P 40:1, distinct trends are observed for transfection efficiency and
cytotoxicity for all tercopolymers constructs. As shown in Figure 4.17, the transfection
efficiency of the polyplexes appears to hinge on the cationic density provided by p(LLys) segments. Tercopolymers containing 40 L-Lys units show higher transfection
independent upon the tercopolymer structure. By reducing the cationic density in half to
20 L-Lys units, transfection is decreased 5-25% based upon the tercopolymer structure.
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Subsequent addition of hydrophobicity by increasing from 10 to 20 L-Leu units further
lessened transfection efficiency, especially in PEG-b-p(L-Lys)x-b-p(L-Leu)y by 53%.
Although higher cationic charge density allows for better transfection, it also
causes higher levels of toxicity that is inherent to all cationic polymer transfection
systems used within this project. For example at 40:1 N:P ratio, the total protein
observed was dependent upon overall catonic density within each tercopolymer construct
(Figure 4.18). By comparison, when decreasing the cationic L-Lys units from 40 to 20
the total protein concentration is improved by 40-57% for block constructs and 18% for
random constructs. The further increase of L-Leu units from 10 to 20 units leads to an
improvement of total protein concentration by 40-60% for all tercopolymers. A similar
transfection and cytotoxicity trend can be observed for tercopolymers at 20:1, but the
effect of cationic density is suppressed (Appendix C; Figure C.10 and C.11). At 10:1, all
trends are negligible or not observed (Appendix C; Figure C.12 and C.13).
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CHAPTER 5

PEGYLATED ANIONIC POLY(AMINO ACID) TERCOPOLYMERS AS DRUG
DELIVERY VECTORS

4.1. Introduction
Drug delivery is significant as the delivery vehicle can influence the efficiency
and efficacy of drugs. Polymers have played an important role in the improvement of
drug delivery technology by providing vesicles for small molecule encapsulation, from
which the incorporated drug can released to the environment in a controlled manner. The
delivery of therapeutic compounds can be minimized by their poor water solubility.
Many polymers have been used in the form of nanoparticles acting as efficient
solubilizing agents, from which the incorporated drug is released to the environment in a
controlled manner.182
Block copolymers, similar to small molecule surfactants, can assemble into
micellar structures in a particular medium that selectively solvates only one of the two
polymer segments. Compared to surfactants, block polymers can maintain very low
critical micelle concentrations, which leads to thermodynamically stable nanostructures.
Micelle structures can be formed through the self-assembly of either amphiphilic or
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oppositely charged copolymers in aqueous medium, where the hydrophilic and
hydrophobic segments form the corona and the core of the micelles, respectively. The
ability of polymeric micelles to form 10-100 nm nanostructures can restrict their
clearance and avoid renal excretion, allowing for an enhanced permeation and retention
effect.183
Many polymeric drug delivery systems consist of biodegradable polymers due to
their biocompatibility and biodegradability. The use of poly(amino acid)s are desirable
as drug delivery vectors because they contain both these attributes. Poly(amino acid)s
allow for the incorporation of specific amino acids, containing properties such as
hydrophilicity and hydrophobicity, that produce amphiphilic block copolymer sequences
that self assemble in aqueous solution.141
Here, the use of PEG-b-p(L-Glu)x-b-p(L-Leu)y, PEG-b-p(L-Leu)x-b-p(L-Glu)y,
and PEG-b-p((L-Leu)x-co-(L-Glu)y) tercopolymers were investigated for their capability
of forming stable self-assemblies that can encapsulate biologically active drugs. The
order and physical characteristics of the polymer structure can affect chain conformation
in the poly(amino acid) and the nature of self-assembly. Likewise, altering these factors
can either disturb or enhance nanoparticle formation and drug encapsulation.

5.2. Experimental
5.2.1. Materials
Dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), triethylamine (TEA), and
Drierite™ were purchased from Fisher Scientific (Waltham, MA). Dialysis bags
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(Spectrum™ Labs Spectra/Por™ 7 6000-8000 D and Spectra/Por™ 3 3500 D molecular
weight cut off (MWCO) Standard RC) and Polyvinylidene fluoride (PVDF) syringe
filters were purchased from Thermo Scientific (Waltham, MA). Indomethacin, nile red,
and pyrene were purchased from Sigma Aldrich (St. Louis, MO). Doxorubicin
hydrochloride (DOX-HCl) was purchased from Cayman Chemicals (Ann Arbor, MI).
Water was deionized through a Millipore Milli-Q using a UV Gradient A10 Ultrapure
Water System.

5.2.2. Methods
5.2.2.a. Anionic Nanoparticle Formation
Nanoparticles of protected and deprotected anionic PEG-PAA tercopolymers
were investigated and prepared using the same nanoprecipitation, direct solvation, and
evaporation method protocols as described for cationic tercopolymers (section 4.2.2.a).
Particle size data of PEGylated anionic PAA tercopolymers was measured by DLS at λ =
532 nm and analyzed by BIC software. Particle size was measured in triplicate at a
single angle approach of 90° and at 25°C.

5.2.2.b. Critical Micelle Concentration
The critical micelle concentrations for all anionic tercopolymers was determined
using the same pyrene fluorescent probe used previously in section 4.2.2.a. Fluorescence
spectra were recorded on a FluoroMax-3 spectrometer (Horiba, JobinYvon) equipped

171

with a GRAMS/32 data analysis system. All measurements were carried out at 25 °C and
slit widths were set at 2 nm and 1.5 nm for the excitation and emission monochromators,
respectively. The onset of association (cass) was determined by ranging polymer
concentrations from 5.0 mg/mL to 6.0 × 10−6 mg/mL in aqueous pyrene solution (Py ~
10−6 M). The emission intensities measured at the first (373 nm (I1)) and third (383 nm
(I3)) vibronic peaks in the fluorescence emission spectrum of pyrene were utilized to
calculate the ratio I1/I3. Ratios of the emission intensities (I1/I3) were then plotted against
polymer concentrations to determine CMC values for the PEGylated anionic PAA
tercopolymer.

5.2.2.c. Confocal Laser Scanning Microscopy
2 mg of all tercopolymers where dissolved in 2 mL for deionized water to achieve
a final concentration of 1 mg/mL. 20 µL of 0.2 mM hydrophobic fluorescent dye (Nile
Red in DMSO) was added under ultrasonication and mixed gently for 4 hours. The
mixture was then placed with a dialysis bag (Spectra/Por™; MWCO 3,500) in order to
remove DMSO. A drop of the dye incorporated samples was placed on a glass slide and
covered using an 18 mm square coverslip. Nanoparticles were visualized using a Zeiss
LSM 700 confocal laser scanning microscope (CLSM) (Leica Microsystems, Wetzlar,
Germany) with a 100x/1.46 oil immersion objective. Emission was captured, in which
the emission spectrum of Nile Red was recorded for one excitation wavelength at 550
nm. An excitation-emission scan was captured at a detection range that varied from 560
to 700 nm.
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5.2.2.d. Small-angle Neutron Scattering
Small-angle neutron scattering (SANS) measurements were performed at the BL6B (EQ-SANS), Spallation Neutron Source at Oakridge National Laboratory. A 4-meter
sample-to-detector distance and 60-Hz operation mode with neutron wavelength bands
with minima of 2.5 and 9.5 Å were used. Benzyl-protected block copolymers (10 mg)
were dissolved in 3 mL of tetrahydrofuran (THF). The organic phase was added dropwise
into the D2O phase (10 mL) and gently stirred at 35-40 °C in a warm oil bath until the
evaporation of the organic solvent was complete. If necessary, sufficient amounts of D2O
were added to obtain between 1.7 and 1.8 wt.% sample concentration. The solution was
filtered (0.45-μm Millex micropore Millipore poly(vinylidene fluoride), PVDF, filter)
directly loaded into dustfree 1 mm path length quartz sample cells. Five measurements
were carried out and all measurements were performed at 20 °C.

5.2.2.e. Drug Loading of Doxorubicin
Drug-loaded micelles were prepared at 20% and 40% w/w of doxorubicin (DOX)
to tercopolymer. A DOX stock solutions (2.6 and 5.3 mg/mL) were prepared in DMSO
for the 20% and 40% w/w DOX loading respectively. For the DOX-loaded micelles,
DOX was first neutralized before micelle preparation. Triethylamine (TEA) (10 µL) was
added to each stock solution and stirred for 1 hr. Each tercopolymer (4 mg) was
dissolved in deionized water (4 mL) and sonicated for 1 minute or until all copolymer
was completely dissolved.
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Afterwards, 300 µL of each organic solution containing the drug was added
dropwise to the dissolved polymer under vigorous ultrasonication using a sonification
bath (Fisher Scientific, Waltham, MA) for 2 min. The doxorubicin-loaded micelle
solution was dialyzed against 1 L of deionized water for 24 h at 25°C using a regenerated
cellulose membrane bag (MWCO = 6,000-8,000) to remove unloaded doxorubicin. The
deionized water was substituted every 1 h for the first 3 h and then every 6 h.
In order to examine the extent of doxorubicin loaded into the micelles, the product
was freeze dried and the contents were dissolved in 4 mL of a DMSO and methanol
mixture (4:1). Using UV-Vis spectroscopy, results were determined from a calibration
curve of pure doxorubicin prepared at different concentrations (0-150 µg/mL) in the same
solvent. The absorbance was measured at 486 nm using a GENESYS 10S UV-Vis
spectrophotometer (Thermo Scientific, Waltham, MA) (Appendix D.1.B). Using the
equation of the calibration curve (y = 0.0181x + 0.0102, R² = 0.9991), the amount of
DOX entrapped was determined.
The particle size and its polydispersity were determined by DLS at 25°C using an
excitation of 532 nm illuminated at a fixed angle of 90°. The nanoparticle solutions,
prepared as described prior to lyophilization, were filtered through a PVDF 0.45 µm filter
prior to measurements to eliminate the polymer and doxorubicin aggregates. All the
procedures were carried out under light protection.
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5.2.2.f. Drug Loading of Indomethacin
Indomethacin (IMC) was used as a model drug due to its hydrophobic properties.
Each anionic tercopolymer (4 mg) was dissolved in 4 mL of deionized water via
ultrasonication followed by dropwise addition of IMC under sonication with a 0.25:1,
0.50:1, and 1:1 drug to polymer weight ratio. Mixtures were further sonicated for 2
minutes after IMC addition. To form IMC-loaded nanoparticles and remove free IMC,
the solution was dialyzed for 24 h against 4 L of deionized water using regenerated
cellulose dialysis membranes (MWCO = 6,000-8,000).
The nanoparticle solution was sonicated for 30 seconds and then centrifuged
through a 0.45 µm PVDF filter to eliminate unloaded IMC and aggregated particles.
DLS was used to determine particle size of IMC loaded nanoparticles at 25°C. Once
completed, the filtered solution was frozen and lyophilized (Labconco, USA), to obtain
dried nanoparticle products. The dried nanoparticles were disrupted by the addition of
THF and ethanol (1:1 v/v), the amount of entrapped IMC was determined by measuring
the UV absorbance at 319 nm using a GENESYS 10S UV-Vis spectrophotometer. For
this analysis, a calibration curve of standard solutions containing 0-250 µg/mL of IMC
was generated by UV absorbance at 319 nm (Appendix D.2.B). Using the equation of the
calibration curve of IMC (y = 11.169x - 0.0085, R² = 0.9988), the quantity of entrapped
IMC was verified.
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5.3. Results and Discussion
5.3.1 Particle Formation Behavior of Anionic Tercopolymer Self Assemblies
Nanoparticles can offer distinct advantages over micron sized nanostructures
when trying the deliver encapsulated small molecule drugs. Nanoparticles have
demonstrated relatively higher intracellular and submucosal uptake when compared to
microparticles both in vitro and in vivo respectively.184–186 Thus, the particle size of
nanostructures can affect the efficacy of delivery systems carrying drug therapeutics.
Similar to cationic tercopolymers, various methods of particle formation of both
protected and deprotected PEGylated tercopolymers were executed to prepare
nanoparticles of the smallest size. DLS was performed to determine the size of the selfassembled tercopolymer nanoparticles. The aggregation behavior of tercopolymers was
found to be contingent upon (i) the protection and deprotection of p(L-Glu) blocks, (ii)
the method of nanoparticle formation for deprotected tercopolymers, and (iii) the
placement of the anionic segments within the polymer construct.
Tables 5.1 and 5.2 summarize DLS results for both protected and deprotected
tercopolymers. As shown for cationic tercopolymers, bimodal distribution with two
different particle populations were observed for anionic tercopolymers as well. The
nanoprecipitation method was performed for protected tercopolymers through
evaporation of a THF/H2O solvent mixture. Due to the lack of copolymer solubility in
aqueous solutions, large aggregates formed.
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Table 5.1. Light scattering data for solutions of PEG-b-p(Bnl-L-Glu)x-b-p(L-Leu)y, PEG-b-p(LLeu)x-b-p(Bnl-L-Glu)y, PEG-b-p((L-Leu)x-co-(Bnl-L-Glu)y) tercopolymers in dilute aqueous
solutions (polymer concentration: 1.0 g L−1) at 24°C via nanoprecipitation method.
Nanoprecipitation Method
Polymer

Micelle Group
(nm)

Aggregate
Group
(nm)

Effective
Diameter
(nm)

PEG-b-p(Bnl-L-Glu)52-b-p(L-Leu)12

27.2
36.4
27.6 (min.)

180.1
133.7
124.1

83.1
92.5
97.5

19.8 (min.)
21.8 (min.)
40.4

134.3
104.5
159.8

109.1
104.3
117.1

40.3
37.2
35.2

140.1
138.9
140.9

91.2
71.5
111.9

PEG-b-p(L-Leu)12-b-p(Bnl-L-Glu)50
PEG-b-p((L-Leu)12-co-(Bnl-L-Glu)50)
PEG-b-p(Bnl-L-Glu)20-b-p(L-Leu)9
PEG-b-p(L-Leu)12-b-p(Bnl-L-Glu)22
PEG-b-p((L-Leu)12-co-(Bnl-L-Glu)22)
PEG-b-p(Bnl-L-Glu)24-b-p(L-Leu)23
PEG-b-p(L-Leu)23-b-p(Bnl-L-Glu)24
PEG-b-p((L-Leu)23-co-(Bnl-L-Glu)26)

Table 5.2. Light scattering data for solutions of PEG-b-p(L-Glu)x-b-p(L-Leu)y, PEG-b-p(L-Leu)xb-p(L-Glu)y, PEG-b-p((L-Leu)x-co-(L-Glu)y) tercopolymers in dilute aqueous solutions (polymer
concentration: 1.0 g L−1) at 24°C via the evaporation method.
Evaporation Method
Polymer
PEG-b-p(L-Glu)40-b-p(L-Leu)12
PEG-b-p(L-Leu)12-b-p(L-Glu)44
PEG-b-p((L-Leu)13-co-(L-Glu)40)
PEG-b-p(L-Glu)19-b-p(L-Leu)11
PEG-b-p(L-Leu)12-b-p(L-Glu)18
PEG-b-p((L-Leu)11-co-(L-Glu)19)
PEG-b-p(L-Glu)23-b-p(L-Leu)22
PEG-b-p(L-Leu)24-b-p(L-Glu)20
PEG-b-p((L-Leu)23-co-(L-Glu)23)

Micelle Group (nm)

Aggregate Group
(nm)

Effective
Diameter (nm)

37.9 (min.)
126.0
138.9

161.6
254.1
416.4 (min.)

152.3
155.6
155.5

N/A
87.0 (min.)
43.4 (min.)

158.9
213.9
159.2

162.5
179.5
138.6

145.1
138.2
53.1 (min.)

379.5 (min.)
329.1 (min.)
151.9

160.9
143.1
139.7

177

As briefly mentioned, a bimodal distribution of particles in H2O for all protected
and deprotected tercopolymer samples was observed, independent of block length and
molecular architecture. Further investigation of these particle size groupings was done
through small-angle neutron scattering (SANS) of selected benzyl-protected
tercopolymers and compared with DLS results.
An overlay of a typical DLS spectrum with SANS data are shown for PEG-bp(Bnl-L-Glu)20-b-p(L-Leu)10 in Figure 5.1. As shown in Table 5.3., results show that the
maxima of the DLS particle size distribution (hydrodynamic radius RH) are in good
agreement with the SANS data (radius of gyration RG). For poly(amino acid)s, a contour
length of disordered peptide structures can be normally estimated at ~3.8 Å per monomer
unit.187 SANS results show three different structural groupings. RG1 values were found
between 3.5-4.9 nm for our individual tercopolymers consisting of 144 to 163 total
monomer units of PEG and PAA. DLS does not show these small signals possibly due to
the suppression of the signal intensities of single chains when larger particles are
observed, producing a weak signal of single molecules.
DLS results of amphiphilic PEGylated PAAs solutions in H2O show a bimodal
distribution with two distinct RH; one ranging at a size that is characteristic for polymeric
micelles (RH,1 ~7 to 12 nm), and the other one is indicative of micelle aggregates (RH,2
~26 to 40 nm). It is assumed that nanoparticle structures are formed with a corona
consisting of larger number of amino acids and an outer shell of PEG, thus the maximum
core radius can be estimated from the PAA contour length. For example, sample 1 can be
estimated at 30×0.38 nm=11.4 nm and sample 6 can be estimated at 49×0.38 nm=18.6
nm. Based on previous research, our PEG shell should be twice as large as the RH of a
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single PEG chain (1.9 nm), with the assumption that the equilibrium formation of the
PEG chain in water is the same.188,189 PEG conjugation with a more hydrophobic
copolymer than the PAAs can put stress upon the PEG block during self assembly and
lead to chain extension and thicker shells. Nonetheless, the observed radii of 7-13 nm
(RH,1 from DLS and RG,2 from SANS, Table 5.3.) are in good agreement with the
anticipated dimension of micelle structures. Larger structures of 26-41 nm (RH,2 from
DLS and RG,3 from SANS, Table 5.3.) cannot be caused by an ordinary micellar shape,
indicating that micelles interact to form aggregates, see Scheme 5.1. Graphs for all other
samples can be found in Appendix D; Figure D.3.

Table 5.3. Hydrodynamic radii and radii of gyration for PEGylated PAAs.190

Polymer composition

RH,1
(nm)

RH,2
(nm)

RG,1
(nm)

RG,2
(nm)

RG,3
(nm)

1

PEG-b-p(Bnl-L-Glu)20-b-p(L-Leu)10

7.3

33.3

3.0

9.3

32.4

2

PEG-b-p(L-Leu)12-b-p(Bnl-L-Glu)22

9.2

40.2

3.2

9.5

41.2

3

PEG-b-p((L-Leu)12-co-(Bnl-L-Glu)23

12.0

35.6

4.5

10.2

27.4

4

PEG-b-p(Bnl-L-Glu)24-b-p(L-Leu)23

12.0

35.6

4.5

10.2

27.4

5

PEG-b-p(L-Leu)23-b-p(Bnl-L-Glu)24

10.2

30.6

4.8

12.9

33.8

6

PEG-b-p((L-Leu)23-co-(Bnl-L-Glu)26

8.7

26.8

4.9

11.7

25.3

Sample
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Figure 5.1. Apparent hydrodynamic radius (RH) distribution from DLS analysis (open bars) and
radius of gyration (RG) from SANS analysis (black bars) with their relative intensities for PEG-bp(Bnl-L-Glu)20-b-p(L-Leu)10 (Sample 1).190

Effective diameters of all aggregates formed by protected tercopolymers using
nanoprecipitation were between 83.1 and 117.1 nm. Random copolymer constructs were
shown to exhibit larger particle sizes in each tercopolymer grouping, suggesting that the
packing for these nanoparticles differ from those consisting of block tercopolymers.
Although random copolymers show larger sizes, all protected copolymers displayed
overall effective diameters around 100 nm. Unfornately, these tercopolymers are not
optimal as drug delivery vechicles because of their high hydrophobicity due to γ-benzyl
protection of p(L-Glu) amino acids.
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Scheme 5.1. Graphical representation of polymeric aggregate formation: single chains form
micelles, which then aggregate into larger structures.190

Larger particle sizes can be seen when using the nanoprecipitation (Table 5.1) and
THF evaporation (Table 5.2) methods for protected and deprotected copolymers,
respectively. Comparable to cationic tercopolymers, swelling of nanoparticles from 75117 nm to 138-180 nm are attributable to the solubility of the negatively charged L-Glu.
No distinguishable swelling trend can be seen by increasing the anionic character for all
deprotected copolymers within both the evaporation and direct solvation methods (Tables
5.2 and 5.4).
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Table 5.4. Light scattering data for solutions of PEG-b-p(L-Glu)x-b-p(L-Leu)y, PEG-b-p(L-Leu)xb-p(L-Glu)y, PEG-b-p((L-Leu)x-co-(L-Glu)y) tercopolymers in dilute aqueous solutions (polymer
concentration: 1.0 g L−1) at 24°C via the direct solvation method.
Direct Solvation Method
Polymer

Micelle Group
(nm)

Aggregate Group
(nm)

Effective
Diameter (nm)

PEG-b-p(L-Glu)40-b-p(L-Leu)12

26.6 (min.)
31.6
30.6 (min.)

77.9
166.5
138.3

77.7
121.9
127.9

47.8
13.0 (min.)
28.3 (min.)

182.3
83.6
155.1

89.7
69.6
113.7

60.1
74.6
24.8 (min.)

196.8
196.6
134.3

97.7
110.6
117.4

PEG-b-p(L-Leu)12-b-p(L-Glu)44
PEG-b-p((L-Leu)13-co-(L-Glu)40)
PEG-b-p(L-Glu)19-b-p(L-Leu)11
PEG-b-p(L-Leu)12-b-p(L-Glu)18
PEG-b-p((L-Leu)11-co-(L-Glu)19)
PEG-b-p(L-Glu)23-b-p(L-Leu)22
PEG-b-p(L-Leu)24-b-p(L-Glu)20
PEG-b-p((L-Leu)23-co-(L-Glu)23)

As seen in Table 5.4, deprotected random anionic tercopolymers swell more
strongly than their respective block copolymers. If the p(L-Glu) is formed into block
segments, it allows for PEG-b-p(L-Glu)x-b-p(L-Leu)y and PEG-b-p(L-Leu)x-b-p(L-Glu)y
tercopolymers to form tighter nanostructures that can affect the entrapment and release of
encapsulated drugs. Random anionic tercopolymers obstruct aggregation and do not
allow the hydrophobic blocks to produce a tightly packed aggregates through
hydrophobic intermolecular interactions.
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A

B

C

Scheme 5.2. Graphical representation of possible tercopolymer nanoparticle structures for: A)
PEG-b-p(L-Glu)x-b-p(L-Leu)y, B) PEG-b-p(L-Leu)x-b-p(L-Glu)y, and C) PEG-b-p((L-Leu)x-co(L-Glu)y).

Deprotected copolymers created smaller particles (78-128 nm) when solvated
directly in water after ultra sonication when compared to particle formation within a
THF/H2O mixture. Again, THF disrupts smaller micellar structures for all deprotected
tercopolymers, leading to larger aggregation (138-180 nm). Therefore, all deprotected
anionic tercopolymers should be directly solvated in water to generate lower sized
nanoparticles that can entrap, solubilize, and hold small molecule drugs.
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5.3.2. Critical Micelle Concentration
As seen in Figure 5.2, CMC varied based upon the overall hydrophobicity of each
tercopolymer. CMC results for all tercopolymers range from 4-90 µg/mL (Table 5.5)
with lower values (4-10 µg/mL) occurring for tercopolymers containing 20 p(L-Leu)
repeat units. When compared to PEGylated cationic PAA tercopolymers, PEG-b-p(LGlu)x-b-p(L-Leu)y, PEG-b-p(L-Leu)x-b-p(L-Glu)y, and PEG-b-p((L-Leu)x-co-(L-Glu)y)
tercopolymers show more stability in aqueous environments, suggesting that swelling and
disruption of their nanoparticles by water molecules is much lower.
Particle stability within block tercopolymers was shown to be independent upon
the amount of anionic p(L-Glu) and hydrophobic p(L-Leu) within each polymer
construct. Decreasing or increasing the p(L-Glu) and p(L-Leu) blocks did not
significantly affect the CMC of each block copolymer construct. If p(L-Leu) is contained
within the middle segment of block tercopolymers, the CMC slightly increases by 1-2
µg/mL.
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Figure 5.2. CMC analysis of PEG-b-p((L-Glu)x-b-p(L-Leu)y), PEG-b-p((L-Leu)x-b-p(L-Glu)y),
and PEG-b-p((L-Leu)x-co-(L-Glu)y) copolymers.
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Table 5.5. Final composition of deprotected PEGylated anionic PAA tercopolymers in addition
to their CMC values.

Tercopolymer

PEG/L-Glu/L-Leu
ratio actual
composition

Mw (Da)

CMC
(µg/mL)

PEG-b-p(L-Glu)40-bp(L-Leu)12

1:40:12

11,500

6

PEG-b-p(L-Glu)19-bp(L-Leu)11

1:19:11

8,700

8

PEG-b-p(L-Glu)23-bp(L-Leu)22

1:23:22

10,400

4

Tercopolymer

PEG/L-Leu/L-Glu
ratio actual
composition

Mw (Da)

CMC
(µg/mL)

PEG-b-p(L-Leu)12-bp(L-Glu)44

1:12:44

12,000

7

PEG-b-p(L-Leu)12-bp(L-Glu)18

1:12:18

8,700

9

PEG-b-p(L-Leu)24-bp(L-Glu)20

1:24:20

10,300

6

Tercopolymer

PEG/L-Leu/L-Glu
ratio actual
composition

Mw (Da)

CMC
(µg/mL)

PEG-b-p((L-Leu)13co-(L-Glu)40)

1:13:40

11,600

90

PEG-b-p((L-Leu)11co-(L-Glu)19)

1:11:19

8,700

60

PEG-b-p((L-Leu)23co-(L-Glu)23)

1:23:23

10,600

10

CMC values were dependent upon distribution of hydrophobicity within the
tercopolymers (Table 5.5). Random tercopolymers spread out the hydrophobicity
allowing for the disruption of stabilization provided by p(L-Leu), leading to higher CMC
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values (10-90 µg/mL). By decreasing the L-Glu units from 40 to 20, the CMC is
decreased 33% from 90 to 60 µg/mL. However when the L-Leu content is increased to
20 repeat units and 20 L-Glu repeat units is maintained, hydrophobicity of L-Leu
segments supersedes disassembly and the CMC lowers by 87% from 60 to 10 µg/mL.
Overall, PEG-b-p(L-Glu)x-b-p(L-Leu)y, PEG-b-p(L-Leu)x-b-p(L-Glu)y, and PEG-b-p((LLeu)x-co-(L-Glu)y) tercopolymers containing larger p(L-Leu) segments exhibit higher
micelle stability that can be more profound within random PAA copolymer constructs.
By modifying the amphiphilic balance of the tercopolymers, it is possible to target
desired CMC values, especially within random tercopolymers.

5.3.3. Fluorescence Microscopy of Dye Loaded Tercopolymer Self Assemblies
Once establishing a particle formation method that produces nanometer-sized self
assemblies (section 4.2.2.a), PEGylated anionic tercopolymers were investigated for their
ability to encapsulate hydrophobic molecules inside. The hydrophobic dye Nile Red was
selected to investigate the loading properties of these nanoparticles. Nile Red does not
show distinctive fluorescence in polar aqueous environments, however it emits red
fluorescence under hydrophobic conditions.191,192 As seen in Figure 5.3., CLSM showed
red fluorescent spherical dots dispersed in water, indicating the successful incorporation
and sequestration of hydrophobic molecules inside PEGylated anionic PAA tercopolymer
nanoparticles. The encapsulation of Nile Red is driven by the hydrophobicity the p(LLeu) segments found within each tercopolymer. As a control, Nile Red was added to
water at the same concentration as tercopolymer samples, exhibiting negligible
fluorescence and no spherical aggregates (not shown).
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Figure 5.3. CLSM of A) PEG-b-p((L-Glu)40-b-p(L-Leu)10), B) PEG-b-p((L-Leu)10-b-p(L-Glu)40),
C) PEG-b-p((L-Leu)10-co-(L-Glu)40), D) PEG-b-p((L-Glu)20-b-p(L-Leu)10), E) PEG-b-p((LLeu)10-b-p(L-Glu)20), F) PEG-b-p((L-Leu)10-co-(L-Glu)20), G) PEG-b-p((L-Glu)20-b-p(L-Leu)20,
H) PEG-b-p((L-Leu)20-b-p(L-Glu)20), and I) PEG-b-p((L-Leu)20-co-(L-Glu)20) dye loaded
nanoparticles.
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5.3.4. Nanoparticle Encapsulation of Doxorubicin
Two main concerns in the design of drug-loaded polymeric self assemblies (e.g.
micelles and nanoparticles) exist when producing convenient and reproducible methods
to obtain nanosized systems with high drug loading characteristics. 1) Polymeric
micelles have a relatively low loading of partially water soluble drugs due to a limited
partitioning of these drugs into the hydrophobic corona. 2) Doxorubicin (DOX) is a
small molecule used in cancer chemotherapy that exhibits low water solubility which
affects its acute therapeutic effect upon normal epithelial cells.
Here, PEGylated PAA tercopolymer micelles are described through DLS and UVVis spectroscopy to determine their particle size and versatility to encapsulate DOX
therapeutic payloads, respectively. It is expected that a greater amount of doxorubicin
could be loaded into the inner core of these polymeric micelles to keep them suspended
in aqueous media, relative to free doxorubicin. Loading of doxorubicin was achieved at a
higher pH through the addition of triethylamine (TEA) during nanoparticle formation.
The adjustment of the pH to increase DOX loading has been previously explored by
Kataoka et al. who added an organic solution of DOX containing TEA to an aqueous
solution of preformed micelles.193 TEA deprotonates Dox, resulting in a decreased
solubility within aqueous nanoparticle solutions, allowing higher loading into the
hydrophobic nanoparticle core.
DLS was performed on drug loaded tercopolymer nanoparticles at a weight ratio
of 20% w/w drug to polymer. As seen in Table 5.6., the particle size of DOX-loaded
nanoparticles increased by 30 to 60 nm when compared to DOX-free nanoparticles
described in Table 5.3. The effective diameters of the DOX-loaded micelles ranged from
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90 to 169 nm and developed no distinct pattern based upon each tercopolymer
physiochemical characteristic. Similar to drug-free nanoparticles, drug loaded random
PAA constructs form larger nanoparticles due to their inability to form compact
structures in aqueous environments when compared to block tercopolymers. Free
doxorubicin was found to produce very large aggregates with an effective diameter of
1893 nm.

Table 5.6. Size distribution and effective diameters of doxorubicin loaded polymeric
nanoparticles.
Doxorubicin 20% w/w
Polymer

Micelle Group
(nm)

Aggregate Group
(nm)

Effective Diameter
(nm)

PEG-b-p(L-Glu)40-b-p(L-Leu)12

62.3
78.8
29.6 (min.)

234.4
229.4
183.7

116.7
152.0
169.3

92.7
59.8
62.5

221.5
272.9
222.9

151.4
160.3
161.5

PEG-b-p((L-Leu)23-co-(L-Glu)23)

34.2
42.9
34.3 (min.)

255.2
169.9
209.4

129.3
90.1
166.3

Doxorubicin

799.5

5143.5

1892.6

PEG-b-p(L-Leu)12-b-p(L-Glu)44
PEG-b-p((L-Leu)13-co-(L-Glu)40)
PEG-b-p(L-Glu)19-b-p(L-Leu)11
PEG-b-p(L-Leu)12-b-p(L-Glu)18
PEG-b-p((L-Leu)11-co-(L-Glu)19)
PEG-b-p(L-Glu)23-b-p(L-Leu)22
PEG-b-p(L-Leu)24-b-p(L-Glu)20

Drug loading contents and drug loading efficiencies were determined by UV-Vis
spectrophotometry at 486 nm. Doxorubicin loading was performed at two different
weight ratios (20% and 40% w/w) of drug to polymer under ultrasonication and dialysis
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was used to remove unloaded drug and DMSO over 24 hours. The drug loading content
(DLC) is the ratio of encapsulated drug mass within the nanoparticles to the total mass of
drug-loaded nanoparticles. The drug loading efficiency (DLE) is the ratio of mass of
drug loaded into nanoparticles to the mass of initial drug added. The DLC and EE were
calculated according to the following equations:

DLC wt% =

mass of drug encapsulated in nanoparticles

DLE % =

mass drug-loaded nanoparticles

mass of drug loaded in nanoparticles
mass of drug initally added

x 100 %

x 100 %

(Eq. 5.1.)

(Eq. 5.2.)

As shown in Table 5.7., the drug loading content and drug loading efficiency were
calculated in a range of 5-10% and 27-54% at 20% w/w DOX loading. By increasing
initial DOX loading from 20% to 40% w/w, the drug loading content and encapsulation
efficiency improved to 14-20% and 41-62%, respectively. The DOX was physically
encapsulated into copolymeric nanoparticles due to the hydrophobic interaction of drug
and hydrophobic p(L-Leu) core. Dox loading content increased almost linearly with
DOX weight ratio because more molecules are available for entrapment. Loading
efficiency, which corresponds to the percentage of DOX encapsulated for a given amount
of DOX used, also enhanced up to 35% when DOX feed weight ratio is doubled from
20% to 40%.
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Table 5.7. Loading content (DLC) and encapsulation loading efficiency (DLE) of doxorubicin
loaded triblock polymeric nanoparticles after 24 hour dialysis.
Doxorubicin Loading (20%
w/w)
Loading
Loading
content (%)
efficiency (%)

Doxorubicin Loading (40%
w/w)
Loading
Loading
content (%)
efficiency (%)

PEG-b-p(L-Glu)40-bp(L-Leu)12

8.09 ± 1.83

44.04 ± 9.34

15.38 ± 4.68

45.43 ± 12.27

PEG-b-p(L-Leu)12-bp(L-Glu)44

7.35 ± 0.01

39.66 ± 0.05

18.30 ± 2.05

56.01 ± 5.24

PEG-b-p((L-Leu)13-co(L-Glu)40)

7.02 ± 2.11

37.75 ± 10.79

16.37 ± 2.25

48.94 ± 5.75

PEG-b-p(L-Glu)19-bp(L-Leu)11

6.19 ± 1.20

33.01 ± 6.09

14.30 ± 0.52

41.71 ± 1.31

PEG-b-p(L-Leu)12-bp(L-Glu)18

5.78 ± 1.93

30.68 ± 9.86

18.14 ± 3.05

55.41 ± 7.86

PEG-b-p((L-Leu)11-co(L-Glu)19)

5.85 ± 1.32

31.09 ± 6.68

18.19 ± 1.97

55.58 ± 5.01

PEG-b-p(L-Glu)23-bp(L-Leu)22

9.81 ± 2.18

54.39 ± 11.15

19.20 ± 5.39

59.41 ± 14.23

PEG-b-p(L-Leu)24-bp(L-Glu)20

7.22 ± 2.16

38.90 ± 11.03

16.50 ± 2.19

49.39 ± 5.60

PEG-b-p((L-Leu)23-co(L-Glu)23)

5.08 ± 0.77

26.74 ± 3.85

19.88 ± 1.99

62.05 ± 5.06

Sample

The results showed that DLC and DLE were dependent on the composition of
ABC triblock copolymers at lower feed weight ratios. PEG-b-p(L-Glu)-b-p(L-Leu)
tercopolymers contained larger encapsulated drug amounts (7-10 %) and encapsulation
efficiencies (33-54%). These tercopolymer constructs allow for better compaction during
nanoparticle formation due to the hydrophobic p(L-Leu) C block positioning at the chain
end, which also affects the nanoparticle stability over 24 hours. Stability trends have
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shown that PEG-b-p(L-Lys)-b-p(L-Leu) tercopolymers have shown lower CMC values
than other tercopolymer constructs (Table 5.5.). PEG-b-p(L-Leu)-b-p(L-Glu)
tercopolymer nanoparticles need both PEG A-block and p(L-Glu) C-block segments to
form in such a way that both hydrophilic segments are located on the outside shell of the
nanoparticle. This organization can lead to strain on the hydrophobic p(L-Leu) B-block
that does not allow for stability of the nanoparticles, causing leakage of DOX into the
aqueous medium during the stirring procedure and less encapsulation over 24 hours.
Also, random PEG-b-p((L-Leu)-co-(L-Glu)) tercopolymers exhibit lower DOX loading
due to the lack of proper compaction of p(L-Leu) segments during nanoparticle
formation. These “loose” nanostructures allow for less DOX to become entrapped within
and may permit an easier release of the drug over time. When increasing DOX loading to
40% these patterns are not observed and drug encapsulation is not as controllable due to
possible saturation or overloading of the nanoparticles.

5.3.4. Nanoparticle Encapsulation of Indomethacin
The size and size distribution of IMC loaded nanospheres were measured by DLS.
As micelles were prepared by a method using a mixture both organic and aqueous solvent
(section 5.2.2.e.), an organic solvent used to dissolve the drug should be miscible with
water. Consequently, it could be anticipated that miscibilities of polymer and solvent or
water and solvent may affect the formation of nanoparticles.
From the DLS measurements, the average size of the tercopolymer varied based
upon the polymer construct and amount of drug loaded. Even though effective diameters
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are being evaluated, bimodal size distributions were observed for all IMC loaded
nanoparticles (values not shown). The larger particles are thought to be micelles that
further associated into aggregates, while the smaller particles were attributed to
individual micelles. Free IMC was found to produce no particles (data not shown) due to
the elimination of large aggregates after syringe filtration.
As seen in Table 5.8., the size of nanoparticles increases (89 to 203 nm) with the
loading amount of drug in comparison to that of unloaded tercopolymer micelles using
the direct solvation method (Table 5.4.; 78 to 128 nm). By increasing the drug payload,
nanoparticles exhibited a similar tendency to that of DOX loading where nanoparticle
sizes swelled depending upon the amount of drug being loaded. When doubling IMC
from 25% w/w to 50% w/w particle size increased from 89-160 nm to 90-200 nm. By
further increasing drug payload from 50% w/w to 100% w/w, particle size grew
minimally from 90-200 nm to 94-203 nm indicating that IMC drug loading showed little
effect on particle size above 50% w/w.
The size of nanoparticles was also influenced by the orientation and
hydrophobicity of the tercopolymer construct. Random tercopolymers developed larger
particle sizes at all IMC loading concentrations where larger nanoparticles are formed
due to lower compacted nanostructures. Tercopolymers containing the largest
hydrophobicity (20 L-Leu units) exhibited the smallest particle sizes for each
tercopolymer construct at all drug loading concentrations. These tercopolymers are also
less affected by the amount of drug being loaded into the nanoparticles. Particle size of
these tercopolymers increases by 5-30 nm whereas other tercopolymers containing less
hydrophobicity increased by 23-60 nm. These trends coincide well with results
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previously discussed for unloaded (section 5.3.1) and DOX loaded (section 5.3.4.)
tercopolymer nanoparticles

Table 5.8. Effective diameters of indomethacin loaded polymeric nanoparticles.
Indomethacin
Loading
(25% w/w)

Indomethacin
Loading
(50% w/w)

Indomethacin
Loading
(100% w/w)

Effective
Diameter (nm)

Effective
Diameter (nm)

Effective
Diameter (nm)

PEG-b-p(L-Glu)40-b-p(L-Leu)12

112.3

136.3

137.9

PEG-b-p(L-Leu)12-b-p(L-Glu)44

144.1

168.2

167.7

PEG-b-p((L-Leu)13-co-(L-Glu)40)

160.7

194.5

200.3

PEG-b-p(L-Glu)19-b-p(L-Leu)11

125.6

150.5

160.5

PEG-b-p(L-Leu)12-b-p(L-Glu)18

124.7

197.7

203.2

PEG-b-p((L-Leu)11-co-(L-Glu)19)

140.4

199.6

200.5

PEG-b-p(L-Glu)23-b-p(L-Leu)22

106.6

130.3

132.8

PEG-b-p(L-Leu)24-b-p(L-Glu)20

89.1

90.1

93.9

PEG-b-p((L-Leu)23-co-(L-Glu)23)

143.6

175.3

173.0

Sample
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Table 5.9. Loading content (DLC) and encapsulation loading efficiency (DLE) of indomethacin
loaded triblock polymeric nanoparticles after 24 hour dialysis.
Indomethacin Loading
(25% w/w)
Sample

Indomethacin Loading
(50% w/w)

Indomethacin Loading
(100% w/w)

Loading
content (%)

Loading
efficiency
(%)

Loading
content (%)

Loading
efficiency
(%)

Loading
content (%)

Loading
efficiency
(%)

PEG-b-p(L-Glu)40-b-p(L-Leu)12

2.06 ± 0.04

8.40 ± 0.16

4.22 ± 0.01

17.64 ± 0.04

13.44 ± 1.87

31.05 ± 3.81

PEG-b-p(L-Leu)12-b-p(L-Glu)44

4.26 ± 0.08

17.78 ± 0.33

1.43 ± 0.01

5.80 ± 0.06

13.48 ± 2.51

31.15 ± 5.16

PEG-b-p((L-Leu)13-co-(L-Glu)40)

0.52 ± 0.01

2.10 ± 0.04

0.82 ± 0.12

3.30 ± 0.50

9.74 ± 0.59

21.59 ± 1.19

PEG-b-p(L-Glu)19-b-p(L-Leu)11

3.95 ± 0.04

16.47 ± 0.18

2.10 ± 0.08

8.57 ± 0.32

16.45 ± 1.52

39.39 ± 3.09

PEG-b-p(L-Leu)12-b-p(L-Glu)18

1.72 ± 0.02

6.99 ±0.09

1.99 ± 0.35

8.12 ± 1.40

14.38 ± 0.15

33.60 ± 0.30

PEG-b-p((L-Leu)11-co-(L-Glu)19)

0.83 ± 0.01

3.35 ±0.02

1.75 ± 0.00

7.12 ± 0.01

12.61 ± 1.94

28.86 ± 3.96

PEG-b-p(L-Glu)23-b-p(L-Leu)22

5.90 ± 0.00

25.07 ± 0.01

7.98 ± 0.21

34.70 ± 0.86

15.09 ± 1.61

35.53 ± 3.26

PEG-b-p(L-Leu)24-b-p(L-Glu)20

1.49 ± 0.05

6.04 ±0.21

6.52 ± 0.01

27.91 ± 0.03

15.12 ± 2.28

35.63 ± 4.67

PEG-b-p((L-Leu)23-co-(L-Glu)23)

1.35 ± 0.13

5.46 ± 0.54

1.85 ± 0.01

7.56 ± 0.04

13.73 ± 0.85

31.83 ± 1.72

Similar to DOX loading, encapsulation of IMC into nanoparticles is based upon
the physiochemical characteristics of the tercopolymers being used. The amphilicity of
the tercopolymers allows for interactions between IMC and hydrophobic p(L-Leu) core
of the nanoparticles. IMC loading contents and efficiencies become more proficient as
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both the IMC feed weight ratio and tercopolymer hydrophobicity increases. As shown in
Table 5.9., DLC and DLE values were calculated for 25%, 50%, and 100% w/w IMC
loading. DLC and DLE tended to increase respectively to the escalation in percent drug
loading. Initial drug loading at 25% w/w exhibits efficiencies between 3.35% and
25.07%, but when doubling the drug concentration to 50%, efficiencies between 3.30%
and 34.70% were observed. By further increasing drug loading concentration,
nanoparticles with relatively high DLE of about 21.6% to 39.4% could be obtained when
the feed weight ratio of IMC to polymer was 1:1. This trend confirms that drug loading
efficiency and the size of micelle increased with the ratio of drug to polymer.
Aggregation can be seen when the amount of drug is higher than the amount of polymer
being used, therefore the weight ratio of IMC to polymer was fixed to ≤ 1:1 for all
samples.
At 100% w/w, the decrease of the p(L-Glu) content from 40 to 20 units all
tercopolymer constructs produced a growth of 2-8% in loading efficiencies, suggesting
that the balance of amphilicity is an important factor that affects the loading of
hydrophobic drugs within these systems. Increasing the p(L-Glu) units from 10 to 20
units led to negligible or minimal improvement of loading efficiencies. This pattern is
less clear lower loading percentages of 25% and 50% w/w.
DLC and DLE were also dependent on the orientation of ABC triblock
tercopolymers. Block tercopolymers exhibit higher efficiencies than random
tercopolymers at all drug feed weight ratios. At 25%, 50%, and 100% w/w, loading
efficiencies between 6.0-25.1%, 5.8-34.7%, and 31.1-39.4% for block PAA
tercopolymers and 2.0-5.5%, 3.3-7.5%, and 21.6-31.8% for random PAA tercopolymers
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were determined, respectively. As discussed previously (section 5.3.4.), block
tercopolymer constructs tend to be more stable with smaller particle sizes, allowing for
better stability and more encapsulation.
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CHAPTER 6

CONCLUSIONS AND FUTURE WORK

6.1. Conclusions
Polymeric gene and drug delivery vectors have been investigated for many years.
Current technologies extend to applications in which biocompatible properties of certain
polymer materials may be utilized to form nanoparticles. These nanostructures can
improve the solubility, stability, circulation half-life and biodistribution of the
encapsulated agent. The physicochemical properties of each delivery system, such as
size, shape, charge densities, drug loading and release, are critical factors in their
efficacy. Poly(amino acid)s have been produced to form nanoparticles that are able to
carry therapeutic agents, such as genetic materials and small molecule drugs.
As an extension of this idea, the present study sought to synthesize cationic and
anionic PEG-PAA triblock copolymers that allow for the manipulation PAA components.
Polymers were synthesized through ring opening polymerization of N-carboxyanhydrides
in order to produce different molecular architectures, such as block and random PAA
copolymers, with varying chain lengths. Once PEG-PAAs were synthesized desired
molecular weight and composition, the impact of their molecular architectures on their
efficacy in gene delivery and drug encapsulation was assessed.
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Cationic PEG-PAAs containing p(L-Lys) and p(L-Leu) segments were evaluated
as a gene delivery agent. It was shown that these tercopolymers bound and condensed
plasmid DNA into particles < 200 nm at 2:1 N:P ratio. The molecular architecture
determined how effective each tercopolymer condensed and protected the plasmid DNA
from nuclease degradation. Block copolymers protected plasmid DNA for up to 60 min
at 37°C, however random copolymers produced DNA degradation at 1 minute
incubation. It was also shown that transfection efficiency and toxicity is affected by
tercopolymer structure and charge density. The ability to manipulate these factors
through polymer structure lets these cationic tercopolymers be tunable gene delivery
systems.
Anionic PEG-PAAs containing p(L-Glu) and p(L-Leu) segments were shown to
produce nanoparticles with sizes < 200 nm, with increased diameters consisting of those
containing random tercopolymers. Nanoparticle stability was shown to be reduced when
PAA contents were randomized, but could be regained through the increase of
hydrophobicity. Although encapsulation of small molecules is found using a fluorescent
dye, the loading content and efficiency is dependent upon a structure of the tercopolymer
being used. Block tercopolymers exhibited larger loading due to an increased
compactiveness of their nanoparticles.
This work showed that PEGylated poly(amino acid)s containing multiple PAA
components can be used for potential biological applications. Each PAA constituent can
be manipulated by modifying their lengths and placements throughout the tercopolymer
structure. The alteration of these PEG-PAA components allows for their ability to be
tunable polymer gene and drug delivery systems.
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6.1. Future Work
The ring opening polymerization of N-δ-trityl-L-glutamine and N-δ-isopropyl-Lglutamine NCAs did not allow for proper monomer incorporation and accurate molecular
weights. In order to produce poly(L-glutamine) with controlled lengths, the conversion
from L-glutamate into L-glutamine should be investigated. The use of L-glutamate and γbenzyl-L-glutamate allows for side chain manipulation before NCA synthesis or after
polymerization of poly(Bnl-L-glutamate), respectively. The use of 2,2,2-trifluoroethanol
can provide a way to produce a more cleavable ester group that will allow for conversion
to the necessary amide using ammonium in organic solvent.
Polyplex formation of cationic PEG-PAAs need to be further investigated. The
difference in tercopolymer constructs can change the formation of these polyplexes. In
order to determine these variations, transmission electron microscopy (TEM) needs to be
used. Polyplex morphology can play an important role in determining the transfection
efficiency of these cationic gene carriers. Therefore, polyplex morphology should be
considered when designing polymer structures as well as their formulation properties
such as cationic density.
Although encapsulation efficiency has been previously shown, the structure of
anionic PEG-PAAs can also affect the release of small molecule drugs. In vitro
experiments need to be performed to determine how loaded nanoparticles containing
different tercopolymer constructs influence drug release. TEM can also be used to
investigate differences in nanoparticle structures that can alter the efficiency of drug
encapsulation.
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APPENDIX A
NMR SPECTRA

Figure A.1. 1H-NMR spectrum of PEG-b-p(TFA-L-Lys)22-b-p(L-Leu)12

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.2. 1H-NMR spectrum of PEG-b-p(L-Leu)14-b-p(TFA-L-Lys)24

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.3. 1H-NMR spectrum of PEG-b-p((L-Leu)13-co-(TFA-L-Lys)22)

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.4. 1H-NMR spectrum of PEG-b-p(TFA-L-Lys)23-b-p(L-Leu)23

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.5. 1H-NMR spectrum of PEG-b-p(L-Leu)24-b-p(TFA-L-Lys)23

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds

207

Figure A.6. 1H-NMR spectrum of PEG-b-p((L-Leu)23-co-(TFA-L-Lys)22)

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.7. 1H-NMR spectrum of PEG-b-p(L-Lys)22-b-p(L-Leu)12

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.8. 1H-NMR spectrum of PEG-b-p(L-Leu)14-b-p(L-Lys)24

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.9. 1H-NMR spectrum of PEG-b-p((L-Leu)13-co-(L-Lys)22)

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.10. 1H-NMR spectrum of PEG-b-p(L-Lys)23-b-p(L-Leu)23

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.11. 1H-NMR spectrum of PEG-b-p(L-Leu)24-b-p(L-Lys)23

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.12. 1H-NMR spectrum of PEG-b-p((L-Leu)23-co-(L-Lys)22)

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.13. 1H-NMR spectrum of PEG-b-p(Bnl-L-Glu)20-b-p(L-Leu)9.

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds

215

Figure A.14. 1H-NMR spectrum of PEG-b-p(L-Leu)12-b-p(Bnl-L-Glu)22.

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.15. 1H-NMR spectrum of PEG-b-p((L-Leu)12-co-(Bnl-L-Glu)22).

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.16. 1H-NMR spectrum of PEG-b-p(Bnl-L-Glu)24-b-p(L-Leu)23.

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.17. 1H-NMR spectrum of PEG-b-p(L-Leu)23-b-p(Bnl-L-Glu)24.

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.18. 1H-NMR spectrum of PEG-b-p((L-Leu)23-co-(Bnl-L-Glu)26).

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.19. 1H-NMR spectrum of PEG-b-p(L-Glu)19-b-p(L-Leu)11.

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.20. 1H-NMR spectrum of PEG-b-p(L-Leu)13-b-p(L-Glu)18.

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.21. 1H-NMR spectrum of PEG-b-p((L-Leu)11-co-(L-Glu)19).

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.22. 1H-NMR spectrum of PEG-b-p(L-Glu)22-b-p(L-Leu)23

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.23. 1H-NMR spectrum of PEG-b-p(L-Leu)20-b-p(L-Glu)24

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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Figure A.24. 1H-NMR spectrum of PEG-b-p((L-Leu)23-co-(L-Glu)23)

Parameters:
Frequency: 500 MHz
Experiment: 1H
Temperature: 25°C
Solvent: TFAA-d
Scans: 32
Relaxation Delay: 25 seconds
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IR SPECTRA

Figure A.25. IR spectrum of PEG-b-p(TFA-L-Lys)42-b-p(L-Leu)12 and PEG-b-p(LLys)42-b-p(L-Leu)12
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.26. IR spectrum of PEG-b-p(L-Leu)12-b-p(TFA-L-Lys)43 and PEG-b-p(LLeu)12-b-p(L-Lys)43
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.27. IR spectrum of PEG-b-p((L-Leu)14-co-(TFA-L-Lys)45) and PEG-b-p((LLeu)14-co-(L-Lys)45)
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.28. IR spectrum of PEG-b-p(TFA-L-Lys)22-b-p(L-Leu)12 and PEG-b-p(LLys)22-b-p(L-Leu)12
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.29. IR spectrum of PEG-b-p(L-Leu)14-b-p(TFA-L-Lys)24 and PEG-b-p(LLeu)14-b-p(L-Lys)24
Parameters:
Experiment: ATR-IR
Scans: 16

231

Figure A.30. 1H-NMR spectrum of PEG-b-p((L-Leu)13-co-(TFA-L-Lys)22) and PEG-bp((L-Leu)13-co-(L-Lys)22)
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.31. 1H-NMR spectrum of PEG-b-p(TFA-L-Lys)23-b-p(L-Leu)23 and PEG-bp(L-Lys)23-b-p(L-Leu)23
Parameters:
FreqExperiment: ATR-IR
Scans: 16
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Figure A.32. IR spectrum of PEG-b-p(L-Leu)24-b-p(TFA-L-Lys)23 and PEG-b-p(LLeu)24-b-p(L-Lys)23
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.33. IR spectrum of PEG-b-p((L-Leu)23-co-(TFA-L-Lys)22) and PEG-b-p((LLeu)23-co-(L-Lys)22)
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.34. IR spectrum of PEG-b-p(Bnl-L-Glu)52-b-p(L-Leu)12 and PEG-b-p(LGlu)40-b-p(L-Leu)12
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.35. IR spectrum of PEG-b-p(L-Leu)12-b-p(Bnl-L-Glu)50 and PEG-b-p(LLeu)12-b-p(L-Glu)44
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.36. IR spectrum of PEG-b-p((L-Leu)12-co-(Bnl-L-Glu)50) and PEG-b-p((LLeu)13-co-(L-Glu)40)
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.37. IR spectrum of PEG-b-p(Bnl-L-Glu)20-b-p(L-Leu)9 and PEG-b-p(L-Glu)19b-p(L-Leu)11
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.38. IR spectrum of PEG-b-p(L-Leu)12-b-p(Bnl-L-Glu)22 and PEG-b-p(LLeu)13-b-p(L-Glu)18
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.39. IR spectrum of PEG-b-p((L-Leu)12-co-(Bnl-L-Glu)22) and PEG-b-p((LLeu)12-co-(L-Glu)22)
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.40. IR spectrum of PEG-b-p(Bnl-L-Glu)24-b-p(L-Leu)23 and PEG-b-p(LGlu)23-b-p(L-Leu)22
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.41. IR spectrum of PEG-b-p(L-Leu)23-b-p(Bnl-L-Glu)24 and PEG-b-p(LLeu)24-b-p(L-Glu)20
Parameters:
Experiment: ATR-IR
Scans: 16
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Figure A.42. IR spectrum of PEG-b-p((L-Leu)23-co-(Bnl-L-Glu)26) and PEG-b-p((LLeu)23-co-(L-Glu)23)
Parameters:
Experiment: ATR-IR
Scans: 16
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APPENDIX B
GPC SPECTRA
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Figure B.1. GPC spectrum of PEG-b-p(TFA-L-Lys)42-b-p(L-Leu)12
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.2. GPC spectrum of PEG-b-p(L-Leu)12-b-p(TFA-L-Lys)43
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.3. GPC spectrum of PEG-b-p((L-Leu)14-co-(TFA-L-Lys)45)
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.4. GPC spectrum of PEG-b-p(TFA-L-Lys)22-b-p(L-Leu)12
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.5. GPC spectrum of PEG-b-p(L-Leu)14-b-p(TFA-L-Lys)24
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.6. GPC spectrum of PEG-b-p((L-Leu)13-co-(TFA-L-Lys)22)
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.7. GPC spectrum of PEG-b-p(TFA-L-Lys)23-b-p(L-Leu)23
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.8. GPC spectrum of PEG-b-p(L-Leu)24-b-p(TFA-L-Lys)23
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.9. GPC spectrum of PEG-b-p((L-Leu)23-co-(TFA-L-Lys)22)
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.10. GPC spectrum of PEG-b-p(Bnl-L-Glu)52-b-p(L-Leu)12.
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.11. GPC spectrum of PEG-b-p(L-Leu)12-b-p(Bnl-L-Glu)50.
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.12. GPC spectrum of PEG-b-p((L-Leu)12-co-(Bnl-L-Glu)50).
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.13. GPC spectrum of PEG-b-p(Bnl-L-Glu)20-b-p(L-Leu)9.
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.14. GPC spectrum of PEG-b-p(L-Leu)12-b-p(Bnl-L-Glu)22.
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.15. GPC spectrum of PEG-b-p((L-Leu)12-co-(Bnl-L-Glu)22).
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.16. GPC spectrum of PEG-b-p(Bnl-L-Glu)24-b-p(L-Leu)23.
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.17. GPC spectrum of PEG-b-p(L-Leu)23-b-p(Bnl-L-Glu)24.
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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Figure B.18. GPC spectrum of PEG-b-p((L-Leu)23-co-(Bnl-L-Glu)26).
Parameters:
Experiment. GPC
Temperature: 50°C
Solvent: 0.1 M LiBr in DMF
Flow Rate: 0.45 mL/min
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APPENDIX C
PARTICLE SIZE AND ZETA POTENTIAL
mPEG-b-p((L-Lys20)-b-p(L-Leu10))
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Figure C.1. Particle size (bars) and zeta potential (dotted lines) of mPEG-b-p((L-Lys)20b-p(L-Leu)10), mPEG-b-p((L-Leu)10-b-p(L-Lys)20), and mPEG-b-p((L-Leu)10-co-(LLys)20) polyplexes at different N:P ratios.
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Figure C.2. Particle size (bars) and zeta potential (dotted lines) of mPEG-b-p((L-Lys)20b-p(L-Leu)20), mPEG-b-p((L-Leu)20-b-p(L-Lys)20), and mPEG-b-p((L-Leu)20-co-(LLys)20) polyplexes at different N:P ratios.
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RIBOGREEN ANALYSIS
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Figure C.3. RiboGreen analysis of mPEG-b-p((L-Lys)20-b-p(L-Leu)10), mPEG-b-p((LLeu)10-b-p(L-Lys)20), and mPEG-b-p((L-Leu)10-co-(L-Lys)20) polyplexes at different N:P
ratios. Release was performed via heparin sodium salt addition to aliquots of each
polyplex at different N:P ratios.
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Figure C.4. RiboGreen analysis of PEG-b-p((L-Lys)20-b-p(L-Leu)20), PEG-b-p((LLeu)20-b-p(L-Lys)20), and PEG-b-p((L-Leu)20-co-(L-Lys)20) polyplexes at different N:P
ratios. Release was performed via heparin sodium salt addition to aliquots of each
polyplex at different N:P ratios.
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NUCLEASE DEGRADATION STUDIES
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Figure C.5. DNAse protections assays carried out on three tercopolymer constructs at
N:P ratio 20:1: A) PEG-b-p(L-Lys)20-b-p(L-Leu)10, B) PEG-b-p(L-Leu)10-b-p(L-Lys)20,
and C) PEG-b-p((L-Leu)10-co-p(L-Lys)20.
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Figure C.6. DNAse protections assays carried out on three tercopolymer constructs at
N:P ratio 20:1: A) PEG-b-p(L-Lys)20-b-p(L-Leu)20, B) PEG-b-p(L-Leu)20-b-p(L-Lys)20,
and C) PEG-b-p((L-Leu)20-co-p(L-Lys)20.
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SERUM STABILITY

Figure C.7. Serum stability and nuclease degradation of Luciferase plasmid DNA in the
presence of 50% FBS serum.
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Figure C.8. Serum stability analysis through DLS (A-C), serum nuclease protection (D),
and turbidity testing (E) of PEG-b-p(L-Lys)20-b-p(L-Leu)10, PEG-b-p(L-Leu)10-b-p(LLys)20, and PEG-b-p((L-Leu)10-co-p(L-Lys)20).
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Figure C.9. Serum stability analysis through DLS (A-C), serum nuclease protection (D),
and turbidity testing (E) of PEG-b-p(L-Lys)20-b-p(L-Leu)20, PEG-b-p(L-Leu)20-b-p(LLys)20, and PEG-b-p((L-Leu)20-co-p(L-Lys)20).
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Figure C.10. Transfection efficiency of different DNA complexes in COS-1 cells at 20:1
N:P ratio. Bars shown are mean ± SE (n =3-4). **: p < 0.05.
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Figure C.11. Total protein concentration observed from different DNA complexes in
COS-1 cells at 20:1 N:P ratio. Bars shown are mean ± SE (n =3-4). **: p < 0.05.
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Figure C.12. Transfection efficiency of different DNA complexes in COS-1 cells at 10:1
N:P ratio. Bars shown are mean ± SE (n =3-4). **: p < 0.05.
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Figure C.13. Total protein concentration observed from different DNA complexes in
COS-1 cells at 10:1 N:P ratio. Bars shown are mean ± SE (n =3-4). **: p < 0.05.
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APPENDIX D
DRUG CALIBRATION CURVES
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Figure D.1. (A) Raw data and (B) calibration curve for Doxorubicin at various
concentrations in 4:1 DMSO/MeOH solvent.
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Figure D.2. (A) Variation of the emission spectra and (B) calibration curve for
Indomethacin at various concentrations in 1:1 THF/EtOH solvent.
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DLS AND NEUTRON SCATTERING OVERLAYS
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Figure D.3. Apparent hydrodynamic radius (RH) distribution from DLS analysis (open
bars) and radius of gyration (RG) from SANS analysis (black bars) with their relative
intensities for: a) PEG-b-p(Bnl-L-Glu)20-b-p(L-Leu)10, b) PEG-b-p(L-Leu)12-b-p(Bnl-LGlu)22, c) PEG-b-p((L-Leu)12-co-(Bnl-L-Glu)23, d) PEG-b-p(Bnl-L-Glu)24-b-p(L-Leu)23,
e) PEG-b-p(L-Leu)23-b-p(Bnl-L-Glu)24, and f) PEG-b-p((L-Leu)23-co-(Bnl-L-Glu)26.
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